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Jillian Nicole Noblet 
CORONARY PERIVASCULAR ADIPOSE TISSUE AND VASCULAR SMOOTH 
MUSCLE FUNCTION: INFLUENCE OF OBESITY 
Factors released from coronary perivascular adipose tissue (PVAT), which 
surrounds large coronary arteries, have been implicated in the development of coronary 
disease. However, the precise contribution of coronary PVAT-derived factors to the 
initiation and progression of coronary vascular dysfunction remains ill defined. 
Accordingly, this investigation was designed to delineate the mechanisms by which PVAT-
derived factors influence obesity-induced coronary smooth muscle dysfunction. Isometric 
tension studies of coronary arteries from lean and obese swine demonstrated that both 
lean and obese coronary PVAT attenuate vasodilation via inhibitory effects on smooth 
muscle K+ channels. Specifically, lean coronary PVAT attenuated KCa and KV7 channel-
mediated dilation, whereas obese coronary PVAT impaired KATP channel-mediated 
dilation. Importantly, these effects were independent of alterations in underlying smooth 
muscle function in obese arteries. The PVAT-derived factor calpastatin impaired 
adenosine dilation in lean but not obese arteries, suggesting that alterations in specific 
factors may contribute to the development of smooth muscle dysfunction. Further studies 
tested the hypothesis that leptin, which is expressed in coronary PVAT and is upregulated 
in obesity, acts as an upstream mediator of coronary smooth muscle dysfunction. Long-
term administration (3 day culture) of obese concentrations of leptin markedly altered the 
coronary artery proteome, favoring pathways associated with calcium signaling and 
cellular proliferation. Isometric tension studies demonstrated that short-term (30 min) 
exposure to leptin potentiated depolarization-induced contraction of coronary arteries and 
that this effect was augmented following longer-term leptin administration (3 days). 
Inhibition of Rho kinase reduced leptin-mediated increases in coronary artery contractions. 
vi 
Acute treatment was associated with increased Rho kinase activity, whereas longer-term 
exposure was associated with increases in Rho kinase protein abundance. Alterations in 
Rho kinase signaling were also associated with leptin-mediated increases in coronary 
vascular smooth muscle proliferation. These findings provide novel mechanistic evidence 
linking coronary PVAT with vascular dysfunction and further support a role for coronary 
PVAT in the pathogenesis of coronary disease. 
 
Johnathan D. Tune, Ph.D., Chair 
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Chapter 1 
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The Global Pandemic of Obesity  
 Over the last several decades, an overabundance of food and an increasingly 
sedentary lifestyle have contributed to the advancement obesity from a relatively minor 
health issue to a major threat to public health throughout the world. In fact, the increasing 
prevalence of overweight and obese individuals has been described as a global pandemic 
(Figure 1.1).3;23;24 Recent estimates indicate that approximately 2 billion individuals are 
overweight (defined as a body mass index, BMI ≥ 25 kg/m2)25 or obese (BMI ≥ 30 kg/m2),25 
with at least one-third of the world’s adult population considered obese.11;26 The Global  
Burden of Disease Study 2013 further revealed that the proportion of adults with a BMI of 
25 or greater increased from 29% to 37% in men and from 30% to 38% in women between 
1980 and 2013 (Figure 1.2).11 Both developed and developing countries are plagued by 
the obesity epidemic,25 as no country in the world has had a significant decrease in obesity 
Figure 1.1 Pandemic of obesity in men aged 18+. In 2014, more than half a billion adults 
worldwide were classed as obese (BMI ≥ 30 kg/m2).3 
3 
in the past 33 years.11 Currently, 
the United States is among the top 
15 countries worldwide in terms of 
increases in obesity since 1980.11 
Although some data suggest that 
this increase in obesity is levelling 
off among adults in the United 
States,27-29 cases of severe obesity 
(BMI ≥ 35 kg/m2)25 are accounting 
for an increasingly large proportion 
of the obese population over time, 
with 1 in 7 Americans now 
considered severely obese.30;31 As 
evidenced by the substantial 
increase in prevalence and 
severity, obesity has clearly 
become a major national and global 
health crisis.  
 
Obesity and Cardiovascular Disease 
 Perhaps more alarming than the rising prevalence of obesity are the established 
health risks associated with this condition. Throughout the world, overweight and obesity 
account for nearly 3.5 million deaths and 95 million disability-adjusted life years (i.e., the 
number of years lost due to ill-health, disability or early death) per year.3 Medical care 
costs of obesity and its related health complications reach an estimated $150 billion dollars 
Figure 1.2 Global prevalence of overweight and 
obesity in adults. Age-standardized prevalence of 
overweight and obesity (BMI ≥ 25, A) and obesity 
(BMI ≥ 25, B) increased in both developed and 
developing countries between 1980 and 2013.11 
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annually in the United States.32 This includes both direct costs related to diagnostic and 
treatment services as well as indirect costs related to the impact of obesity on morbidity 
and mortality.33;34 Weight gain is associated with numerous comorbidities that contribute 
to a reduced quality of life including limited mobility, depression, and respiratory ailments 
such as asthma and sleep apnea.35;36 Excess weight also leads to adverse metabolic 
effects on blood pressure, cholesterol, triglycerides, and insulin resistance.13;25;36 Since 
1988, investigators have systematically outlined a clustering of several risk factors 
associated with cardiovascular disease including but not limited to abdominal obesity, 
hypertension, dyslipidemia, and glucose intolerance which are now referred to as 
“metabolic syndrome” 
(MetS).37-39 An estimated 30% 
of the total U.S. population and 
near 60% of those considered 
obese exhibit characteristics of 
the MetS.40;41 Individuals with 
MetS are at a significantly 
increased overall risk for 
developing cardiovascular 
disease, and each component 
of the MetS is considered an independent risk factor.38;39;42;43 Obesity, in particular, is 
considered a major risk factor for a cardiovascular event such as a myocardial infarction 
or stroke.44;45 Cardiovascular disease is the leading cause of death in the United States, 
accounting for 31% of all deaths.7 A large proportion of cardiovascular related deaths are 
a result of coronary artery disease (Figure 1.3), the complications of which are responsible 
for approximately 1 of every 7 deaths in the United States.7 Prospective studies provide 
strong support that obesity alone is associated with increased risk of coronary artery 
Figure 1.3 Cardiovascular disease mortality in the 
United States. Coronary heart disease accounts for 
nearly half of all cardiovascular related deaths.7  
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disease, even prior to the development of overt clinical symptoms (i.e., morbid obesity or 
type 2 diabetes).46 Taken together, an even larger proportion of the population may be at 
increased risk of coronary disease than has been currently identified. These findings 
highlight the importance of understanding the complex relationship between obesity and 
coronary disease.  
 Despite the growing global pandemic of obesity and the incidence of obesity-
related cardiovascular disease, the precise mechanisms by which excess adiposity 
predisposes individuals to coronary disease remain poorly understood. Recent attention 
has been given to adipose tissue, an active endocrine and paracrine organ that releases 
a variety of bioactive mediators that may provide a molecular link between obesity and 
cardiovascular disease.13;47-49  
 
Adipose Tissue and Obesity-induced Coronary Disease 
 Numerous investigations have focused on the multifaceted relationships between 
adipose tissue, metabolic dysfunction, chronic inflammation, and cardiovascular disease 
in the setting of obesity. Historically, adipose tissue was thought simply as lipid-laden 
connective tissue responsible for insulating the body, storing triglycerides during energy 
surplus, and releasing energy in the form of free fatty acids during periods of energy 
shortage.50;51 However, it is now commonly accepted that adipose tissue is also an 
endocrine and paracrine organ capable of secreting a multitude of bioactive proteins and 
peptides, collectively referred to as adipokines.13;47 Adipose tissue is composed of several 
cell types such as adipocytes, preadipocytes, and the stromal vascular fraction which 
includes macrophages, leukocytes, and endothelial cells (Figure 1.4).13;52 The majority of 
adipokines are released from adipocytes, whereas non-fat cells (i.e., stromal vascular 
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fraction) secrete inflammatory 
cytokines.53 Recent studies have 
identified adipose tissue 
dysfunction (i.e., heightened 
inflammatory status) as a defining 
characteristic of obesity/MetS and 
its related pathologies.  
 In the setting of obesity, 
factors that promote adipogenesis 
such as lipoprotein lipase and 
cholesterol ester transfer protein 
act via paracrine and/or autocrine mechanisms to increase adipose depot size and/or 
modulate body fat distribution.54 Both adipocyte hyperplasia (increase in cell number) and 
hypertrophy (increase in cell size) have been observed in the obese state.55 The persistent 
state of energy excess exerts an increased burden on adipose tissue causing various 
effects, predominantly inflammation, within the tissue (Figure 1.5).6;56 This chronic 
inflammatory state modifies the cellular composition and/or phenotype of the tissue, 
resulting in marked alterations in secretory output.6;13;48 Adipocyte hypertrophy is 
associated with a pro-inflammatory adipose secretome, evidenced by a positive 
correlation between adipocyte size and secretion of pro-inflammatory factors such as 
tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein (MCP-1), leptin, 
interleukin-6 (IL-6), and interleukin-8 (IL-8).57 Subsequent infiltration of macrophages and 
lymphocytes are not only a source of inflammation but also contribute to increased 
secretion of pro-inflammatory adipokines, which further exacerbate the inflammatory 
status of adipose tissue.6;58 This rich source of pro-inflammatory mediators has the 
Figure 1.4 Components of adipose tissue. 
Adipocytes and the stromal vascular fraction 
constitute the main cellular component of adipose 
tissue. Blood vessels distributed throughout adipose 
provide oxygen and nutrients to the tissue and allow 
for the distribution of adipokines.13  
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potential to contribute to the development of obesity-induced insulin resistance, 
cardiovascular dysfunction, and atherogenesis.48 On the other hand, adipose tissue has 
been shown to produce adipokines, such as adiponectin, that confer protection against 
inflammation and vascular injury.59-62 However, several studies have documented that 
plasma levels of adiponectin and other anti-inflammatory and cardioprotective adipokines 
is markedly reduced in the setting of obesity.63  
 The role of adipose tissue in the pathogenesis of coronary artery disease and 
atherosclerosis has received considerable research interest in recent years. Figure 1.6 
outlines the cascade of events involved in coronary atherosclerotic plaque formation. The 
initiation of atherosclerosis is triggered by various inflammatory stimuli including increased 
adiposity, hypercholesterolemia, and insulin resistance.6;64 The initiation of atherosclerotic 
disease begins with endothelial dysfunction, characterized by the adhesion of platelets 
Figure 1.5 Obesity-induced adipose tissue dysfunction. Chronic inflammation 
of adipose tissue in obesity markedly alters the adipokine expression profile. 
Augmented secretion of pro-inflammatory adipokines from adipose tissue triggers 
endothelial dysfunction and vascular inflammation.6 
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and inflammatory cells in the vessel wall.65 If the inflammatory stimulus persists, 
leukocytes migrate and accumulate beneath the endothelial layer.66 The subsequent 
formation of lipid laden foam cells and the proliferation and migration of smooth muscle 
cells contribute to the formation of an atherosclerotic plaque.48;64;67-69 Plaque development 
continues in the presence of atherogenic stimuli until destabilizing factors (i.e., thinning of 
the fibrous cap) trigger plaque rupture and thrombus formation, which then have the 
potential to occlude blood flow and trigger a myocardial infarction.67;68  
Figure 1.6 Pathogenesis of atherosclerosis. Endothelial dysfunction stimulates 
chemokine production and the upregulation of leukocyte adhesion molecules on 
the surface of endothelial cells. These changes, along with increased endothelial 
permeability, result in migration of leukocytes into the artery wall. Monocytes 
differentiate into macrophages, which take up modified LDL to form foam cells. 
Pro-inflammatory chemokines promote proliferation and migration of smooth 
muscle cells into the developing plaque. A fibrous cap forms over the top of the 
plaque, providing temporary stabilization and isolation from the circulation.  
Hypoxia and oxidative stress may cause foam-cell apoptosis and lead to the 
formation of a lipid-laden necrotic core. As the plaque enlarges, it may become 
large enough to impede blood flow (i.e., flow limiting stenosis) and/or the fibrous 
cap thins and ruptures leading to acute thrombosis and occlusion.14 
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 Recent studies suggest the potential for adipokines to influence various 
components of atherogenesis (Figure 1.7). For example, adipose-derived leptin has been 
implicated in the development of endothelial dysfunction,2;70;71 and the production of MCP-
1 by adipocytes has been shown to directly promote leukocyte transmigration.65 Adipose-
derived factors may also have the potential to induce proliferation and migration of smooth 
muscle cells.6  These early findings indicate the potential for adipose tissue to causally 
contribute to the development of obesity-associated coronary disease via cross talk 
between adipokines and the vascular wall. However, several key factors have made 
elucidating the relationship between adipose tissue and coronary vascular disease an 
Figure 1.7 Factors derived from adipose tissue contribute to atherogenesis. 
Adipokines are known to influence nearly all critical aspects of atherogenesis including 
endothelial dysfunction, leukocyte recruitment and transmigration, lipid oxidation, foam 
cell formation, smooth muscle cell proliferation and migration, plaque rupture, and 
thrombus formation. Red arrows represent pro-inflammatory pathways that are stimulated 
during obesity. Blue arrows represent anti-inflammatory pathways that are inhibited during 
obesity. Green arrows represent the stimulation of adipokine secretion.12 
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exceptionally complex endeavor. First, the adipokine secretion profile may vary between 
adipose tissue depots depending on anatomic location.13;17;72;73 Second, the secretory 
status of adipose tissue can vary dramatically depending on the underlying disease state 
(i.e. obesity, inflammation) and the particular organism being studied.9;13;74;75 Finally, novel 
adipokines are continually being discovered, adding to the list of hundreds of adipose-
derived factors identified to date that warrant further investigation.13;48;76 It is evident that 
these issues must be collectively considered in order to better understand the growing 
paradigm of a role for adipose tissue in obesity-induced coronary disease.  
 
Perivascular Adipose Tissue 
 The majority of large blood vessels (internal diameter > 100 µm) throughout the 
body, apart from cerebral and pulmonary arteries, are surrounded by various quantities of 
perivascular adipose tissue, or PVAT (Figure 1.8).8;62;77 In particular, PVAT has been 
described around large arteries (e.g. aorta, coronary, mammary, femoral), veins, small 
and resistance vessels, and skeletal 
muscle microvessels.78 Similar to other 
adipose tissue depots, PVAT is a highly 
vascularized network comprised of 
several cell types including adipocytes, 
pre-adipocytes, inflammatory cells, and 
stem cells capable of producing 
metabolically active factors.62;79;80 
Uniquely, PVAT directly abuts the 
adventitia of most conduit arteries, due 
to an absence of a fascial layer 
Figure 1.8 Anatomic locations of 
perivascular adipose tissue. Types of 
perivascular adipose tissue (PVAT) can be 
classified according to anatomic location. Note 
that PVAT is absent from the murine coronary 
artery.8 
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separating adipocytes from the vessel wall.81;82 As a result, adipocytes from PVAT have 
been shown to infiltrate into the adventitia, providing for direct paracrine physiological and 
pathophysiological communication with the vasculature.75;81;83  
 This emerging view of “outside in” signaling between vasoactive factors from PVAT 
and the vascular wall is supported by evidence that PVAT depots are associated with 
specific vascular complications depending on the anatomic location of the vascular bed. 
For example, PVAT surrounding the microcirculation of the gracilis muscle modulates 
insulin-dependent vascular function and has been associated with insulin resistance.84 
Additionally, increases in peripheral artery PVAT are associated with peripheral artery 
disease and vascular calcification.85 It is proposed that these differential paracrine effects 
are related to the unique adipokine profiles of anatomically distinct PVAT depots.8;17;78 
Perhaps the most physiological and pathophysiological role of a PVAT depot has been 
described for coronary PVAT.  
 
Coronary Perivascular Adipose Tissue 
 Coronary PVAT surrounds the major conduit coronary arteries on the surface of 
the heart (Figure 1.9).17;86 Studies suggest that coronary PVAT shares characteristics with 
both white and brown adipose tissue.15;17;87 Other data, however, indicate that human 
coronary perivascular adipocytes display a histologic appearance and gene expression 
pattern more consistent with white rather than brown adipose tissue.73;75;81 Further study 
of human perivascular adipocytes revealed that those surrounding coronary arteries are 
smaller in size and exhibit a reduced state of adipogenic differentiation compared to 
peripheral (subcutaneous and perirenal) adipocytes, evidenced by decreased expression 
of adipocyte-specific genes.73;75 These differences are likely a result of a distinct 
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developmental origin of PVAT. Although 
studies of perivascular adipocyte origin are 
scarce, evidence points towards vascular 
smooth muscle progenitors, an origin distinct 
from adipocytes of other depots.88;89 Further 
studies are needed to characterize the 
developmental origin of perivascular 
adipocytes and to examine potential 
differences between peripheral (non-coronary) 
and coronary PVAT depots.  
 Currently, there is some inconsistency 
in the literature regarding the nomenclature of 
cardiac fat depots. Coronary PVAT immediately surrounds the coronary arteries and is 
functionally distinct from the adipose tissue found on the surface of the myocardium, which 
termed myocardial or epicardial adipose tissue.90;90;91 However, the term epicardial 
adipose tissue is often used to describe both myocardial/epicardial and coronary PVAT 
depots. Altogether though, cardiac adiposity is highly and directly correlated with 
abdominal visceral adipose tissue volume92;93 and has been shown to expand with 
obesity.94 Epicardial adipose tissue volume also increases with the number of MetS risk 
factors.95-97 Several studies demonstrate that atherosclerotic plaques occur predominantly 
in coronary arteries that are encased in PVAT20;94;95;98 and that coronary PVAT volume is 
positively associated with underlying plaque burden.99;100 A recent study by McKenney et 
al. documented that resection of coronary PVAT decreased the progression of coronary 
atherosclerosis in obese swine, further supporting that PVAT exacerbates the progression 
Figure 1.9 Coronary perivascular 
adipose tissue. Representative image of 
naturally occurring coronary perivascular 
adipose tissue (PVAT) on the heart. RA, 
right atrium; LA, left atrium; RV, right 
ventricle; LV, left ventricle; RCA, right 
coronary artery; LAD, left anterior 
descending artery; LCX, left circumflex 
artery.15 
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of disease.101 Together, these findings support cardiac adiposity as an independent risk 
factor for coronary artery disease.98;102;103  
 Although a positive association between coronary PVAT and coronary artery 
disease is clear, the precise link between the two is unknown. Recent studies propose 
that the association between PVAT and vascular disease is related to direct effects of 
PVAT-derived factors on endothelial and smooth muscle function. In fact, a disruption of 
normal vascular function (i.e., an imbalance between vasodilation and vasoconstriction) 
is a central component in the pathogenesis of coronary vascular disease.48  In order to 
comprehend the potential mechanisms by which coronary PVAT could contribute to the 
development of vascular dysfunction, an understanding of how obesity affects the 
coronary circulation is important.  
 
Obesity and Coronary Vascular Dysfunction 
 Coronary arteries are responsible for the delivery of oxygen and energy substrates 
to the myocardium which generates the pressure necessary to drive blood throughout the 
circulatory system. Since the myocardium has a limited anaerobic capacity, utilizing a rate 
of 70-80% oxygen extraction at rest, the heart is highly dependent on a continuous supply 
of oxygen from the coronary circulation.104-106 Within seconds, inadequate oxygen delivery 
(i.e. ischemia) can significantly impair cardiac contractile function.107-109 Thus, tight control 
of coronary blood flow is essential for normal cardiac function. As such, during normal 
physiologic conditions, oxygen delivery (i.e., coronary blood flow) is tightly matched with 
myocardial oxygen consumption (MVO2). This process is regulated by affecting one or 
more of the primary determinants of coronary blood flow including arterial pressure, 
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myocardial metabolism, neuro-hormonal influences, and extravascular myocardial 
compression.106;110  
 Growing evidence supports dysfunction of the control of coronary blood flow as an 
important contributor to the increased cardiovascular morbidity and mortality associated 
with obesity/MetS. In the setting of obesity, repeated measures of coronary blood flow 
reveal little or no difference at rest.111;112 However, although myocardial perfusion may be 
equivalent, myocardial oxygen consumption (MVO2) is elevated in obesity in proportion to 
increases in stroke volume, cardiac output, and blood pressure.113;114 This “hyperdynamic 
circulation” results in increased myocardial oxygen demand and is a defining characteristic 
of the obese coronary circulation. Obesity is also clearly associated with reduced coronary 
flow reserve, defined as the difference between maximal and resting coronary blood 
flow.111;115;116 Decreases in coronary flow reserve are directly correlated with increases in 
waist-to-hip ratio, body mass index, blood pressure, and diagnosis of MetS.111;112;115;117 
The reduction in flow reserve could be due to the effects of diffuse atherosclerosis on fluid 
dynamics, the extent of focal coronary stenosis, and/or the presence of microvascular 
dysfunction.111;118 The coronary microcirculation regulates vascular resistance in order to 
balance myocardial oxygen supply and demand. In obesity, coronary blood flow is 
decreased at a given coronary venous PO2 (an index of myocardial tissue PO2 which is a 
stimulus for metabolic vasodilation)104;110 and PO2 is reduced relative to alterations in 
MVO2 (the primary determinant of myocardial perfusion) at rest and during exercise 
(Figure 1.10).4 Furthermore, coronary vasodilation in response to myocardial ischemia 
has also been shown to be impaired by obesity/MetS.4;119 Together, these findings indicate 
that coronary microvascular dysfunction in obesity leads to an imbalance between 
coronary blood flow and myocardial metabolism. This imbalance likely contributes to the 
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cardiac contractile dysfunction 
and high incidence of myocardial 
ischemia observed in obese 
subjects.42;120  
 Several potential 
mechanisms underlying 
alterations in the control of 
coronary blood flow have been 
explored including the role of 
neurohormonal modulation. It is 
well established that obesity is 
associated with increased sympathetic tone.121;122 Several studies have documented 
elevated plasma catecholamines as well as increased sympathetic nerve activity and 
cardiac autonomic activity in obese subjects.121-124 In particular, data from both in vitro and 
in vivo studies demonstrate increased coronary α1-adrenoceptor signaling and α1-
adrenoceptor-mediated vasoconstriction, independent of alterations in α1-adrenoceptor 
expression.4;125;126 These findings suggest that α1-adrenoceptor signaling likely contributes 
to the myocardial oxygen supply demand imbalance, particularly during heightened 
sympathetic activity. Substantial evidence also supports a role for the renin-angiotensin-
aldosterone system (RAAS) in the regulation of coronary blood flow in obesity. Data 
indicate an increase in angiotensin II type 1 (AT1) receptor expression and angiotensin II-
mediated vasoconstriction in obese coronary arteries.4;114 Additionally, aldosterone 
produces dose-dependent coronary vasoconstriction in vitro and in vivo and has been 
shown to exacerbate contractile dysfunction during myocardial ischemia.127;128 Together, 
present data implicate increased sympathetic activity and upregulation of the RAAS as 
Figure 1.10 Effects of metabolic syndrome on 
coronary blood flow. Metabolic syndrome (MetS) 
diminishes local metabolic control of coronary blood 
flow, evidenced by decreased coronary blood flow at 
a given coronary venous PO2 (left). MetS also results 
in an imbalance between myocardial oxygen supply 
and demand, evidenced by the reduction in coronary 
venous PO2 relative to alterations in myocardial 
oxygen consumption (right). Modified from Berwick et 
al., J Mol Cell Cardiol, 2012.4 
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potential mechanisms responsible for the dysregulation of coronary blood flow control in 
obesity. 
 Alterations in the functional expression of coronary vascular K+ and Ca2+ channels 
in the setting of obesity is a topic of intense study, as such changes could contribute to 
coronary vascular dysfunction. In coronary artery smooth muscle cells, K+ channels 
dominate membrane conductance and thus determine the resting membrane potential.4;129 
The equilibrium potential for K+ is an estimated -83 mV, but due to the balancing 
depolarizing influence of other ion channels, the resting membrane potential of coronary 
smooth muscle cells is less negative, typically between -60 mV and -40 mV.129 The 
threshold for L-type (CaV1.2) Ca2+ channels, and thus contraction, is in this range.130;131 
When K+ channels open, K+ moves down its electrochemical gradient, hyperpolarizing the 
membrane, and smooth muscle relaxes to produce vasodilation. In contrast, when the 
inhibition of K+ channels reduces K+ efflux, the membrane depolarizes, activating CaV1.2 
channels, and the resulting increase in intracellular Ca2+ produces vasoconstriction. This 
interplay between K+ and voltage-gated Ca2+ channels represents electromechanical 
coupling. A variety of K+ channels are expressed in coronary smooth muscle including 
voltage-dependent (KV), large conductance Ca2+ activated (BKCa), and ATP-sensitive 
(KATP) channels, and serve as important regulators of coronary vascular reactivity. KV 
channels have been implicated in the control of coronary vascular tone.129 Studies in lean, 
healthy animals demonstrate that KV channels regulate coronary blood flow at rest, with 
increasing MVO2 and during ischemia.21;132;133 Recent findings indicate that obesity 
markedly alters the functional expression of KV channels, as reductions in smooth muscle 
KV current were observed in coronary arteries from swine with the MetS (Figure 1.11).21 
BKCa channels have been shown to influence coronary endothelial-dependent 
vasodilation134;135 but data fail to support a significant role for BKCa channels in the 
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regulation of coronary blood flow in lean, healthy 
subjects.1;136 However, the induction of MetS has 
been shown to attenuate BKCa channel-mediated 
vasodilation (Figure 1.12) and induce a 
paradoxical increase in BKCa channel 
expression.136 Decreases in spontaneous 
transient outward currents, which are indicative 
of BKCa channel activation have also been 
reported in coronary smooth muscle cells from 
diabetic dyslipidemic swine.137 Evidence also 
supports that coronary KATP channels are altered 
in the setting of obesity. In particular, the contribution of KATP channels to coronary 
vasodilation in response to brief coronary artery occlusion was reduced in obese 
compared to lean swine.119  
 In coronary smooth muscle cells, intracellular Ca+ regulates both contraction and 
gene expression. Thus, alterations in CaV1.2 channel activity, the predominant voltage-
dependent Ca+ channel in 
smooth muscle cells could 
contribute significantly to 
coronary vascular 
dysfunction. Both decreases 
in the functional expression 
of K+ channels and increases 
in vasoconstrictor pathway 
(e.g., α1-adrenoceptor) 
Figure 1.11 KV channel dysfunction 
in metabolic syndrome. Whole-cell 
voltage-dependent K+ current was 
impaired at currents consistent with KV 
channel activation (i.e., greater than 0 
mV) in coronary smooth muscle cells 
from metabolic syndrome (MetS) 
swine. Modified from Berwick et al., J 
Mol Cell Cardiol, 2012.21 
Figure 1.12 BKCa channel dysfunction in metabolic 
syndrome. Coronary smooth muscle cell current in 
response to the BKCa channel agonist, NS1619, was 
reduced in metabolic syndrome (MetS; left). Reductions in 
BKCa channel current correspond to diminished 
vasodilation to NS1619 in MetS swine (right). Modified 
from Berwick et al., J Mol Cell Cardiol, 2012.4 
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activation, both of which are well documented in 
obesity, would serve to augment CaV1.2 channel-
mediated coronary vasoconstriction. Initial studies in 
coronary smooth muscle from dyslipidemic swine 
documented reductions in CaV1.2 channel 
current.138;139 In contrast, other studies support that 
MetS is associated with increased CaV1.2 channel 
expression and activity as well as CaV1.2 channel 
agonist-mediated vasoconstriction (Figure 
1.13).1;4;140;141 Together, the present data support 
that alterations in the functional expression of both 
K+ and Ca2+ channels contribute to obesity-induced 
coronary microvascular dysfunction. At present, the 
precise mechanisms responsible for these alterations are under active investigation.  
 An understanding of the factors and cellular pathways that mediate the 
development of coronary vascular dysfunction is important, as microvascular dysfunction 
precedes overt atherosclerosis.142 Although larger conduit vessels, or macrovessels, 
contribute very little to the regulation of coronary blood flow,143 the macrovasculature is 
more prone to atherosclerosis.65 As described above, it is well understood that endothelial 
dysfunction initiates and exacerbates atherosclerotic disease. However, smooth muscle 
dysfunction also contributes to the progression of atherosclerosis. It should be noted that 
obesity is associated with alterations in several mechanisms of Ca2+ handling including 
impaired Ca2+ extrusion via the plasmalemma Ca2+ ATPase (PMCA), increased Ca2+ 
sequestration by the sarcoplasmic reticulum Ca2+ ATPase (SERCA), and increased 
nuclear Ca2+ localization.144 These changes in Ca2+ handling have been implicated in 
Figure 1.13 Increased CaV1.2 
channel-mediated coronary 
vasoconstriction in metabolic 
syndrome. Contractile responses to 
the CaV1.2 channel agonist, BayK 
8644, were augmented in coronary 
arteries from metabolic syndrome 
(MetS) swine. Modified from 
Borbouse et al., Am J Physiol Heart 
Circ Physiol, 2009.1 
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phenotypic modulation of smooth muscle cells, characterized by enhanced proliferation 
and migration,145;146 in obesity-induced coronary disease.144;147;148 
 Taken together, it is evident that obesity is associated with numerous deleterious 
effects on coronary endothelial and smooth muscle function and that the disruption of 
normal vascular function is central to the initiation and progression of coronary disease. 
Thus, potential effects of coronary PVAT-derived factors on vascular reactivity provide 
plausible mechanisms by which adipose tissue could influence the development of 
obesity-induced coronary disease. 
 
Vascular Effects of Perivascular Adipose Tissue 
Peripheral (non-cardiac) PVAT 
 Initial studies into the vascular effects of PVAT were conducted in peripheral (non-
cardiac) tissues. In 1991, Soltis and Cassis were the first to systematically investigate the 
hypothesis that PVAT influences vascular tone by comparing contractile responses of 
segments of rat aorta cleaned of adipose with those with the surrounding PVAT still intact. 
These studies revealed that vessels with PVAT intact were less responsive to 
norepinephrine, suggesting that PVAT was buffering the degree of vasoconstriction.149 
The next major discovery came in 2002 when Löhn et al. described an adipocyte-derived 
relaxing factor (ADRF), a vasoactive factor produced by perivascular adipocytes.5;150 The 
inhibitory, or “anti-contractile” effect of PVAT on contractile responses to angiotensin II 
confirmed the presence of ADRF in intact aortic rings (Figure 1.14).5;150;151 The presence 
of ADRF has also been detected in mesenteric arteries.152-154 Depending on the vascular 
bed, PVAT may stimulate endothelial dependent and/or independent vasodilation.5;155 
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Several transfer experiments have 
demonstrated that the these effects are in 
fact a result of the paracrine function of the 
tissue, rather than the absorption or 
blocking of vasoactive mediators,150;156;157 
and have established ADRF as a 
transferrable factor.5 While the majority of 
vasoreactivity studies have been 
conducted using murine tissues, studies of 
human internal thoracic and gluteal arteries 
have consistently documented an anti-
contractile response to PVAT.158-160 Several 
potential candidates for the anti-contractile 
factor (ADRF) have been identified including adiponectin,160;161 hydrogen sulfide,153;155 
angiotensin-(1-7), and hydrogen peroxide,151 although it is becoming increasingly 
apparent that likely more than one factor represents the ADRF. Regardless, it has been 
established that the end-effector mechanism of ADRF(s) is the opening of vascular 
smooth muscle K+ channels to illicit vasorelaxation.5;154;161;162 Furthermore, recent studies 
have delineated subtypes of K+ channels attributed to the anticontractile effect of PVAT, 
namely voltage-dependent KV7 (voltage-dependent K) channels,153;157;163 BKCa (large 
conductance calcium-activated K) channels,159;164 and Kir (inward-rectifying K) 
channels.151;165 It should be noted that, alternatively, peripheral PVAT has also been 
shown to potentiate contraction. Data indicate that PVAT augments contraction of 
mesenteric arteries to electric field stimulation via increased production of angiotensin II 
and superoxide.156;166 Other studies have also documented that PVAT from obese rodents 
attenuates endothelial-dependent vasodilation in aorta167 and mesenteric arteries.168;169 
Figure 1.14 Perivascular adipose tissue 
releases a relaxing factor. Contractile 
responses of rat aortic rings with 
surrounding fat intact (bottom) were 
significantly impaired relative to contractions 
in the absence of fat (top). Modified from 
Löhn et al., FASEB J, 2002.5 
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The adipokine chemerin has been implicated as a PVAT-derived constricting factor 
responsible for these effects in mesenteric and aortic vascular beds.170 Thus, present data 
support that peripheral (non-cardiac) PVAT is capable of producing factors that illicit both 
vasodilation and vasoconstriction. 
 
Coronary PVAT 
 Current data to support the vascular effects of coronary PVAT are rather limited 
and somewhat conflicting. Initial studies revealed that coronary PVAT diminishes 
endothelial-dependent dilation in vitro and in vivo in normal, healthy dogs.171;172 In contrast, 
coronary PVAT appears to have little/no effect on endothelial-dependent dilation in 
normal, lean swine.2;173;174 These disparate findings are likely related to species 
differences in adipokine expression, although they suggest a potential regulatory role for 
PVAT-derived factors in the healthy coronary circulation. In contrast, in the setting of 
coronary disease, Payne et al. demonstrated that MetS coronary PVAT markedly 
augments underlying endothelial dysfunction of isolated coronary arteries from swine with 
the MetS.2 Studies in both lean and hypercholesterolemic swine show little/no effect of 
coronary PVAT on contractile responses to endothelin-1, angiotensin II, or the 
thromboxane A2 mimetic U46619.2;173;174 Alternatively, a seminal study by Owen et al. 
revealed that the addition of lean coronary PVAT to isolated, clean (PVAT free) coronary 
arteries from lean swine potentiates contractile responses to KCl-induced depolarization 
and to prostaglandin F2α (PGF2α) in direct proportion to the amount of PVAT (Figure 
1.15).9 In this study, the effect of mesenteric PVAT on KCl contractions was similar to that 
of coronary PVAT, but subcutaneous adipose tissue had no effect on coronary 
vasoconstriction, highlighting the specificity of the adipose tissue depot.9 Bioassay 
22 
experiments also support that, similar to 
peripheral PVAT, the vascular effects of 
coronary PVAT are mediated via the 
paracrine production of a transferable 
factor(s). Interestingly, Owen et al. 
documented that the contractile effect of 
coronary PVAT was augmented in coronary 
arteries from obese versus lean swine.9 
Regardless of health status, coronary PVAT 
potentiated coronary artery contractions in 
both endothelium intact and denuded 
coronary arteries.9 Thus, it is hypothesized 
that the vascular effects of coronary PVAT are 
influenced by obesity due to alterations in the 
adipokine expression profile of PVAT and/or 
inherent phenotypic differences in coronary 
vascular smooth muscle.  
 Taken together, the current literature 
suggest that the vascular effects of PVAT are 
highly dependent on the anatomic location of 
the artery/adipose tissue depot, the species being studied, the pharmacological agonists 
used, and the underlying phenotype of the endothelium and smooth muscle in relation to 
the overall health status of the animal model being studied.9;17;175 In general, peripheral 
PVAT exerts anticontractile effects, while recent data suggest that coronary PVAT induces 
vasoconstrictor effects on both endothelial-dependent dilation and depolarization-induced 
Figure 1.15 Coronary perivascular 
adipose tissue potentiates coronary 
artery contractions. Representative wire 
myograph tracing of tension generated by 
coronary arteries in response to 
prostaglandin F2α (PGF2α) and the 
addition of perivascular adipose tissue 
(PVAT) to the organ bath (top). Active 
tension development stimulated by 
coronary PVAT was proportional to the 
amount of PVAT added and was 
significantly augmented in swine with 
metabolic syndrome (MetS). Modified 
from Owen et al., Circulation, 2013.9 
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contraction, although the specific factors and cellular mechanisms responsible for these 
effects are not well understood.  
 
Expression Profiles in Coronary PVAT 
 Recent evidence supports that there are substantial differences in gene and 
protein expression among adipose tissue depots depending on anatomic location. Results 
from Baker et al. and Cheng et al. were among the first to document adipokine expression 
profiles from human coronary PVAT and found augmented expression of leptin, TNF-α, 
and IL-6 in coronary relative to abdominal adipose tissue.176;177 Significant macrophage 
infiltration was also reported, suggesting an increased inflammation.177 Recent data from 
the Weintraub laboratory indicate that adipocytes from human coronary PVAT exhibit 
augmented gene expression and secretion of pro-inflammatory cytokines such as IL-6, IL-
8, and MCP-1 compared to other adipose tissue depots and in the presence of coronary 
artery disease73;75 (Table 1.1). Additional studies support that this heightened pro-
inflammatory environment of coronary PVAT is markedly exacerbated in the setting of 
obesity and with the progression of coronary artery disease.2;9;48;178  
 Overall, evidence is mounting in support of marked upregulation of pro-atherogenic 
adipokine expression profiles in coronary PVAT in the setting of obesity-induced coronary 
disesase.9;15;73;177 In particular, increased expression of pro-atherogenic factors including 
leptin, resistin, TNF-α, IL-6, chemerin, and calpastatin have been identified to 
date.2;9;170;176;177;179 Interestingly, expression of the osteogenic factors osteoprotegerin and 
osteoglycin, which have been linked to atherosclerosis and the severity of coronary artery 
disease,18;180 were recently identified in coronary PVAT.9;73 Furthermore, diminished 
expression of potentially vasculoprotective adipokines such as adiponectin, which is 
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associated with improvements in endothelial function,60 is well established in human 
coronary PVAT in the setting of obesity and coronary artery disease.177;181;182 This aberrant 
regulation of coronary PVAT correlates with the well-documented underlying vascular 
dysfunction observed in obesity-induced coronary disease.4;9;101;171;177;183 Thus, there is a 
strong and growing body of evidence to support that coronary PVAT has the potential to 
locally produce factors (i.e., independent of changes in visceral adipose tissue and/or 
circulating adipokine levels) that directly influence the initiation and progression of 
coronary vascular dysfunction and disease. 
 
Table 1.1 Adipokine expression of coronary perivascular relative to subcutaneous 
adipose tissue in health and coronary artery disease. 
Adipokine Condition 
Coronary PVAT Expression 
Relative to Subcutaneous 
References 
Leptin NCAD ↓ mRNA 75 
 CAD ↓ mRNA 176 
Adiponectin NCAD ↓ mRNA, ↓ protein secretion 75 
 CAD ↑ protein secretion 177 
TNF-α NCAD+CAD ↑ mRNA 179 
 CAD ↑ mRNA, ↑ protein secretion 184 
  ↓ protein secretion 177 
IL-6 NCAD ↑ mRNA 75 
 NCAD+CAD ↑ mRNA 179 
 CAD ↓ mRNA 176 
  ↑ protein secretion 184 
IL-1β NCAD+CAD ↑ mRNA 179 
 CAD ↑ mRNA, ↑ protein secretion 184 
MCP-1 NCAD ↑ protein secretion 75 
 NCAD+CAD ↑ mRNA 179 
 CAD ↑ mRNA, ↑ protein secretion 184 
PAI-1 CAD ↓ mRNA 176 
CAD indicates coronary artery disease; NCAD, no coronary artery disease; NCAD+CAD, 
group populations. ↑ indicates significant increase in expression in coronary perivascular 
adipose tissue (PVAT); ↓ indicates significant decrease in expression; TNF-α, tumor 
necrosis factor-alpha; IL-6, interleukin, 6; IL-1β, interleukin-1 beta; MCP-1, monocyte 
chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1. Modified from Owen 
et al., Arterioscler Thromb Vasc Biol, 2014.17 
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 It is important to consider how 
factors produced by coronary PVAT are 
able to traverse the arterial wall to influence 
the endothelium and vascular smooth 
muscle. The prevailing hypothesis is that 
the vasa vasorum, a network of small blood 
vessels that is interspersed within the 
PVAT and supplies blood to the walls of 
large blood vessels,185-187 serves as a 
potential conduit (Figure 1.16). This 
hypothesis is supported by Herrmann et al. 
which demonstrated that increases in coronary vasa vasorum neovascularization precede 
the development of coronary endothelial dysfunction in swine fed a high cholesterol diet.185 
These findings have been confirmed in human patient populations, with several studies 
documenting an association between neovascularization of the vasa vasorum with the 
extent of inflammation and coronary disease.188;189 Although the association between the 
expansion of the coronary vasa vasorum and the development of atherosclerosis is 
intriguing, the transit of PVAT-derived factors across the coronary wall continues to be an 
active area of research.  
 One adipose-derived factor that has received significant attention is leptin. 
Produced and secreted predominantly from adipose tissue, leptin was initially implicated 
in the regulation of energy balance and metabolism.190;191 Since its discovery, a significant 
research effort has focused on elucidating the effects of leptin on the cardiovascular 
system. In the setting of obesity, plasma leptin concentrations can rise from normal, 
healthy levels of 3-5 ng/mL to as high as 90-95 ng/mL (typical range 8-90 ng/mL).192  An 
Figure 1.16 The coronary vasa vasorum. 
Epicardial adipokines may be delivered to 
the vessel wall via paracrine signaling by 
diffusing through the interstitial fluid (1) or via 
vasocrine signaling through the network of 
blood vessels supplying the vessel wall, the 
vasa vasorum (2).20 
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elevated plasma leptin level (hyperleptinemia) is nearly universal in obese humans191 and 
is a key component of the MetS.38;39 Thus, hyperleptinemia is also independent risk factor 
for cardiovascular disease.193 Importantly, leptin receptors (ObRb) are expressed in 
endothelial cells and smooth muscle cells and have been detected throughout the wall of 
diseased coronary arteries.2;70;194 Leptin has been implicated in several key aspects of 
atherogenesis including chemoattraction of circulating myocytes,195 accumulation of 
cholesterol esters in foam cells,196 and vascular smooth muscle cell proliferation.197;198 
Leptin has also been shown to have vasomotor effects on the coronary circulation. 
Although initial studies suggested that leptin stimulates endothelium-dependent 
vasodilation, the vast majority of these studies were conducted using concentrations of 
leptin well above both physiologic and pathophysiologic plasma concentrations.16 A study 
by Knudson et al. revealed that, in the coronary circulation, endothelial-dependent dilation 
only occurs at concentrations above those documented in obese humans (>160 ng/mL).194 
Interestingly, Knudson et al. also demonstrated that while healthy (normal physiologic) 
concentrations of leptin have no effect, “obese” concentrations of leptin (i.e. plasma 
concentrations typically observed in obese subjects) impair endothelial-dependent dilation 
to acetylcholine both in vitro and in vivo (Figure 1.17).194  
 Mounting evidence suggests that PVAT-derived leptin may locally contribute to 
obesity-associated coronary disease. Several studies have documented increased leptin 
mRNA and protein expression in coronary PVAT from obese subjects with evidence of 
coronary artery disease.177;179;181;199 Interestingly, no correlation between plasma leptin 
concentration and PVAT leptin mRNA expression has been observed.179;200 This suggests 
that alterations in the PVAT adipokine profile are not necessarily a result of increased 
global adiposity and the potential for the effects of local PVAT-derived leptin to occur 
independently from those of circulating plasma leptin. This is supported by recent studies  
27 
in obese swine in which the exacerbation of endothelial dysfunction by obese PVAT was 
significantly reversed by the inhibition of leptin signaling, implicating PVAT-derived leptin 
in mediating endothelial dysfunction in the coronary circulation (Figure 1.18).2  
 An imbalance between pro-atherogenic 
adipokines (i.e., leptin) and anti-atherogenic 
adipokines could activate key regulatory 
pathways, such as endothelial dysfunction, that 
promote obesity-induced coronary disease 
(Figure 1.19). The anti-atherogenic adipokine 
adiponectin has been shown to increase NO 
bioavailability and stimulate endothelial-
dependent vasodilation in gluteal arteries from 
healthy patients, but data indicate that this effect 
is lost in the setting of obesity/MetS.160 This loss 
of function of adiponectin, along with the 
reduction in adiponectin expression in obese 
Figure 1.17 Leptin impairs coronary endothelial-dependent dilation in 
vitro and in vivo. Leptin impaired endothelial-dependent vasodilation of 
isolated canine coronary arteries to acetylcholine (ACh) at a concentration of 
10 ng/mL but not 4 ng/mL (left). In open chest anesthetized dogs, 
concentrations of leptin in the obese range attenuated coronary vasodilation 
to acetylcholine (right). Modified from Knudson et al., Exp Biol Med 
(Maywood), 2007.16 
Figure 1.18 Coronary perivascular 
adipose-derived leptin exacerbates 
endothelial dysfunction. Endothelial-
dependent vasodilation to bradykinin 
is impaired in coronary arteries from 
metabolic syndrome (MetS) swine. 
This endothelial dysfunction was 
exacerbated in the presence of 
perivascular adipose tissue (PVAT) 
from the same animal. Addition of a 
pegylated leptin antagonist to inhibit 
leptin signaling significantly improved 
dilation to bradykinin.   Modified from 
Payne et al., Arterioscler Thromb Vasc 
Biol, 2010.2 
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coronary PVAT, could 
facilitate inflammation, 
endothelial dysfunction and 
atherogenesis.177;182;201 
Recent evidence that 
recombinant adiponectin 
administration reversed 
obese PVAT-mediated 
atherogenic changes in 
endothelial cells, including 
the increased expression of 
endothelial cell adhesion 
molecules, support this hypothesis.201 Together, these findings implicate the down-
regulation of coronary PVAT adiponectin expression along with the up-regulation of PVAT-
derived leptin expression in the pathogenesis of coronary vascular dysfunction and 
disease.  
 Data regarding the effect of leptin on vascular smooth muscle function, particularly 
in the coronary circulation, are limited. In parallel to the early disparate findings on 
endothelial function, studies have documented either a modest anti-contractile effect or 
no effect on smooth muscle contraction in peripheral (non-coronary) arteries.202-204 
Evidence also points to effects of leptin on vascular smooth muscle proliferation. Barandier 
et al. demonstrated that obese PVAT stimulates aortic smooth muscle proliferation in 
healthy rats but not in leptin-receptor deficient Zucker rats.205  Recent data also suggest 
that perivascular overexpression of leptin promotes neointima formation after carotid 
artery wire injury in mice.206;207 Although these findings suggest the potential for leptin to 
Figure 1.19 Imbalance between leptin and adiponectin 
as an upstream mediator of atherogenesis. In the setting 
of obesity, increased expression of leptin and diminished 
expression of adiponectin in coronary PVAT is associated 
with the activation of several complex atherogenic 
pathways. CRP, C-reactive protein; IL, interleukin-1 and 6; 
TNFα, tumor necrosis factor-alpha; oxLDL, oxidized low 
density lipoprotein.15 
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influence smooth muscle contraction and proliferation, the effects of leptin on coronary 
vascular smooth muscle function are still unclear. Overall, studies to directly investigate a 
causal role for PVAT-derived leptin in the pathogenesis of coronary disease are needed. 
 Another coronary PVAT-derived adipokine of particular interest is calpastatin. A 
recent global proteomic screening of coronary PVAT in lean versus obese swine revealed 
a significant upregulation of calpastatin fragments in obese PVAT.9 Calpastatin, an 
endogenous calpain inhibitor, has been suggested to be a partial agonist of CaV1.2 
channels, although the precise mechanisms by which the peptide interacts with the 
channel and regulates its activity have not been clearly defined.208-210 Owen et al. 
documented that calpastatin dose-dependently augments coronary artery contractions to 
a similar degree as that observed in response to coronary PVAT.9 Although these initial 
findings suggest that calpastatin is a PVAT-derived constricting factor, the vascular effects 
of calpastatin warrant further investigation.  
 
Pathways Influenced by Coronary Perivascular Adipose Tissue 
 Recent investigations provide insight into potential mechanisms responsible for 
PVAT-induced coronary vascular dysfunction. As outlined above, initial studies of the 
vascular effects of coronary PVAT demonstrated that adipokines (i.e., leptin, adiponectin) 
produced by this depot influence endothelial-dependent vasodilation, especially in the 
setting of obesity.2;194 The mechanism of this impairment was initially described as a 
reduction in nitric oxide (NO) production via the inhibition of endothelial nitric oxide 
synthase (eNOS).171 Further examination revealed protein kinase C (PKC)-β dependent, 
site-specific phosphorylation of eNOS at the Thr495 inhibitory site.172 This mechanism is 
supported by additional studies in which the inhibition of PKC-β with ruboxistaurin 
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abrogated the endothelial effects of obese coronary PVAT.2 These particular findings are 
consistent with other studies documenting leptin-induced activation of PKC-β211 and are 
corroborated by reported increases in PKC-β activation in the setting of obesity.212-214 An 
apparent loss of function of PVAT-derived adiponectin also contributes to endothelial 
dysfunction in obesity. This loss of function may be a result of decreased adiponectin 
levels and/or downregulation of adiponectin receptors,215 although the exact cause 
remains unclear. Regardless, several studies demonstrate that administration of 
adiponectin improves endothelial function via adenosine monophosphate-activated 
protein kinase (AMPK)-induced phosphorylation of eNOS.216;217 Thus, alterations in this 
signaling pathway may also contribute to the development of endothelial dysfunction.  
 Evidence regarding the mechanistic effects of coronary PVAT derived factors on 
vascular smooth muscle are much more limited. Owen et al. proposed that coronary PVAT 
potentiates coronary artery contractions via activation of voltage-dependent ion channels 
(i.e., CaV1.2 channels). The augmented contractile effect of obese coronary PVAT is 
consistent with reports of increased coronary vascular smooth muscle CaV1.2 current and 
vasoconstriction in the setting of obesity.1;21;141 It has also been proposed that PVAT-
derived factors inhibit vascular smooth muscle K+ channels. This is supported by studies 
in which H2O2-induced dilation of coronary arteries, which was completely abolished by 
pre-constriction with KCl, was markedly attenuated in the presence of coronary PVAT.9 
Importantly, inhibitory effects on K+ channels would also serve to activate CaV1.2 channels 
and augment coronary artery contractions. However, the effects of coronary PVAT on 
smooth muscle K+ channels and the precise K+ channel subtypes involved warrant further 
investigation. 
 A proteomic assessment of coronary PVAT from lean and obese swine indicated 
that coronary PVAT produces factors capable of influencing several key regulatory 
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pathways including cellular growth and 
proliferation, and cellular movement.9 
Interestingly, RhoA was significantly 
elevated in samples from obese coronary 
PVAT.9 RhoA is a molecular GTPase 
regulatory switch that interacts with 
downstream effectors, such as Rho kinase, 
to elicit cellular responses.218 Rho kinases 
regulate a variety of cellular functions such 
as contraction, motility, and proliferation.219 
In smooth muscle, contraction is regulated 
by the phosphorylation/dephosphorylation 
of myosin light chain via Ca2+-dependent 
(i.e., rise in cytosolic Ca2+) and Ca2+-
independent mechanisms.220 The inhibitory phosphorylation of myosin light chain 
phosphatase by Rho kinase sensitizes the contractile apparatus to Ca2+ and allows for 
agonist-induced contraction independent of changes in cytosolic Ca2+ concentration.221 
Interrogation of the Rho kinase pathway in coronary arteries (Figure 1.20) indicated that 
PVAT-derived factors potentiate vasoconstriction via a Rho kinase-dependent mechanism 
in lean arteries, while PVAT mediated increases in contraction in the setting of obesity 
occur via Rho-independent pathways (i.e., functional alterations in CaV1.2 and/or K+ 
channels).9  
 Numerous studies also implicate Rho kinase in several mechanisms of 
atherogenesis including vascular smooth muscle proliferation and migration. In particular, 
Rho kinase signaling has been implicated in both platelet-derived growth factor(PGDF)-
Figure 1.20 Effects of Rho kinase 
signaling on the vascular effects of 
coronary PVAT. Addition of the Rho kinase 
inhibitor, fasudil, significantly reduced the 
contractile effect of PVAT in isolated 
coronary arteries from lean, but not obese 
swine. The difference in tension generated 
by each isolated porcine coronary artery 
before and after the addition of perivascular 
adipose tissue (PVAT) is expressed as delta 
active tension. Modified from Owen et al., 
2013.9 
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stimulated and G-protein-coupled receptor (i.e. thrombin)-induced proliferation of vascular 
smooth muscle cells.222;223 A potential mechanism by which Rho kinase may regulate 
smooth muscle cell proliferation involves the activation of extracellular-regulated kinase 
1/2 (ERK 1/2), as inhibition of Rho kinase has been found to suppress PDGF-induced 
activation of ERK1/2.222 In animal models of vascular injury, the inhibition of Rho kinase 
has been shown to reduce intimal hyperplasia via effects on smooth muscle 
proliferation.224;225 Other studies, however, suggest that Rho kinase influences neointimal 
formation primarily via effects on apoptosis and vascular inflammation and fail to 
demonstrate a substantial role for Rho kinase in smooth muscle cell proliferation.226;227 
Importantly, the present studies have been conducted in peripheral (non-coronary) 
vascular beds and thus the involvement of Rho kinase in coronary smooth muscle cell 
proliferation remains to be elucidated. Altogether, these observations support that the role 
of Rho kinase signaling in vascular smooth muscle cell proliferation and the potential 
upstream atherogenic factors responsible for activating this pathway require further 
investigation. 
 
Summary and Proposed Experimental Aims 
 The pandemic of obesity is an urgent global healthcare crisis. Particularly alarming 
is the dramatically increased risk of cardiovascular disease associated with obesity. While 
many studies have resulted in significant improvements in the ability to manage and 
mitigate obesity-induced cardiovascular complications, current understanding of the 
causal link between obesity and coronary artery disease remains rather limited.  Such 
understanding is needed in order to elucidate potential therapeutic targets for the effective 
treatment and perhaps prevention of obesity-induced coronary disease.  
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 To that end, many investigations have demonstrated that adipose tissue is an 
endocrine and paracrine organ, producing adipokines that have the potential to influence 
several mechanisms of atherogenesis, namely vascular dysfunction, in the setting of 
obesity. Recent data implicate the adipose tissue depot surrounding the vasculature, 
PVAT, in the pathogenesis of vascular disease. In particular, coronary PVAT, which 
immediately surrounds the large coronary arteries of the heart, has been identified as a 
risk factor for coronary artery disease. 
 A growing body of evidence supports that changes in the adipokine expression 
profile of coronary PVAT occur concomitantly with phenotypic alterations in the coronary 
endothelium and vascular smooth muscle in the setting of obesity (Figure 1.21).  
However, the contribution of PVAT-derived factors (e.g., leptin) to the initiation and 
progression of coronary vascular dysfunction and disease is still not well understood. 
Accordingly, the goal of this investigation is to delineate the mechanisms by which PVAT-
derived factors influence coronary vascular smooth muscle function and the development 
of obesity-induced coronary disease. This goal will be directly addressed by the following 
Specific Aims: 
1. Delineate the mechanisms by which lean versus obese coronary PVAT 
influences coronary vascular smooth muscle reactivity. Rationale for Aim 1 is 
based on recent findings suggesting that the vascular effects of coronary PVAT 
are related to alterations in the functional expression of smooth muscle K+ 
channels in the setting of obesity. Studies will test the hypothesis that lean and 
obese PVAT differentially attenuates KCa, KV, and KATP channel-mediated 
vasodilation in the coronary circulation.  
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2. Test the hypothesis that leptin acts as an upstream mediator in the 
development of coronary vascular smooth muscle dysfunction and disease. 
Rationale for Aim 2 is based on evidence that coronary PVAT-derived factors 
potentiate contraction of vascular smooth muscle via a Rho kinase-dependent 
mechanism and that PVAT-derived leptin impairs coronary vasodilation and 
promotes neointima formation. Studies will test the hypothesis that leptin promotes 
progressive alterations in coronary smooth muscle contraction via alterations in 
Rho kinase signaling and markedly alters the coronary artery proteome in favor of 
pathways associated with the initiation and progression of coronary artery disease.  
  
Figure 1.21 Alterations in coronary perivascular adipose tissue (PVAT)-derived 
adipokines and potential downstream effector mechanisms in endothelium and 
vascular smooth muscle. Coronary PVAT-derived leptin diminishes endothelial nitric 
oxide synthase (eNOS) activity, reducing nitric oxide (NO)-mediated dilation of vascular 
smooth muscle via K+ channel activation and contributes to the recruitment and retention 
of macrophages. Adipose-derived constricting factors (ADCF), such as calpastatin and 
other presently unknown factors, increase vasodilation via activation of CaV1.2 channels, 
inhibition of K+ channels, and/or alterations in Rho kinase signaling. Production of other 
adipokines that may play a role in endothelial and smooth muscle dysfunction include, but 
are not limited to, increased resistin, chemerin, osteoglycin and osteoprotegerin, and 
decreased adiponectin. H2O2, hydrogen peroxide; TNF, tumor necrosis factor.17 
35 
Chapter 2 
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ABSTRACT 
Objective – The effects of coronary perivascular adipose tissue (PVAT) on vasomotor tone 
are influenced by an obese phenotype and are distinct from other adipose tissue depots. 
The purpose of this investigation was to examine the effects of lean and obese coronary 
PVAT on end-effector mechanisms of coronary vasodilation and to identify potential 
factors involved.  
Approach and Results – Hematoxylin and eosin staining revealed similarities in coronary 
perivascular adipocyte size between lean and obese Ossabaw swine. Isometric tension 
studies of isolated coronary arteries from Ossabaw swine revealed that factors derived 
from lean and obese coronary PVAT attenuated vasodilation to adenosine. Lean coronary 
PVAT inhibited KCa and KV7, but not KATP channel mediated dilation in lean arteries. In the 
absence of PVAT, vasodilation to KCa and KV7 channel activation was impaired in obese 
arteries relative to lean arteries. Obese PVAT had no effect on KCa or KV7 channel 
mediated dilation in obese arteries. In contrast, obese PVAT inhibited KATP channel 
mediated dilation in both lean and obese arteries. The differential effects of obese versus 
lean PVAT were not associated with changes in either coronary KV7 or KATP channel 
expression. Incubation with calpastatin attenuated coronary vasodilation to adenosine in 
lean but not obese arteries.  
Conclusions – These findings indicate that lean and obese coronary PVAT attenuates 
vasodilation via inhibitory effects on vascular smooth muscle K+ channels and that 
alterations in specific factors such as calpastatin are capable of contributing to the initiation 
and/or progression of smooth muscle dysfunction in obesity. 
 
Nonstandard Abbreviations and Acronyms 
PVAT – perivascular adipose tissue 
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INTRODUCTION 
 Perivascular adipose tissue (PVAT) surrounds large arteries throughout the body 
and is capable of producing adipokines that act directly upon the adjacent 
vasculature.17;228 PVAT-derived factors have been shown to stimulate chemotaxis, 
inflammation, and endothelial dysfunction, thereby implicating local PVAT signaling in the 
initiation and progression of vascular disease.2;56;83;91;171;172 Data from recent studies 
investigating vascular responses to PVAT-derived factors suggest that the endothelial and 
smooth muscle effects of these substances are highly dependent on anatomic location of 
the adipose/vascular depot and the underlying disease state of the subjects from which 
the tissues were obtained.17 Such discrepant phenotypic effects of PVAT are not 
surprising given marked differences in protein expression and secretion profiles of adipose 
tissue depots from lean versus obese subjects.9;73;75;101;176;177;181 However, current 
understanding of how these alterations influence mechanisms of vascular function 
remains limited.  
 Differences in the vascular effects of PVAT-derived factors are evident when 
comparing peripheral (non-cardiac) versus coronary-cardiac PVAT. In particular, 
aortic,150;229 mesenteric,153;154 and internal thoracic artery158;159 PVAT have been shown to 
significantly diminish contractile responses to a variety of agonists. This vasodilator or 
“anti-contractile” effect is attributed to production of adipose-derived relaxing factor(s) 
(ADRF(s)) that promote endothelial dependent and/or independent vasodilation via 
activation of voltage-dependent KV7 channels,153 BKCa channels,159;164 and Kir channels.151 
In contrast, factors released from coronary PVAT have been shown to attenuate 
endothelial-dependent dilation171;172 and potentiate coronary artery contractions.9 These 
deleterious effects of coronary PVAT are augmented in the setting of obesity and are 
directly associated with marked alterations in the coronary PVAT proteome and the 
functional expression of coronary K+ and Ca2+ channels.1;9;21 Specifically, our laboratory 
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has recently demonstrated that the endogenous calpain inhibitor calpastatin208;230 is 
significantly elevated in the secreted protein expression profile of obese coronary PVAT 
and is sufficient to dose-dependently augment coronary artery contractions in the absence 
of PVAT.9 Obesity has also been found to diminish the contribution of end-effector K+ 
channels to coronary vasodilator responses.4 These channels include voltage-dependent 
(KV), Ca2+-activated (KCa), and ATP-sensitive (KATP) channels, which regulate smooth 
muscle membrane potential and participate in the regulation of coronary vascular 
resistance.129 However, the extent to which coronary PVAT-derived factors modulate the 
role of these channels has not been investigated.    
 Accordingly, the purpose of this investigation was to delineate the effects of lean 
and obese coronary PVAT on end-effector mechanisms of coronary vasodilation and to 
identify potential PVAT-derived factors involved. Studies were specifically designed to test 
the hypothesis that lean and obese PVAT differentially attenuate KCa, KV, and KATP channel 
mediated vasodilation in the coronary circulation and that calpastatin contributes to these 
effects. Findings from this investigation add to growing evidence supporting a role for 
PVAT in the pathogenesis of vascular dysfunction in obesity-induced coronary disease. 
 
MATERIALS AND METHODS 
Ossabaw Swine Model of Obesity 
 All experimental protocols and procedures were approved by the Institutional 
Animal Care and Use Committee in accordance with the Guide for the Care and Use of 
Laboratory Animals. Lean Ossabaw swine (n=30) were fed ~2000 kcal/day standard chow 
containing 18% kcal from protein, 71% kcal from complex carbohydrates, and 11% kcal 
from fat. Obese Ossabaw swine (n=28) were fed  ≥8000 kcal/day atherogenic diet 
containing 16% kcal from protein 41% kcal from complex carbohydrates, 43% kcal from 
fat, and supplemented with 2.0% cholesterol and 0.7% sodium cholate by weight (5L80 
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and KT324, Purina Test Diet, Richmond, IN). Swine were fed their respective diets for ~6 
months prior to sacrifice.  
 
Immunohistochemistry 
 Immunohistochemical analyses were performed in conjunction with Indiana 
University Health Pathology Laboratory (Indianapolis, IN). Briefly, hearts from lean and 
obese swine were excised upon sacrifice and immediately perfused with 4°C, Ca2+-free 
Krebs buffer (131.5 mM NaCl, 5 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 25 mM 
NaHCO3, 10 mM glucose) via aortic cannulation. Segments of coronary arteries with 
perivascular adipose tissue (PVAT) intact were grossly dissected from the heart and 
placed in 10% Formalin (Fisher Scientific, Fair Lawn, NJ, SF98-4). Similar segments of 
coronary artery were harvested from a formalin fixed human heart obtained via Indiana 
University Health Pathology Laboratory (Indianapolis, IN) and with approval of the 
Institutional Review Board of Indiana University (IRB #1306011568). Fixed artery 
segments were embedded in paraffin and cross sectioned. Verhoeff-van Gieson (VVG) 
and Hematoxylin and Eosin (H&E) staining were performed. Additionally, sections were 
exposed to anti-CD163 antibody (1:100; Abcam, Cambridge, MA, ab87099), a marker for 
cells of the monocyte/macrophage lineage231 and anti-Rabbit IgG (1:100; Abcam, 
Cambridge, MA, ab172730) as an isotype control. Slides were imaged at 4X or 10X 
magnification, as indicated, on a Nikon Eclipse 80i microscope and images captured with 
a Nikon DS-Fi1 and associated Nikon Elements software. Linear adjustments of contrast, 
applied equally to all parts of an image, were made using ImageJ software Fiji.232 
Diameters of adipocytes within 500 µm of the vessel wall were determined using Leica 
image processing system. 
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Functional Assessment of Isolated Coronary Rings 
 Functional studies on isolated coronary artery rings were performed as previously 
described.2;9 After the perfusion described above, coronary arteries from lean and obese 
swine were grossly dissected from the heart (Figure 2.1A), removed from the myocardium 
(Figure 2.1B) and cleaned of surrounding coronary PVAT (Figure 2.1C). Subsequently, 
coronary PVAT was cut into ~50 mg pieces and stored in Ca2+-free Krebs buffer at 4°C 
for later use. Cleaned coronary arteries were cut into 3 mm rings and mounted in organ 
baths filled with Ca2+-containing Krebs buffer (131.5 mM NaCl, 5 mM KCl, 1.2 mM 
NaH2PO4, 1.2 mM MgCl2, 25 mM NaHCO3, 10 mM glucose, 4mM CaCl2) at 37°C. Once 
stabilized at optimal passive tension (~4 g), arteries were subjected to the experimental 
protocols outlined below.  
 Lean and obese coronary arteries were incubated with coronary PVAT from the 
same animal (Figure 2.2B and 2.2C), or left untreated as time-control (Figure 2.2A and 
2.2D) for 30 minutes at 37°C. For arteries incubated with PVAT, 0.3 g of PVAT (~50 mg 
pieces) was weighed and then added directly to the organ bath, as previously described.2;9  
Arteries were then pre-constricted with the thromboxane A2 mimetic, U46619 (1 µM: Santa 
Cruz Biotechnology, Dallas, TX, sc-201242) or KCl (60 mM: Sigma Aldrich, St. Louis, MO, 
P9333), indicated as “KCl control” in (Figure 2.4). Active tension development (peak 
tension minus baseline tension) was recorded for each treatment group. Upon stabilization 
of contractions, arteries were exposed to increasing concentrations of adenosine (10 nM 
Figure 2.1 Representative pictures illustrating the isolation of coronary artery rings 
and perivascular adipose tissue (PVAT) from lean and obese hearts prior to isometric 
tension studies. Images adapted from Owen et al.,9 with permissions from Wolters Kluwer 
Health Publishing. Copyright 2013, Circulation. 
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– 30 µM: Sigma Aldrich, St. Louis, MO, 
A9251), the KCa channel agonist NS-1619 
(1 µM – 30 µM: Sigma Aldrich, St. Louis, 
MO, N170), the KV7 channel agonist L-
364,373 (10 nM – 10 µM: Tocris, 
Minneapolis, MN, Cat.No.2660), or the 
KATP channel agonist cromakalim (30 nM 
– 1 µM: Sigma Aldrich, St. Louis, MO, 
C1055). For crossover experiments 
(Figure 2.8), lean arteries cleaned of 
PVAT, indicated as “control” were 
incubated with known quantities (0.3 g) of 
either lean PVAT from the same animal, 
indicated as “lean PVAT,” or obese PVAT 
from an obese animal sacrificed on the 
same day, indicated as “obese PVAT” (Figure 2.2). For calpastatin studies, both lean and 
obese coronary arteries cleaned of PVAT were incubated with calpastatin (10 µM: 
Calbiochem, San Diego, CA, Cat#208902), or left untreated as control for 30 minutes at 
37°C. Arteries were then pre-constricted with U46619 (1 µM) and exposed to increasing 
concentrations of adenosine (10 nM – 30 µM) in the presence or absence of calpastatin. 
Additional experiments were also conducted in endothelium denuded coronary arteries 
from lean swine. The endothelium was removed by gently rubbing fine-tip forceps along 
the lumen of the artery. Denudation was confirmed by <15% relaxation to bradykinin (1µM: 
Sigma Aldrich, St. Louis, MO, B3259). Results are reported as the percent relaxation for 
each animal and rings with the same treatment from the same animal were averaged for 
Figure 2.2 Experimental design for 
isometric tension studies. Illustrations 
correspond to studies presented in Figure 2.5 
and Figure 2.6. 
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n = 1. One hundred percent relaxation is defined as a return to the level of baseline 
tension.  
 
Western Analysis 
 Coronary arteries from lean (n=3) and obese (n=3) swine were cleaned of adipose 
tissue, frozen in liquid N2 and stored at -80°C.  Arteries were homogenized and total 
protein collected and quantified as previously described.233 Equivalent amounts of protein 
were loaded onto 10% polyacrylamide gels (Life Technologies, Carlsbad, CA, NP0302) 
for electrophoresis and blotting. Membranes were incubated overnight at 4°C with primary 
antibodies directed against Kir6.1 (1:200, Santa Cruz Biotechnology, Dallas, TX, sc-
11224) or KCNQ1 (1:400, Sigma-Aldrich, St. Louis, MO, AV35529). The blots were 
washed and incubated with donkey anti-goat (1:5000, Santa Cruz Biotechnology, Dallas, 
TX, sc-2020) or goat anti-rabbit (1:1000, Santa Cruz Biotechnology, Dallas, TX, sc-2004) 
IgG-horseradish peroxidase secondary antibodies for 1.5 h at ambient temperature. To 
verify equal protein loading, membranes were washed and incubated with antibody to β-
actin (1:200, Santa Cruz Biotechnology, Dallas, TX, sc-1616). Immunoreactivity was 
visualized using ECL (Thermo Scientific, Rockford, IL, Prod#32106) and the G:BOX 
system (Syngene).   MagicMark XP Western Standard (Life Technologies, Carlsbad, CA, 
LC5602) was used as a protein ladder. Densitometry analyses were conducted using 
Figure 2.3 Experimental design for crossover isometric tension 
studies. Illustrations correspond to studies presented in Figure 2.8. 
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ImageJ. Protein levels of KCNQ1, Kir6.1, and β-actin are reported as “% lean;” i.e. protein 
levels from each sample were normalized to the average level of the respective protein in 
lean arteries.   
 
Statistical Analysis 
 Data are presented as mean ± SE. A t-test was used to compare phenotypic data 
(lean vs. obese) and densitometry of Western blot analyses.  For isometric tension studies, 
a two-way ANOVA was used to test the effects of PVAT (Factor A) relative to doses of 
specific treatments (Factor B). If assumptions of normality and equal variance for 
parametric ANOVA were not met, a Kruskal-Wallis non-parametric ANOVA was 
performed.  Importantly, results of non-parametric ANOVAs were consistent with those of 
the parametric ANOVA.  When statistical differences were found with ANOVA (P < 0.05), 
a Student-Newman-Keuls multiple comparison test was performed. SigmaPlot version 
11.0 (Systat Software Inc, San Jose, CA) was used for graphics and statistical analyses.  
 
RESULTS 
Phenotype of Lean and Obese Ossabaw Swine 
 Compared to their lean counterparts, obese swine exhibited significant increases  
in body weight, fasting glucose, total cholesterol, and triglycerides (Table 2.1). 
Histopathological analyses to examine the morphology of perivascular adipocytes were 
performed on sections of coronary arteries with the adjacent PVAT intact. Hematoxylin 
and eosin staining revealed apparent similarities in perivascular adipocyte size between 
lean (Figure 2.4A) and obese (Figure 2.4B) swine. Specifically, adipocyte diameter 
averaged 70 ± 1 µm in lean and 67 ± 2 µm in obese swine (P = 0.24). These values are 
consistent with measures of coronary perivascular adipocyte diameter (Figure 2.4C, 
average = 66 ± 2 µm, n =2) from human subjects with evidence of coronary artery disease  
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(Figure 2.4F). Verhoeff-van Gieson elastin stain demonstrated the presence of atheroma 
formation in obese (Figure 2.4E) compared to lean (Figure 2.4D) swine. These data are 
consistent with findings from other studies from our investigative team which documented 
~15-20% stenosis of major coronary arteries (using intravascular ultrasound) in obese 
Ossabaw swine.234-236 Immunostaining for CD163, a marker for cells of the 
monocyte/macrophage lineage,231 revealed prominent staining in the medial layer of 
obese arteries (Figure 2.4I) with only modest staining evident in lean arteries (Figure 
2.4H) relative to isotype control (Figure 2.4G). These findings are consistent with prior 
reports of inflammation in coronary arteries from obese swine.237  
 
Lean and Obese PVAT Attenuate Coronary Vasodilation  
 To initially examine the effects of PVAT on vasodilation, coronary arteries cleaned 
of surrounding PVAT from lean and obese swine were incubated with or without a known 
quantity of coronary PVAT (0.3 g) from the same animal for 30 min (Figure 2.5). Arteries 
were then pre-constricted with the thromboxane A2 mimetic U46619 (1 µM). Active tension 
development of control arteries to U46619 (1 µM) in the absence of PVAT averaged 9.01 
± 0.41 g in lean and 10.20 ± 0.61 g in obese arteries (P = 0.09). In arteries treated with 
PVAT, active tension development averaged 9.61 ± 0.42 g in lean and 9.88 ± 0.53 g in 
Table 2.1 Phenotypic characteristics of lean and obese Ossabaw swine 
  Lean   Obese   
Body weight (kg) 62 ± 6 100 ± 5* 
Heart weight (g) 182 ± 16 222 ± 15 
Mean arterial pressure (mmHg) 102 ± 9 107 ± 5 
Glucose (mg/dL) 154 ± 14 232 ± 21* 
Insulin (µU/mL) 12 ± 1 14 ± 3 
Total cholesterol (mg/dL) 74 ± 4 340 ± 61* 
Triglycerides (mg/dL) 46 ± 5 78 ± 14* 
Values are mean ± SE for lean (n=10) and obese (n=10) swine. *P<0.05 vs. lean. 
45 
obese arteries (P = 0.68). Vasodilation to adenosine (30 µM) was reduced ~25% in obese  
(Figure 2.5B) compared to lean (Figure 2.5A) arteries in the absence of PVAT (P < 
0.001). The presence of PVAT significantly attenuated adenosine relaxation at 
concentrations >3 µM in arteries from both lean and obese swine. Although maximal 
responses to adenosine were lower in obese arteries, the overall degree of PVAT 
Figure 2.4 Representative images of immunohistochemical analyses of 
coronary arteries and associated PVAT. Arteries were obtained from humans 
(n=2), and lean and obese swine (n=4, each group). Hematoxylin and eosin-
stained sections (10X) illustrated similarities in perivascular adipocyte morphology 
between humans and swine (A-C). Verhoeff-van Gieson stained sections (4X) 
showed evidence of atheroma formation in human (F) and obese (E) compared to 
lean (D) arteries. CD163 staining (10X) indicated a marked increase in 
macrophages in obese (I, arrows) compared to lean (H) arteries relative to isotype 
control (G).  
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inhibition on maximal adenosine-induced dilation (30 µM) was similar in lean (~31%) and 
obese (~32%) arteries (Figure 2.5A vs. Figure 2.5B). Pre-constriction with KCl (60 mM), 
which averaged 7.19 ± 0.22 g in lean and 8.27 ± 0.90 g in obese arteries (P = 0.36), 
essentially abolished dilation to adenosine in both lean and obese arteries. Additional 
experiments in endothelium denuded coronary arteries demonstrated that adenosine- 
induced dilation was unaffected by removal of the endothelium in both control (P = 0.94) 
and PVAT treated (P = 0.99) arteries. Denudation was confirmed in these studies by <15% 
relaxation to bradykinin (1µM). 
 
Lean Coronary PVAT Inhibits KCa and KV7 Channels 
 The contribution of KCa channels to coronary vasodilation in lean and obese hearts 
was examined by comparing responses to the KCa channel agonist NS1619 (1 µM – 30 
µM). Overall responses to NS-1619 (30 µM) were reduced ~30% in obese compared to 
lean control arteries in the absence of PVAT (P = 0.01; Figure 2.6A vs. Figure 2.6B). 
Compared to control responses, the addition of PVAT attenuated dilator responses to the 
NS-1619 (30 µM) by ~30% in lean arteries (P < 0.001; Figure 2.6A). In contrast, NS-1619 
Figure 2.5 Coronary PVAT attenuates adenosine induced vasodilation. In control 
arteries cleaned of PVAT (n=6 each group), maximal vasodilation to adenosine was 
reduced ~25% in lean (A) compared to obese (B) arteries. The presence of PVAT from 
the same animal (n=6 each group) impaired dilation to a similar extent and constriction 
with KCl (n=3 each group) abolished adenosine dilation in lean and obese arteries. 
*P<0.05, PVAT vs. control. †P<0.001, lean vs. obese control. 
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mediated dilation was unaffected by the addition of PVAT in obese arteries (P = 0.90; 
Figure 2.6B).  
Figure 2.6 Effect of coronary PVAT on K+ channel mediated dilation is altered in 
obesity.  Arteries were incubated in the absence (control) or presence of PVAT from the 
same animal. PVAT attenuated vasodilation to the KCa channel agonist NS-1619 in lean 
(A) but not obese (B) arteries. Dilation to the KV7 channel agonist L-364,373 was reduced 
in the presence of PVAT in lean (C) but not obese (D) arteries. In the absence of PVAT, 
dilation to NS-1619 and L-364,373 was impaired in obese (B, D) relative to lean (A, C) 
arteries.  KATP channel mediated dilation to cromakalim was unaffected by PVAT in lean 
(E) arteries but was impaired by PVAT in obese (F) arteries. *P<0.05, PVAT vs. control. 
†P<0.05, lean vs. obese control. 
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 To investigate the role of KV7 channels in coronary vasodilation, responses to the 
KV7 channel agonist L-364,373 (10 nM – 10 µM) were examined in lean and obese 
arteries. Dilation to L-364,373 was significantly attenuated at doses >3 µM in obese 
compared to lean control arteries in the absence of PVAT (P < 0.05; Figure 2.6C vs. 
Figure 2.6D). The presence of PVAT attenuated L-364,373 mediated dilation (10 µM) by 
~20% in lean arteries (P = 0.02; Figure 2.6C) but had no effect in obese arteries (P = 
0.98; Figure 2.6D). Western blot analyses of Kv7 channel (KCNQ1) protein indicated that 
the abundance of KCNQ1 was not significantly different in lean versus obese coronary 
arteries (P = 0.11; Figure 2.7A and 2.7C). Abundance of β-actin was not significantly 
Figure 2.7 Western blot analysis of coronary artery KCNQ1 and Kir6.1 
channel expression. Representative blots of KCNQ1 (A) and Kir6.1 (B) channel 
expression in lean and obese arteries. Expression levels of both KCNQ1 (C) and 
Kir6.1 (D) were unaffected by an obese phenotype (P=0.11 and P=0.40, 
respectively). Average data (n=3 for each group) are expressed as % protein 
observed in lean swine. 
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different in lean versus obese arteries (P = 0.91), 
indicating equal protein loading between samples.  
 
Obese coronary PVAT Inhibits KATP Channels 
 Studies to investigate the effect of coronary 
PVAT on KATP channel mediated dilation were 
performed by comparing responses to the KATP 
channel agonist cromakalim (30 nM – 1 µM) in lean 
and obese arteries. Control responses to 
cromakalim (1 µM) were not significantly different 
in lean versus obese arteries in the absence of 
PVAT (P = 0.90; Figure 2.6E and 2.6F). The 
presence of coronary PVAT from the same animal 
had no effect on dilation to cromakalim (1 µM) in 
lean arteries (P = 0.57; Figure 2.6E). In contrast, 
PVAT significantly attenuated dilation to 
cromakalim in obese arteries (P = 0.02; Figure 
2.6F). Western blot analyses show that 
abundance of KATP channel pore forming unit (Kir 
6.1) protein was not different in obese compared 
to lean arteries (P = 0.40; Figure 2.7B and 2.7D). 
Abundance of β-actin was not significantly 
different in lean versus obese arteries (P = 0.34), 
indicating equal protein loading between samples.  
 
 
Figure 2.8 Effects of lean versus 
obese PVAT on coronary K
+
 
channel mediated dilation in lean 
arteries. For comparison purposes, 
lean control and lean PVAT 
responses are re-plotted from Figure 
2A, 2C and 2E. Obese PVAT had no 
effect on vasodilation of lean arteries 
to the K
Ca
 channel agonist NS-1619 
(n=4 [A]) or the K
V
7 channel agonist 
L-364,373 (n=3 [B]). Dilation of lean 
arteries to the K
ATP
 channel agonist 
cromakalim was attenuated by obese 
but not lean PVAT (n=3 [C]). *P<0.05 
lean PVAT vs. control. †P<0.05, 
obese PVAT vs. control. 
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Differential Effects of Lean versus Obese Coronary PVAT 
 In order to evaluate the specific effects of lean versus obese PVAT on K+ channel 
function, independent of differences in coronary artery responsiveness, control coronary 
arteries (cleaned of PVAT) from lean swine were incubated with known quantities of PVAT 
(0.3 g) from either lean or obese swine sacrificed on the same day. In contrast to the 
inhibitory effects of lean PVAT, obese PVAT had no effect on relaxation to NS-1619 (30 
µM) or L-364,373 (10 µM) in lean arteries (P = 0.40; Figure 2.8A and P = 0.10; Figure 
2.8B). Alternatively, obese PVAT significantly attenuated relaxation to cromakalim (1 µM) 
(P < 0.001; Figure 2.8C) while lean PVAT had no effect (P = 0.57).  
 Based on previous findings,9 additional proof-of-principle studies were performed 
to investigate the effects of calpastatin (10 µM) on coronary vasodilation.  Incubation with 
calpastatin significantly attenuated vasodilation to adenosine (from 3 µM to 10 µM) in lean 
arteries cleaned of PVAT (P = 0.001; Figure 2.9A). In contrast, exposure to calpastatin 
had no effect on adenosine dilation in obese arteries cleaned of PVAT (P = 0.30; Figure 
2.9B). 
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Figure 2.9 Effect of calpastatin on coronary artery vasodilation to adenosine. 
Incubation with calpastatin (10 µM) attenuated adenosine dilation in lean (A) but not obese 
(B) arteries. All groups n=5. *P<0.05 vs. control. 
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DISCUSSION 
 This investigation was designed to delineate the effects of lean and obese 
coronary PVAT on end-effector mechanisms of coronary vasodilation and to identify 
potential factors involved. The major new findings of this study are: (1) diameters of 
adipocytes in epicardial coronary PVAT are similar in lean and obese swine (2) factors 
derived from lean and obese coronary PVAT attenuate vasodilation in response to 
adenosine; (3) lean coronary PVAT inhibits KCa and KV7 channel mediated dilation but has 
no effect on KATP channel mediated dilation in lean arteries; (4) coronary vasodilation to 
KCa and KV7 channel activation is impaired in obese relative to lean arteries in the absence 
of PVAT; (5) obese PVAT has no effect on KCa or KV7 channel activation in obese arteries; 
(6) obese PVAT inhibits KATP channel mediated vasodilation in both lean and obese 
coronary arteries; (7) calpastatin attenuates coronary vasodilation to adenosine in lean 
but not obese arteries. These findings provide novel evidence that lean and obese PVAT-
derived factors attenuate coronary vasodilation via differential inhibition of K+ channels 
and implicate a mechanistic link between alterations in PVAT-derived factors, such as 
calpastatin, and diminished functional expression of coronary K+ channels in the setting 
of obesity. 
 Although the ability of PVAT to produce transferrable factors that influence the 
vasculature is well established, current understanding regarding the nature of this effect 
in specific adipose tissue depots remains rather limited. While the majority of studies on 
peripheral (non-cardiac) PVAT support the production of ADRF(s) and an overall “anti-
contractile” effect,152-155;158;159;164;229;238;239 recent data indicate that coronary PVAT is 
unique relative to these other adipose depots both in its expression profile and effects on 
the vasculature.2;9;73 In particular, factors derived from coronary PVAT have been found to 
attenuate endothelial-dependent dilation and potentiate coronary artery contractions, 
especially in the setting of obesity.2;9;171;172 Other studies in lean or hypercholesterolemic 
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swine show little/no anti-contractile effect of coronary PVAT in response to endothelin-1, 
angiotensin II, or the thromboxane A2 mimetic U46619.2;173;174  Results from the present 
study further support the distinct vascular effects of coronary PVAT in that lean and obese 
coronary PVAT significantly attenuate coronary vasodilator responses to adenosine. This 
impaired dilator response is directly related to effects of PVAT-derived factors on smooth 
muscle K+ channels, as adenosine-induced dilation was unaffected by endothelial 
denudation and was essentially abolished by pre-constriction with KCl (Figure 2.5A and 
2.5B). Inhibitory effects of PVAT on K+ channels have significant (patho)physiologic 
implications as prior studies have clearly demonstrated the contribution of KV and KATP 
channels to the regulation of coronary microvascular tone129;240 and KCa channels in 
endothelial-dependent dilation.134;135  
 The present findings provide novel evidence that lean and obese PVAT have 
distinct inhibitory effects on specific K+ channel subtypes in lean and obese coronary 
arteries. Specifically, factors derived from lean coronary PVAT impair KCa and KV7 channel 
mediated dilation, while factors derived from obese coronary PVAT attenuate KATP channel 
mediated dilation (Figure 2.6). The lack of effect of obese coronary PVAT on KCa and KV7 
channels was observed in both obese (Figure 2.6) and lean (Figure 2.8) coronary arteries 
and is thus not related to intrinsic differences in smooth muscle phenotype of lean versus 
obese swine. Therefore, the “cross-over” studies in which lean arteries (i.e. with normal 
vascular smooth muscle function) were incubated with lean and obese PVAT, strongly 
support that lean and obese PVAT-derived factors differentially affect KCa, KV7, and KATP 
channels. This distinction is important as we found that coronary vasodilation in response 
to KCa and KV7 channel agonists is attenuated in obese relative to lean arteries in the 
absence of PVAT (Figure 2.6). These data are consistent with prior work from our 
laboratory and others which demonstrated the functional down-regulation of BKCa and KV 
channels in the coronary circulation1;21;137;241;242 and suggest the potential for PVAT-
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derived factors to contribute to the initiation and progression of coronary vascular 
dysfunction in the setting of obesity.  
 There are several potential mechanisms that could contribute to the effects of 
PVAT-derived factors on coronary K+ channels. In particular, it does not appear that 
differences in K+ channel expression levels are responsible for the divergent effects of 
PVAT, as Western analyses revealed similar levels of KV7 (KCNQ1) and KATP (Kir6.1) 
channels in coronary arteries of lean and obese swine (Figure 2.7). Previous studies from 
our group also found augmented expression of BKCa channel subunits in coronary arteries 
of obese swine.1 However, it is possible that expression of other channel subtypes and/or 
subunits could be altered in the setting of obesity. The potential for direct effects of PVAT-
derived factors on specific coronary K+ channels is supported by prior evidence that NS-
1619, L-364,373, and cromakalim directly open KCa, KV, and KATP channels (i.e. without 
activating transmembrane signaling pathways), as these agonists have been shown to 
bind to sites on channel subunits and increase the open probability of excised membrane 
patches.243-245 Additionally, cellular signaling pathways also influence the response of 
these K+ channels to their respective agonists. For example, ischemic stimuli and Rho 
kinase signaling influence the response of KCa channels to NS-1619, 246;247 while the 
effects of L-364,373 on KV7 channels may intersect with ERK signaling248 and PKC alters 
the KATP channel response to cromakalim.249 Therefore, it is possible that cellular signaling, 
including post-translational modifications such as phosphorylation, influences the 
response of vascular smooth muscle K+ channel activation in the presence of PVAT.163 
Such effects are in line with previous studies from our laboratory which demonstrated that 
coronary PVAT influences both PKC and Rho kinase signaling.2;9 Whether coronary 
PVAT-derived factors interact with K+ channels directly and/or influence their function 
indirectly through intracellular signaling pathways warrants further investigation.  
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 Identification of the precise factors responsible for the vascular effects of coronary 
PVAT remains a daunting task. Recent studies by the Weintraub laboratory have 
established that adipocytes from human coronary PVAT have a distinct phenotype and 
exhibit elevated expression of pro-inflammatory genes and genes associated with 
angiogenesis, coagulation, and vascular morphology.73;75;250;251 Evidence of macrophage 
infiltration (Figure 2.4I) and atheroma formation (Figure 2.4E) in obese arteries support 
a potential role for inflammatory cross-talk between PVAT and the artery wall in the 
pathogenesis of atherosclerosis. A previous global proteomic assessment revealed the 
up-regulation of proteins associated with cellular growth, proliferation, and movement in 
obese versus lean coronary PVAT from swine.9 These differences appear to be 
independent of gross changes in morphology, as similarities in adipocyte diameter were 
found between lean and obese PVAT (Figure 2.4A and 2.4B). Of particular interest is the 
endogenous calpain inhibitor, calpastatin, which we have shown to be significantly 
elevated in supernatant of obese coronary PVAT and to dose-dependently augment 
coronary artery contractions.9 Findings from the current investigation further support that 
calpastatin is capable of mimicking the effects of coronary PVAT in that it acts to impair 
smooth muscle dilation in response to adenosine in lean coronary arteries (Figure 2.9A). 
The loss of this effect in obese coronary arteries (Figure 2.9B) is consistent with the lack 
of effect of obese PVAT on KCa and KV7 channel mediated dilation in obese arteries 
(Figure 2.6B and 2.6D), and suggests that chronic local exposure of the coronary 
circulation to factors such as calpastatin could contribute to the impairment of smooth 
muscle function in the setting of obesity.  
 It is important to recognize that although a differential effect of lean versus obese 
PVAT on vascular function was demonstrated in lean, healthy arteries, the effect of lean 
PVAT on obese arteries was not examined in this investigation. Additionally, findings of 
the present study were produced following short-term (~30 min) exposure to PVAT ex 
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vivo. Thus, a critical question remains as to whether chronic exposure of the coronary 
vasculature to the PVAT milieu directly contributes to the altered functional expression of 
K+ channels in the setting of obesity. We propose that as the severity of obesity and other 
cardiovascular risk factors (insulin resistance, hypercholesterolemia, hypertension) 
progresses, changes in the secretion profile of coronary PVAT adversely influences the 
function and expression of coronary ion channels. However, the extent to which 
phenotypic alterations in coronary PVAT causally contribute to mechanistic alterations in 
the obese coronary circulation merits further study.  
 In summary, the current findings demonstrate that although coronary perivascular 
adipocytes from lean and obese swine share similar morphology, lean and obese PVAT-
derived factors impair vasodilation via differential inhibition of vascular smooth muscle K+ 
channels. Specifically, our data are the first to demonstrate that lean coronary PVAT 
attenuates KCa and KV7 channel mediated dilation, while obese coronary PVAT impairs 
KATP channel mediated dilation. These results further support the paradigm of distinct 
“outside to inside” signaling influences of coronary PVAT and that alterations in specific 
factors such as calpastatin are capable of contributing to the initiation and/or progression 
of smooth muscle dysfunction in the setting of obesity.   
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SIGNIFICANCE 
Coronary perivascular adipose tissue (PVAT) normally surrounds the major 
coronary arteries of the heart. Evidence is mounting to support the potential for factors 
derived from coronary PVAT to influence the pathogenesis of coronary vascular disease. 
In particular, recent studies indicate that coronary PVAT-derived factors initiate/potentiate 
contraction of vascular smooth muscle, a property distinct from other adipose tissue 
depots, and that this effect is significantly augmented in the setting of obesity.  However, 
the effects of coronary PVAT on vasodilation have not been clearly defined. Results from 
this investigation indicate that coronary PVAT attenuates dilation via inhibitory effects on 
vascular K+ channels and that the mechanisms and factors involved in mediating these 
effects are markedly altered in the setting of obesity. These findings provide new insights 
into the unique vasoactive properties of coronary PVAT and the potential role of PVAT-
derived factors in obesity-induced coronary disease.  
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ABSTRACT 
Leptin has been implicated as a key upstream mediator of pathways associated 
with coronary vascular dysfunction and disease. The purpose of this investigation was to 
test the hypothesis that leptin modifies the coronary artery proteome and promotes 
increases in coronary smooth muscle contraction and proliferation via influences on Rho 
kinase signaling. Global proteomic assessment of coronary arteries from lean swine 
cultured with obese concentrations of leptin (30 ng/mL) for 3 days revealed significant 
alterations in the coronary artery proteome (68 proteins) and identified an association 
between leptin treatment and calcium signaling/contraction (4 proteins) and cellular growth 
and proliferation (35 proteins). Isometric tension studies demonstrated that both acute (30 
min) and chronic (3 day, serum-free media) exposure to obese concentrations of leptin 
potentiated depolarization-induced contraction of coronary arteries. Inhibition of Rho 
kinase significantly reduced leptin-mediated increases in coronary artery contractions. 
The effects of leptin on the functional expression of Rho kinase were time-dependent, as 
acute treatment increased Rho kinase activity while chronic (3 day) exposure was 
associated with increases in Rho kinase protein abundance.  Proliferation assays following 
chronic leptin administration (8 day, serum-containing media) demonstrated that leptin 
augmented coronary vascular smooth muscle proliferation and increased Rho kinase 
activity. Inhibition of Rho kinase significantly reduced these effects of leptin. Taken 
together, these findings demonstrate that leptin promotes increases in coronary 
vasoconstriction and smooth muscle proliferation and indicate that these phenotypic 
effects are associated with alterations in the coronary artery proteome and dynamic effects 
on the Rho kinase pathway. 
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INTRODUCTION 
 Numerous studies have suggested that factors derived from adipose tissue have 
the potential to influence several key mechanisms of obesity-induced coronary disease 
including the promotion of vascular dysfunction and smooth muscle proliferation.2;13;48;207 
For example, recent studies support that alterations in the adipokine secretion profile of 
coronary perivascular adipose tissue (PVAT), which surrounds the large conduit arteries 
of the heart, contribute to impaired endothelial-dependent dilation and augmented smooth 
muscle contraction in the setting of obesity2;9;171;172;177;184  Specifically, coronary PVAT has 
been shown to potentiate coronary artery contractions and attenuate vasodilation via 
effects on Rho kinase signaling and smooth muscle CaV1.2 and K+ channels2;141;172;252  
While these effects are in contrast with the anti-contractile effects of peripheral 
PVAT,8;62;157;162 they are consistent with reported increases in pro-inflammatory and pro-
atherogenic factors in coronary PVAT of subjects with documented atherosclerotic 
disease.48;73;75;253 However, the specific adipokines and pathways responsible for these 
deleterious influences remain ill defined.  
 A growing body of evidence implicates a role for the adipose tissue hormone, 
leptin, as a key upstream mediator of pathways associated with coronary vascular 
dysfunction and the initiation and progression of coronary disease in obesity.70;254 Plasma 
concentrations and expression of leptin in coronary PVAT are markedly elevated in obese 
subjects2;177;179;191;251 and leptin receptors (ObR) are highly expressed throughout the wall 
of diseased coronary arteries.2;202;255;256 Increases in leptin levels (30 – 90 ng/mL) have 
been associated with the activation of a number of pro-inflammatory pathways (e.g. 
monocyte chemoattractant protein-1; tumor necrosis factor-α),195;257 attenuation of 
endothelial-dependent dilation, and further impairment of obesity-induced endothelial 
dysfunction. 2;255;258 However, the effects of leptin on coronary vascular smooth muscle 
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remain equivocal, as leptin either attenuates or has no effect on contractile responses to 
a variety of agonists in isolated rat aorta. 202-204 Importantly, the majority of these studies 
were conducted following acute, short-term exposure to leptin (30-60 min). Therefore, 
understanding of the vascular effects of longer-term leptin exposure is rather limited. 
 Several studies suggest an interrelationship between leptin signaling and the 
RhoA/Rho kinase pathway, a known regulator of vascular smooth muscle contraction.259-
261 Recent findings demonstrate that perivascular overexpression of leptin promotes 
neointima formation after carotid artery injury207 and that exogenous administration of 
leptin stimulates proliferation of isolated vascular smooth muscle cells from 
rodents.198;206;262 Interestingly, activation of the RhoA/Rho kinase pathway has been 
implicated in leptin-mediated increases in vascular smooth muscle cell proliferation and 
hypertrophy.260 However, contrasting studies have found that leptin produces dose-
dependent decreases in proliferation256 and have failed to support a role for RhoA/Rho 
kinase in mediating vascular smooth muscle proliferation.226;263 Thus, further studies are 
required to identify the effects of short-term and long-term leptin administration on 
coronary vascular smooth muscle contraction and proliferation and to elucidate the precise 
mechanisms involved. 
 Accordingly, the purpose of this investigation was to test the hypothesis that leptin 
promotes (1) marked alterations in the coronary proteomic expression profile that favor 
pathways associated with vascular smooth muscle contraction and proliferation; and (2) 
increases in coronary smooth muscle contraction and proliferation via a Rho kinase 
dependent pathway. Findings from this investigation provide novel evidence that leptin 
contributes to mechanistic alterations in coronary vascular function and support the 
growing paradigm that leptin acts as an upstream mediator in the development of obesity-
induced coronary disease. 
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MATERIALS AND METHODS 
 All experimental procedures and protocols in this investigation were approved by 
the Institutional Animal Care and Use Committee in accordance with the Guide for the 
Care and Use of Laboratory Animals. Upon sacrifice, hearts from domestic swine (body 
weight ~50 kg) were excised and perfused via aortic cannulation with 4°C, Ca2+-free Krebs 
buffer (131.5 mM NaCl, 5mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 25mM NaHCO3, 10 
mM glucose). Coronary arteries were grossly dissected from the adjacent myocardium 
and epicardial adipose tissue. Arteries were then further isolated from the surrounding 
perivascular adipose tissue and adventitia using a dissecting microscope before being cut 
into 3 mm rings and subjected to the protocols outlined below.  
 
Proteomics 
 Coronary arteries were cut into 3 mm rings and were placed in 12-well tissue 
culture dishes with serum-free, low glucose (100 mg/dL) Dulbecco’s Modified Eagle 
Medium (DMEM: Corning Cellgro, Manassas, VA, 10014CM) containing penicillin (100 
U/mL) and streptomycin (100 µg/mL) (MP Biomedicals, 1670249). Arteries were 
maintained in a 5% CO2 atmosphere at 37°C for three days of incubation without (control) 
or with leptin (30 ng/mL: Sigma Aldrich, St. Louis, MO, L4146) for 3 days. Following the 
culture period, arteries were frozen in liquid N2 and delivered on dry ice to the Ohio State 
University Proteomics Core for protein extraction. Tissues were homogenized in 1:10 w/v 
in ice cold Buffer A (1% digitonin, 0.05% NP-40, NaCl 150 mM, Tris 50 mM, pH 7.4) with 
Complete Protease Inhibitors and PhosSTOP (Roche Diagnostics) using a polytron 
homogenizer (Power Gen 700, Fisher Scientific). Proteins were extracted on ice for 1 hr, 
centrifuged at 80,000g for 30 min, and protein concentration of supernatant was 
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determined with the Dc Protein Assay (Bio-Rad). Proteins were eluted in Laemmli 
Reducing Sample Buffer for 1D gel electrophoresis. 
In-Gel Digestion 
 Each band was cut into 8 fractions based on relative protein abundance and placed 
in 96 well plates for in-gel digestion. Briefly, gel pieces were washed in 100 µl of 50% 
methanol/5% acetic acid for 30 min.  The wash step was repeated a total of 3 times and 
slices were left in a storage solution of 50 µl of 50% methanol/5% acetic acid until 
digestion. Digestion was carried out by adding 100 µl 50 mM ammonium bicarbonate 
(ABC) for 10 min followed by 100 µl acetonitrile for 10 min. The gel bands were rehydrated 
with dithiothreitol (DTT) (prepared as 5 mg/ml in 50 mM ABC) and incubated for 30 min 
followed by a 30 min incubation with iodoacetamide (prepared as 15 mg/ml iodoacetamide 
in 50 mM ABC) in the dark. The gel bands were washed again with 2 cycles of acetonitrile 
and 50 mM ABC in 10 and 5 min increments, respectively and thendried for 10 min.  The 
protease was driven into the gel pieces by rehydrating them in 50 µL of sequencing grade 
modified trypsin from Promega (Madison, WI, prepared at 5 µg/ml with 0.01% 
ProteaseMAX Surfactant in 50 mM ABC) and incubated at room temperature overnight. 
The peptides were extracted from the polyacrylamide with 50 µl 50% acetonitrile and 5% 
formic acid for 10 min a total of 3 times and a final extraction with 50 µl of acetonitrile for 
10 min  and then pooled together. The extracted pools were dried completely and 
resuspended in 20 µl of 50 mM acetic acid. 
 
Mass Spectrometry 
 The final digests were analyzed using capillary-liquid chromatography-nanospray 
tandem mass spectrometry (Capillary-LC/MS/MS) of global protein. Identification was 
performed on a Thermo Finnigan LTQ orbitrap mass spectrometer equipped with a 
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microspray source (Michrom Bioresources Inc, Auburn, CA) operated in positive ion 
mode.  Samples (6.4 µl from each fraction) were separated on a capillary column 
(0.2X150mm Magic C18AQ 3µ 200A, Michrom Bioresources Inc, Auburn, CA) using an 
UltiMate™ 3000 HPLC system (LC-Packings A Dionex Co, Sunnyvale, CA). Each sample 
was injected into the µ-Precolumn Cartridge (Dionex, Sunnyvale, CA) and desalted with 
50 mM acetic acid for 5 min. The injector port was then switched to injection mode and 
the peptides were eluted off of the trap onto the column. Mobile phase A was 50mM acetic 
acid in water and acetonitrile was used as mobile phase B. Flow rate was set at 2µl/min. 
Mobile phase B was increased from 2% to 5% in 5 min and again from 5% to 30% in 30 
min, then from 30% to 50% in 8 min. The gradient was increased again from 50% to 85% 
in 3 min and then kept at 85% for another 1 min before being brought back to 2% in 0.1 
min. The column was equilibrated at 2% of mobile phase B (or 98% A) for 10 min before 
the next sample injection. MS/MS data was acquired with a spray voltage of 2.2 kV and a 
capillary temperature of 175 °C.  The scan sequence of the mass spectrometer was based 
on the data dependent TopTen™ method in preview mode; the analysis was programmed 
for a full scan recorded between 350-2,000 Da and a MS/MS scan to generate product 
ion spectra to determine amino acid sequence in consecutive scans of the ten most 
abundant peaks in the spectrum. The full scan resolution was set at 30,000 to achieve 
high mass accuracy MS determination. The CID fragmentation energy was set to 35%. 
Dynamic exclusion is enabled with a repeat count of 1 within 18 s, a mass list size limit of 
500, exclusion duration of 10 s and a low mass width and high mass width were set at 
30ppm.  
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Protein Identification and Quantitation 
 Sequence information from the MS/MS data was processed by converting the .raw 
files into a mgf files using MsConvert (ProteoWizard) and later merged into a merged file 
(.mgf) using an in-house program, RAW2MZXML_n_MGF_batch (merge.pl, a Perl script) 
and searched using Mascot Daemon by Matrix Science version 2.3.2 (Boston, MA) against 
the NCBInr Other Mammalia Database (version 20150104, 1,412,788 sequences). 
Trypsin was used as the enzyme and four missed cleavages were permitted. Considered 
variable modifications were oxidation (Met), carbamidomethylation (Cys) and deamination 
(Asn, Gln). The mass accuracy of the precursor ions were set to 20ppm and the fragment 
mass accuracy was set to 0.8 Da. One 13C peak was included in the search in case of 
the accidental pick of 13C peaks. A decoy database was also searched to determine the 
false discovery rate (FDR) and peptides were filtered according to the FDR. The 
significance threshold was set at P < 0.05. Percolator score was used to further validate 
the search results and the actual FDR was less than 1% after using percolator scores. 
 Label-free quantitation was performed using the spectral count approach, in which 
the relative protein quantitation is measured by comparing the number of MS/MS spectra 
identified from the same protein in each of the multiple LC/MSMS datasets. Scaffold was 
used for quantitation analysis. The protein filter was set at 99% to ensure the false 
discovery rate is less than 1% and the peptide filter was set at 95%. 
 
Functional Assessment of Isolated Coronary Arteries 
 Isometric tension studies on coronary artery rings were performed as previously 
described.9;252 Briefly, 3 mm coronary artery rings (without PVAT) were mounted in organ 
baths filled with Ca2+-containing Krebs buffer (131.5 mM NaCl, 5mM KCl, 1.2 mM 
65 
NaH2PO4, 1.2 mM MgCl2, 25mM NaHCO3, 10 mM glucose, 4mM CaCl2) and maintained 
at 37°C. Once stabilized at optimal passive tension (~4 g), arteries were incubated without 
(control) or with leptin (30 ng/mL: Sigma Aldrich, L4146) and/or fasudil (1 µM: Sigma 
Aldrich, H139) for 30 minutes (acute exposure) and then exposed to increasing 
concentrations of KCl (10 – 60 mM) and to the thromboxane A2 receptor agonist, U46619 
(1 µM: Tocris, 1932). Coronary arteries cultured in serum-free media for 3 days with or 
without leptin (30 ng/mL: Sigma Aldrich, L4146) and/or fasudil (1 µM: Sigma Aldrich, H139) 
(chronic exposure) were also mounted in organ baths and exposed to increasing 
concentrations of KCl (10 – 60 mM) and to U46619 (1 µM: Tocris, 1932). Acute and chronic 
studies were also conducted in endothelium denuded coronary arteries in which the 
endothelium was removed by gently rubbing fine-tip forceps along the lumen. Active 
tension development (peak tension minus baseline tension) was recorded at each 
concentration for each group. Endothelial denudation was confirmed by <15% relaxation 
to bradykinin (1 µM: Sigma Aldrich, B3259).  
 
Western Analysis 
 Following acute (30 minute) or chronic (3 day culture) incubation with or without 
leptin, coronary arteries were frozen in liquid N2 and stored at -80°C. Arteries were 
homogenized in 70 µL of Tissue Protein Extraction Reagent (Thermo Scientific, 78510) 
and total protein was quantified as previously described.233 Equivalent amounts of protein 
(50 µg) were loaded onto 10% polyacrylamide gels (Life Technologies, NP0302) for 
electrophoresis and blotting. Membranes were incubated with primary antibody directed 
against Rho kinase (Rock-2, 1:200, Santa Cruz Biotechnology, sc-1851) overnight at 4°C 
and donkey anti-goat IRDye 800CW secondary antibody (1:15,000, Li-Cor, 926-32214) 
for 1 hour at room temperature. To verify equal protein loading, membranes were washed 
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and incubated with antibody to β-actin (1:200, Santa Cruz Biotechnology, sc-1616). 
Immunoreactivity was visualized using a Li-Cor Odyssey CLx imaging system. Chameleon 
Duo (Li-Cor) was used as a protein ladder. Densitometry analyses were conducted using 
Li-Cor Image Studio Lite, version 5.2. Protein levels were normalized to levels of β-actin 
and reported as “% control,” i.e. protein levels from each sample were normalized to the 
average level of the protein in control arteries within the same condition. 
 
Rho Kinase Activity Assay 
 Protein homogenates of the samples outlined above were subjected to a 
commercially available enzyme immunoassay for the detection of active Rho kinase (Rho-
associated Kinase (ROCK) Activity Assay, Millipore, CSA001). Briefly, equal amounts of 
protein (50 µg) from each sample were added to plates pre-coated with recombinant 
MYPT1. A detection antibody specific for phosphorylated MYPT1 and a HRP-conjugated 
secondary antibody were added, respectively. The amount of phosphorylated substrate 
was measured by adding the chromogenic substrate tetramethylbenzidine and reading 
the absorbance signal at 450 nm. Absorbance values were then normalized to a standard 
curve of active recombinant ROCK-II enzyme.  
 
Proliferation Assays 
 Additional culture studies were conducted in which arteries were incubated in 
serum-containing (30% fetal bovine serum, Glibco, 10437-028), low glucose (100 mg/dL) 
Dulbecco’s Modified Eagle Medium (DMEM: Corning Cellgro, 10014CM) containing 
penicillin (100 U/mL) and streptomycin (100 µg/mL) (MP Biomedicals, 1670249) at 37°C 
in a 5% CO2 atmosphere. Arteries were incubated with or without leptin (30 ng/mL: Sigma 
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Aldrich, L4146) and/or fasudil (1 µM: Sigma Aldrich, H139) for 8 days, with media changes 
conducted every 2 days. To confirm functional responses at this time point, both intact 
and denuded arteries were subjected to the isometric tension studies outlined above. In a 
subset of untreated and leptin treated arteries, 5-Bromo-2’-deoxyuridine (BrdU; 20 µmol/L) 
was added to the culture medium for the final 6 hours of culture. Arteries were then fixed 
in 10% formalin, paraffin embedded, and processed for BrdU labeling in nuclei utilizing an 
immunohistochemical detection assay (BrdU Labeling and Detection Kit II, Roche, 
11299964001). Arteries left untreated with BrdU were used as negative controls for the 
immunohistochemical procedure. Positive staining for BrdU-labeled nuclei indicates DNA 
synthesis, a marker of cellular proliferation. To specifically investigate vascular smooth 
muscle proliferation, arteries from all treatment groups were formalin fixed, paraffin 
embedded, and processed for co-immunostaining with anti-α smooth muscle actin (1:50, 
Abcam, ab5694) and anti-proliferating cell nuclear antigen (PCNA, 1:2,000, Abcam, ab29). 
Mach 2 Double Stain 2 (Biocare Medical, MRCT525) was used as secondary with 
chromogens Vulcan Fast Red and 3,3′-diaminobenzidine, respectively. 
Immunohistochemistry was performed in conjunction with the Indiana University Health 
Pathology Laboratory (Indianapolis, IN). Slides were imaged at 20X magnification. Four 
distinct fields of view were captured per artery and data were averaged for n=1. 
Quantitation of positive staining was performed using the open source modification of 
Image J (Fiji) 232 and a custom modification of the trichrome quantification macro (The 
University of Chicago Integrated Light Microscopy Core Facility). Positive PCNA staining 
was quantitated in artery regions also staining positively for α-smooth muscle actin. Data 
are reported as “% control,” i.e. percent positive staining from each sample was 
normalized to the average level of positive staining in untreated, control arteries.  
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Statistical Analyses 
 Statistical comparisons of proteomic results were performed on proteins which met 
Scaffold false discovery rate (FDR) criterion by Student’s t-test. Proteins with P < 0.05 
were considered significantly different between treatment groups. Protein lists and 
corresponding expression values were uploaded onto the Ingenuity Pathway Analysis 
software server (content version: 24718999) and analyzed to interpret cellular functions 
and canonical pathways associated with alterations in the proteomic profile between 
treatment groups. For isometric tension studies, a two-way ANOVA was used to test the 
effects of leptin and/or inhibitors (Factor A) relative to concentrations of specific agonists 
(Factor B). When statistical differences were found with ANOVA (P < 0.05), a Student-
Newman-Keuls multiple comparison test was performed. A Student’s t-test was used to 
compare the results of Western blot, Rho Kinase activity, and proliferation assays. Data 
are presented as mean ± SE with “n” equal to number of pigs studied. SigmaPlot version 
11.0 (Systat Software Inc, San Jose, CA) was used for all statistical analyses and 
generation of figures.  
 
RESULTS 
Effect of leptin exposure on the coronary proteomic expression profile 
 To investigate potential factors and pathways affected by leptin exposure, global 
proteomic profiling was performed on coronary arteries cultured in the presence or 
absence of leptin (30 ng/mL) for 3 days. This non-biased target discovery approach 
detected significant alterations in 69 proteins (P ≤ 0.05) in leptin treated arteries. A 
complete list of the 793 detected proteins is provided in Appendix B, Table I. The top 15 
unique upregulated and downregulated proteins are listed in Table 3.1. Ingenuity Pathway 
Analysis (IPA) software identified significant associations (P<0.001) between leptin 
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treatment and numerous cellular functions, namely calcium signaling (4 proteins) and 
cellular growth and proliferation (35 proteins).  
Table 3.1 Protein expression profile of leptin-treated coronary arteries 
Gene Name Protein Name 
Fold                             
Change 
P Value IPA 
Upregulated Proteins 
MYOZ2 Calsarcin-1 (myozenin-2) 5.8 0.02 4 
RAB21 Ras-related protein, Rab-21 4.8 0.0002  
SORBS1 Sorbin and SH3 domain-containing protein 
1, isoform 1 
4.4 0.007 5 
LASP1 LIM and SH3 domain protein 1 3.2 0.05 2,3 
EIF6 Eukaryotic translation initiation factor 6, 
isoform X1 
1.6 0.05 2 
ADIRF* Adipogenesis regulatory factor 1.5 0.02  
Cald1 Non-muscle caldesmon, isoform X1 1.5 0.005  
MTPN Myotrophin 1.5 0.03 2 
S100A11 Protein S100-A11 1.4 0.04 2,3 
RPL12 60S ribosomal protein L12 1.3 0.01  
TPM4 Tropomyosin alpha-4 chain, isoform X3 1.3 0.02 1 
TPM4 Tropomyosin alpha-4 chain, isoform X2 1.3 0.03 1 
TPM4 Tropomyosin alpha-4 chain, isoform X1 1.3 0.02 1 
TUBA1C Tubulin alpha chain-like 1.2 0.02 2,3 
TPM2 Tropomyosin beta chain, isoform X1 1.2 0.03 1 
 
Downregulated Proteins 
MYOF Myoferlin 7.6 0.03 2,4 
ALDH4A1 Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
6.1 0.009  
ATPIF1 ATPase inhibitor, mitochondrial precursor 4.9 0.00003 2 
SRI Sorcin 4.8 0.00003  
SSR4 Translocon-associated protein subunit 
delta, isoform X1 
2.6 0.04  
PRKAR2A cAMP-dependent protein kinase type II-
alpha regulatory subunit 
2.6 0.04 1,2,3 
CSPG4 Chondroitin sulfate proteoglycan 4 2.4 0.03 2,3,5 
HSP90AA1 Heat shock protein HSP 90-alpha 2.3 0.02 2,3 
SLC25A3 Phosphate carrier protein, mitochondrial 2.3 0.02  
FBN1 Fibrillin-1 2.2 0.02 2,3,5 
PDIA4 Protein disulfide-isomerase A4 precursor 2.1 0.04  
RNH1 Ribonuclease inhibitor 2.1 0.03 2,3 
RPN2 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 2 precursor 
2.0 0.02  
GLUD1 Glutamate dehydrogenase 1, mitochondrial 
precursor 
1.8 0.0004  
IGTA1* Integrin alpha 1 1.8 0.04  
Values for fold change in expression of coronary arteries cultured for three days with 
leptin (30 ng/mL)  versus untreated controls (n=4 each group). Ingenuity Pathway 
Analysis (IPA): 1Calcium signaling, 2Cell proliferation, 3Cell movement, migration, 
invasion, 4Quantity of smooth muscle cells, 5Cell spreading. *Bos taurus homolog.  
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These findings are of interest, as previous studies have suggested a potential link between 
leptin and vascular reactivity2;202;203;255 and proliferation.198;207 Additional cellular 
pathways/processes identified include cellular movement, migration, and invasion (25 
proteins), cell spreading (6 proteins) and quantity of smooth muscle cells (4 proteins).  
 
Acute and chronic leptin administration augments coronary artery contractions 
 The effects of leptin on coronary vascular reactivity were examined by comparing 
KCl-induced contractions of coronary arteries following short-term, acute (30 min) and 
long-term, chronic (3 day, serum-free culture) exposure to “obese” concentrations of leptin 
(30 ng/mL), i.e., plasma concentrations typically reported in obese subjects.192;264 Overall 
contractile responses of acute leptin treated arteries were significantly augmented (P = 
0.04), with maximal tension development increased by 1.5 ± 0.2 g at 60 mM KCl (Figure 
3.1A). Chronic exposure to leptin also augmented overall active tension development to 
KCl (P<0.001), with an increase of 2.7 ± 0.49 g at 60 mM (Figure 3.1B). Control responses 
to KCl were reduced following 3 days of culture (P = 0.006, Figure 3.1B vs 3.1A). This 
reduction in contraction was also observed in response to the thromboxane A2 receptor 
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Figure 3.1 Leptin augments depolarization-induced coronary artery contractions. 
Acute (30 min) exposure to leptin (30 ng/mL) increased KCl-induced contractions ~1.3 g 
at doses >40 mM (n=9 [A]). Chronic (3 day culture in serum-free media) leptin 
administration (30 ng/mL) increased tension development ~2.5 g at doses >40 mM (n=4 
[B]). 
71 
agonist, U46619 (1 µM, P = 0.04), although leptin had no effect on U46619 contractions 
following acute (P = 0.58) or chronic (P = 0.34) exposure (Appendix B, Figure I).  KCl 
contractions in control and leptin treated arteries were unaffected by removal of the 
endothelium, and similar effects of leptin were observed in endothelium denuded arteries 
(confirmed by <15% relaxation to 1µM bradykinin) following both acute (Appendix B, 
Figure IIA) and chronic (Appendix B, Figure IID) exposure.  
 
Role of Rho kinase in leptin-mediated coronary contraction 
 To investigate the role of Rho kinase signaling in mediating the functional effects 
of leptin, coronary arteries were co-incubated with/without leptin (30 ng/mL) and/or the 
Rho kinase inhibitor, fasudil (1 µM). Acute fasudil treatment significantly reduced 
vasoconstriction to KCl (10 – 60 mM) compared to untreated (control) arteries (P < 0.001, 
Figure 3.2A). In contrast, fasudil treatment had no effect on contractile responses to KCl 
(10 – 60 mM) in untreated (control) arteries cultured for 3 days (P = 0.50, Figure 3.2B). 
Fasudil administration significantly decreased the effect of acute (P < 0.001, Figure 3.2C) 
and chronic (P = 0.01, Figure 3.2D) leptin exposure on KCl-induced contractions. 
However, this effect of fasudil was markedly greater following acute (~3.8 g at 
concentrations >40 mM) versus chronic exposure (~1.4 g at concentrations >40 mM) to 
leptin (P < 0.001). KCl contractions in arteries treated with leptin and/or fasudil were 
unaffected by removal of the endothelium, and similar effects of fasudil were observed in 
endothelium denuded arteries following both acute (Appendix B, Figure IIB and IIC) and 
chronic (Appendix B, Figure IIE and IIF) exposure. 
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Effects of leptin on Rho kinase expression and activity 
 Further analyses were conducted to examine the effects of leptin on Rho kinase 
abundance and activity. Western blot analyses revealed no difference in normalized 
protein abundance of Rho kinase in acute leptin treated arteries (P = 0.61, Figure 3.3A 
and 3.3B). A commercially available Rho-associated kinase (ROCK) activity assay 
demonstrated that acute leptin exposure significantly increased the level of Rho kinase 
activity from 0.50 ± 0.07 µU/µL in untreated arteries to 1.61 ± 0.25 µU/µL in leptin treated 
arteries (P = 0.01, Figure 3.3C). Following chronic exposure to leptin (3 day, serum-free 
culture), the abundance of Rock-2 protein was increased ~3.5-fold relative to untreated 
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Figure 3.2 Role of Rho kinase in leptin-mediated coronary contraction. In the 
absence of leptin, acute (n=9 [A]), but not chronic (n=4 [B]) treatment with the Rho kinase 
inhibitor, fasudil (1 µM), diminished vasoconstriction to KCl. Inhibition of Rho kinase 
reduced the effect of both acute (n=9 [C]) and chronic (n=4 [D]) leptin administration on 
KCl-induced contractions. However, the fasudil-mediated reduction in tension was greater 
following acute (C) versus chronic (D) leptin exposure. 
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cultured arteries (P = 0.009, Figure 3.3D and 3.3E). While Rho kinase activity level was 
increased relative to acute untreated arteries following 3 days of culture, chronic exposure 
to leptin did not affect overall Rho kinase activity, relative to untreated time-control (1.73 
± 0.36 µU/µL in untreated versus 1.60 ± 0.16 µU/µL in leptin treated arteries; P = 0.92, 
Figure 3.3F).  
 
 
Leptin and vascular smooth muscle cell proliferation 
 Additional studies were conducted to directly investigate the effects of leptin on 
coronary vascular proliferation. In initial experiments, coronary arteries were cultured in 
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Figure 3.3 Effects of acute versus chronic leptin treatment on Rho kinase. 
Representative blots of Rho kinase protein abundance in coronary arteries following acute 
(A) and chronic (3 day culture in serum free media) (D) leptin exposure. Average data are 
expressed as % relative to control. Acute leptin treatment increased Rho kinase activity 
(C) in the absence of a change in protein abundance (B). Following chronic exposure, 
protein abundance was significantly elevated in leptin treated arteries (E), while no 
difference in overall Rho kinase activity was detected relative to untreated control arteries 
(F). All groups n=3. *P<0.05, leptin vs. control. †P<0.05, vs. acute control. 
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serum-containing media for 8 days in the presence or absence of leptin, with 5-Bromo-2’-
deoxyuridine (BrdU) added to the media for the final six hours of culture. Systematic 
quantitation of the BrdU staining pattern using ImageJ revealed a ~32% increase in BrdU-
positive nuclei in leptin treated relative to untreated, control arteries (P = 0.02, Appendix 
B, Figure III). Based on these findings, further studies were conducted in arteries cultured 
with or without leptin (30 ng/mL) and/or fasudil (1 µM) for 8 days. The functional effects of 
leptin and/or fasudil were conserved in both endothelium intact (Appendix B, Figure IVA-
C) and endothelium denuded arteries (Appendix B, Figure IVD-F) at this time point. 
Overall KCl-induced vasoconstriction in untreated, control arteries was reduced following 
8 days of culture (P < 0.001, Appendix B, Figure IVA versus 3.1B). This reduction in 
contraction was also observed in response to U46619 (1 µM, P = 0.002), although leptin 
had no effect on U46619 contractions following chronic, 8 day exposure (P = 0. 61, 
Appendix B, Figure I). 
To investigate the role of Rho kinase on leptin-mediated increases in vascular 
smooth muscle proliferation, arteries were co-immunostained for α-smooth muscle actin 
and proliferating cell nuclear antigen (PCNA). Systematic quantitation of the PCNA 
staining pattern within the vascular smooth muscle layer revealed a ~22% increase in 
PCNA-positive nuclei in leptin treated (Figure 4B) relative to untreated, control arteries (P 
= 0.04, Figure 3.4A). Treatment with fasudil alone had no effect on proliferation relative 
to untreated control arteries (P = 0.50). Co-treatment with leptin and fasudil (Figure 3.4C) 
significantly reduced the effect of leptin on vascular smooth muscle proliferation (P = 
0.002, Figure 3.4D).  
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Increases in proliferation with leptin treatment (8 day, serum-containing culture) 
were associated with a modest increase in Rho kinase protein abundance  (P = 0.18, 
Figure 3.5A and 3.5B) and a significant increase in Rho kinase activity, averaging 1.52 ± 
µU/µL in untreated and 2.40 ± 0.12 µU/µL in leptin treated arteries (P = 0.03, Figure 3.5C). 
The effect of leptin on Rho kinase activity was significantly reduced by co-incubation with 
fasudil (P = 0.002, Figure 3.5C). 
Figure 3.4 Leptin augments coronary vascular smooth muscle proliferation 
via effects on Rho kinase. Representative images of α-smooth muscle actin (red) 
and proliferating cell nuclear antigen (brown) co-immunostaining of untreated, 
control (A), leptin treated (B), and leptin and fasudil co-treated arteries (C) 
following chronic, 8 day culture in serum-containing media. The increase in PCNA-
positive nuclei in leptin treated, relative to untreated arteries was significantly 
reduced by inhibition of Rho kinase with fasudil (D). All groups n=5. *P<0.05, leptin 
vs. control. **P<0.05 leptin vs. leptin+fasudil. 
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DISCUSSION 
 The purpose of this investigation was to test the hypothesis that leptin modifies the 
coronary proteomic expression profile and promotes increases in coronary smooth muscle 
contraction and proliferation via influences on Rho kinase signaling.  The major new fin 
dings are: (1) chronic exposure to obese concentrations of leptin (30 ng/mL, 3 day culture) 
induces marked alterations in the coronary artery proteome (68 proteins) with a significant 
influence on calcium signaling/contraction and cellular growth and proliferation; (2) acute 
(30 min) and chronic (3 day, serum-free media) exposure to leptin potentiates voltage-
dependent contraction of isolated coronary arteries; (3) acute and chronic leptin-mediated 
increases in coronary vasoconstriction occur concomitantly with increases in activity and 
protein abundance of Rho kinase, respectively; (4) chronic leptin administration (8 day, 
serum-containing media) augments vascular smooth muscle proliferation via increases in 
Rho kinase activity; and (5) the contractile and proliferative effects of leptin exposure were 
abolished by the Rho kinase inhibitor fasudil. Taken together, these findings provide novel 
Figure 3.5 Effects of leptin-induced vascular smooth muscle proliferation on Rho 
kinase. Representative blot of Rho kinase protein abundance in control versus leptin 
treated arteries following 8 days of culture in serum-containing media (A). Leptin 
administration significantly increased Rho kinase activity (C), while only a modest increase 
in Rho kinase protein abundance was detected (B). The effect of leptin on Rho kinase 
activity was abolished by co-incubation with fasudil (C) All groups n=5. *P<0.05, leptin vs. 
control. **P<0.05 leptin vs. leptin+fasudil. 
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evidence in support of the paradigm of leptin as an upstream mediator that contributes to 
marked phenotypic alterations in coronary smooth muscle in the setting of obesity.   
 
Leptin as an upstream mediator of coronary vascular disease 
 Although recent findings have implicated leptin as an upstream paracrine mediator 
of a key network of pathways associated with obesity-induced coronary vascular disease, 
no study has systematically investigated the potential factors and/or pathways involved. 
Accordingly, we conducted a global proteomic assessment of coronary arteries with and 
without chronic (3 day) exposure to “obese” concentrations of leptin, i.e., plasma 
concentrations typically reported in obese subjects (30 ng/ml).192;264 This non-biased 
discovery approach revealed that leptin administration markedly influences the 
abundance of numerous proteins (Table 3.1). These data support that leptin signaling 
alters the expression of a large number of factors which have the potential to mediate 
additional paracrine effects within the vascular wall. Indeed, Ingenuity Pathway Analysis 
(IPA) identified alterations within several key cellular processes in leptin treated arteries. 
Specifically, IPA revealed that the detected changes in the proteomic expression profile 
corresponded to pathways associated with calcium signaling (e.g., calreticulin, cAMP-
dependent protein kinase type II, tropomyosin) and cellular growth and proliferation (e.g., 
myotrophin, myoferlin, fibrillin-1). These findings are consistent with a previous proteomics 
assessment from our laboratory which documented an altered secretion profile of coronary 
PVAT in obese swine which corresponded with pathways associated with cellular growth 
and proliferation and cellular movement.9 Furthermore, these alterations in the secretion 
profile were also associated with increases in vascular smooth muscle contraction.9 
Together with reports of elevated expression of leptin in obese coronary PVAT,2 the 
current proteomic findings support a role for leptin in coronary vascular contraction and 
proliferation in the setting of obesity. 
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 These findings have significant (patho)physiologic implications. Recent studies 
from our laboratory and others indicate that obesity augments coronary smooth muscle 
CaV1.2 current and voltage dependent increases in intracellular Ca2+ concentration.9;141;265 
Changes in intracellular Ca2+ handling are known to influence both contraction and 
phenotypic modulation of coronary smooth muscle (i.e. development of a proliferative 
and/or osteogenic phenotype).144;266;267 Recent data also indicate that leptin increases 
proliferation of isolated smooth muscle cells197;198 and that perivascular leptin 
overexpression promotes neointimal formation in peripheral (non-coronary) arteries.207 
Taken together, the present findings and those of others support the growing paradigm 
regarding a mechanistic role for heightened levels of leptin in obesity-induced coronary 
disease. 
 
Leptin and coronary smooth muscle contraction 
 Current understanding of the effects of leptin on vasoconstriction is rather limited 
and conflicting. Acute leptin administration has been shown to inhibit angiotensin (Ang) II-
induced contractions of isolated rat aorta by diminishing the increase in cytosolic [Ca2+] in 
smooth muscle cells.202 In contrast, other studies fail to demonstrate an effect of leptin on 
contractile responses to Ang II, noradrenaline, or endothelin-1.202 Chronic systemic leptin 
administration in normal rats has been shown to produce modest increases in 
phenlyephrine-induced contractions of aortic rings.268 These disparate findings are likely 
related to differences in the concentration of leptin used (0.01 – 100 nmol/L), duration of 
treatment, vascular bed being studied, and/or the overall health status of the animal 
model. Results from this study demonstrate that “obese” concentrations of leptin (30 
ng/mL) potentiate depolarization-induced contraction of coronary arteries following acute 
(30 min, Figure 3.1A) and chronic administration (3 day culture, Figure 3.1B). These 
distinct coronary vascular effects of leptin are consistent with recent studies documenting 
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a unique contractile effect of coronary PVAT on vascular smooth muscle compared to 
other artery/adipose tissue depots that is further augmented in the setting of obesity.9 
Results also demonstrate that leptin has little to no effect on thromboxane A2 receptor-
mediated contractions (Appendix B, Figure II), suggesting that the functional effects of 
leptin observed in this study are specifically related to depolarization-induced contraction. 
This effect of leptin is consistent with reports of augmented coronary vasoconstriction in 
the setting of obesity4 and, together with both elevated plasma leptin concentration191;192 
and increased local (coronary PVAT) leptin production2;177 in the setting of obesity, support 
the potential for leptin (plasma and/or local PVAT-derived) to contribute to the 
development of coronary vascular smooth muscle dysfunction. 
 
Rho kinase and coronary smooth muscle contraction  
 The mechanisms by which leptin influences coronary vascular smooth muscle 
function remain ill defined. Recent studies suggest a connection between leptin and 
RhoA/Rho kinase signaling,259-261 which is a well-known major regulator of smooth muscle 
contraction and vascular tone.220 However, whether RhoA/Rho kinase contributes to the 
coronary vascular effects of leptin has not been determined. Data from this investigation 
support a role for Rho kinase in leptin-mediated increases in depolarization-induced 
coronary artery contraction. These findings are consistent with previous studies from our 
laboratory which found marked increases in RhoA expression in obese coronary PVAT 
and that inhibition of Rho kinase attenuates PVAT-mediated increases in coronary 
vascular smooth muscle contraction.9 We propose the effects of leptin occur independent 
of influences on coronary endothelium as studies in endothelium denuded arteries 
(Appendix B, Figure II) were directionally consistent with studies in endothelium intact 
arteries. 
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 The present findings also indicate that the effects of leptin on the Rho kinase 
pathway are time-dependent. Acutely, inhibition of Rho kinase significantly inhibits 
coronary artery contractions both in the presence (Figure 3.2C) and absence (Figure 
3.2A) of leptin, whereas following chronic culture for 3 days, the inhibition of Rho kinase 
significantly inhibits coronary artery contractions only in the presence of leptin (Figure 
3.2D). It is important to note that, in the absence of leptin, the contribution of Rho kinase 
to KCl-induced contractions was reduced following organ culture (Figure 3.2B versus 
3.2A) and that the effects of the Rho kinase inhibitor, fasudil, on contractile responses 
following chronic (Figure 3.2D) compared to acute (Figure 3.2C) leptin exposure were 
relatively modest. Interestingly, these findings are consistent with previous reports of a 
reduced contribution of Rho kinase to maximal KCl contractions in obese compared to 
lean arteries.9 
 The time-dependent effects of leptin on Rho kinase are further highlighted data 
indicating that acute (30 min) leptin treatment increased Rho kinase activity (Figure 3.3C), 
independent of changes in Rho kinase expression (Figure 3.3A and 3.3B), while chronic 
exposure to leptin (3 day culture) was associated with increased Rho kinase protein 
abundance (Figure 3.3D and 3.3E) with little/no change in overall Rho kinase activity 
(Figure 3.3F). It should be noted, however, that overall Rho kinase activity of cultured 
arteries was significantly elevated relative to untreated, acute controls (Figure 3.3F 
versus Figure 3.3C). Altogether, these findings indicate that the coronary vascular 
actions of leptin are mediated, at least in part, via time-dependent influences on Rho 
kinase activity (acute) and expression (chronic) and are consistent with phenotypic 
changes observed in coronary artery disease. 
 Although the proteomic analyses in this study indicated alterations in pathways 
involved in the regulation of vascular tone, no significant alterations in proteins involved in 
the regulation of Rho kinase activation (e.g., RhoA, rho GDP-dissociation inhibitor, rho 
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GTPase activating protein) or in Rho kinase substrates involved in contraction (e.g., 
MYPT-1, CPI-17, myosin light chain MLC) were detected by Ingenuity Pathway Analysis 
following chronic, 3 day leptin treatment (Appendix A, Table I). However, it is important 
to consider that the proteomics approach used in this study excludes the examination of 
the phosphorylation status of key regulatory proteins in this cascade as well as the 
examination of potential lipid mediators. Despite the lack of detection of a direct 
connection, the proteomic analyses provide valuable insights into the complex cellular 
processes and pathways influenced by chronic leptin exposure.  
 
Leptin and coronary vascular smooth muscle proliferation 
 Based on the current and prior evidence supporting that leptin is associated with 
cellular growth and proliferation pathways, additional experiments were performed to 
directly investigate the effects of leptin on coronary proliferation. In these studies, coronary 
arteries were cultured in serum-containing media for 8 days. Quantitation of co-
immunostaining for PCNA and α-smooth muscle actin revealed a significant increase in 
PCNA-positive vascular smooth muscle cells in arteries exposed to leptin (30 ng/ml) that 
was inhibited by co-incubation with fasudil (Figure 3.4). The leptin-induced increase in 
coronary proliferation reported in this study was associated with a modest increase in Rho 
kinase protein abundance (Figure 3.5A and 3.5B) and a significant increase in Rho 
kinase activity (Figure 3.5C) relative to untreated, controls. These data further support 
that the effects of leptin on Rho kinase protein abundance and activity are dependent, at 
least in part, on the time-course of administration (e.g., acute, 3 day, 8 day) and culture 
condition (e.g., serum-free versus serum-containing). Although the precise molecular 
mechanisms responsible for this dynamic effect of leptin on Rho kinase signaling are 
presently unknown, we postulate that these effects occur independently of influences on 
coronary endothelium, as endothelial denudation had little to no effect on functional 
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responses following chronic, 8 day treatment with leptin and/or fasudil (Appendix B, 
Figure IV). However, the possibility that the observed effects of leptin on proliferation are 
mediated by factors released from endothelial cells cannot be ruled out. Our findings are 
consistent with other studies which have documented leptin-induced vascular smooth 
muscle hypertrophy,260;269 smooth muscle proliferation,197;198;207 and neointimal 
formation206;207 in rodent models, although contrasting evidence in rat aortic smooth 
muscle cells exposed to Ang II270 and in a human smooth muscle cell line256 have also 
been reported. However, to our knowledge, the present data are the first to demonstrate 
that (patho)physiologically relevant (“obese”) concentrations of leptin are capable of 
promoting vascular smooth muscle proliferation and to provide evidence in support of a 
mechanistic linkage between Rho kinase and leptin-mediated increases in proliferation in 
the coronary circulation.  
 
Limitations 
 Although this investigation utilizes arteries from the translationally relevant porcine 
coronary circulation, relevant obese concentrations of leptin, and a time course (i.e., acute 
and chronic) of leptin administration, it is presently unclear to what extent these findings 
translate to the human condition. However, the present study is among the first to 
systematically investigate the factors and pathways involved in leptin-induced phenotypic 
alterations of coronary arteries (i.e., increased contraction and proliferation). While 
functional data support that the vascular smooth muscle layer is responsible for the 
observed effects of leptin, the precise factors and cell types involved remain to be 
definitively determined. Additionally, a pharmacologic approach was utilized to interrogate 
the Rho kinase pathway in this study. Based on reported IC50 values for fasudil,271-273 a 
concentration of 1 µM was chosen to potently inhibit Rho kinase and minimize off target 
effects. Although the possibility of non-specific effects cannot be ruled out, data in which 
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fasudil diminishes Rho kinase activity in this study (Figure 3.5C) support the specificity 
and efficacy of this pharmacologic approach. However, future genetic knockdown (e.g. 
antisense oligonucleotides) studies to confirm the present findings are warranted.  
 
Conclusions & Implications 
 The present data provide novel evidence that relevant obese concentrations of 
leptin promote increases in coronary vasoconstriction and smooth muscle proliferation and 
that these phenotypic effects are directly associated with alterations in the coronary artery 
proteome and dynamic effects on the Rho kinase pathway. Although the current studies 
were conducted using (patho)physiologically relevant (“obese”) concentrations of leptin, a 
critical question remains as to the extent to which locally produced versus circulating leptin 
contributes to the initiation and progression of coronary disease in vivo. Future studies to 
directly investigate the mechanisms responsible for the time-dependent effects of leptin 
on Rho kinase protein abundance and activity are also warranted. Regardless, this 
investigation provides novel evidence in support of leptin as an upstream mediator of the 
hypercontractile and proliferative coronary smooth muscle phenotype reported in obesity-
induced coronary disease.  
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Summary of Findings 
 The World Health Organization has described obesity as one of the most visible, 
yet most neglected, public health crises in recent history, as increased adiposity is a 
significant risk factor for cardiovascular disease, the leading cause of death throughout 
the world.274;275 A recent World Health Organization agreement challenged healthcare 
systems throughout the world to develop innovative strategies to address the burden of 
cardiovascular disease being fueled by the obesity pandemic.276 However, despite 
significant advances in research over the past several decades, the precise mechanism(s) 
linking increased adiposity and cardiovascular disease remain poorly understood.   
 There is a growing body of evidence to support a role for local epicardial adipose 
tissue in the development of obesity-induced cardiovascular disease. In particular, recent 
findings implicate the adipose tissue immediately surrounding the major coronary arteries, 
known as coronary perivascular adipose tissue (PVAT), in the initiation and progression 
of coronary artery disease. Coronary PVAT has been shown to be one of the best 
predictors of the presence and severity of coronary artery disease, even more so than 
other visceral adipose tissue depots (e.g., abdominal adipose).277 This supports a novel 
paracrine pathway for the development of coronary vascular disease that may function 
independently of alterations in circulating adipokine levels. This “outside-in” hypothesis is 
supported by recent studies that reveal an upregulation of pro-atherogenic adipokines 
released from coronary PVAT in the setting of obesity and demonstrate effects of these 
adipokines on inflammation, endothelial and smooth muscle function, and 
atherogenesis.2;9;15;176;177 Although prior findings implicate coronary PVAT in the 
pathogenesis of vascular dysfunction, the precise mechanisms by which specific coronary 
PVAT-derived factors influence smooth muscle function and the progression of 
atherogenesis have not been established. 
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 Accordingly, the central focus of this work was to examine the potential role of 
PVAT in the development of coronary vascular dysfunction in the setting of obesity. 
Specifically, the goal of this investigation was to delineate the mechanisms by which 
PVAT-derived factors (e.g., leptin) influence coronary vascular smooth muscle function 
and the pathogenesis of obesity-induced coronary disease. The findings of the following 
Specific Aims are summarized below: 
 
Aim 1. Delineate the mechanisms by which lean vs. obese coronary PVAT 
influences coronary vascular smooth muscle reactivity.  
Studies were designed to examine the effects of lean and obese coronary PVAT 
on end-effector mechanisms of coronary vasodilation and to identify potential PVAT-
derived factors involved. An initial examination of the effects of PVAT on vasodilation 
revealed that the presence of coronary PVAT attenuated adenosine relaxation in coronary 
arteries from both lean and obese swine (Figure 2.5). Adenosine-induced dilation was 
nearly abolished by pre-constriction with KCl and was unaffected by removal of the 
endothelium in both control and PVAT-treated arteries, suggesting that these particular 
effects of PVAT on coronary vasodilation are mediated by endothelial-independent 
influences on coronary artery K+ channels.   
 Further studies provided novel evidence that lean and obese PVAT have distinct 
inhibitory effects on specific coronary artery K+ channel subtypes. In arteries from the 
same animal, lean coronary PVAT impaired KCa and KV7 channel-mediated dilation while 
obese coronary PVAT impaired KATP but not KCa or KV7 channel-mediated dilation (Figure 
2.3). In the absence of PVAT, vasodilation to KCa and KV7 channel activation was 
attenuated in obese relative to lean coronary arteries. However, cross-over studies in 
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which lean arteries (i.e., normal, healthy vascular reactivity) were incubated with lean and 
obese PVAT also revealed a lack of effect of obese PVAT on KCa and KV7 channels 
(Figure 2.8). These findings strongly support that lean and obese PVAT-derived factors 
differentially affect KCa, KV7 and KATP channels. Figure 4.1 illustrates these important 
findings. 
 
Previous reports of a pro-atherogenic and pro-inflammatory adipokine profile of 
obese coronary PVAT were supported by evidence of atheroma formation (Figure 2.4E) 
and macrophage infiltration (Figure 2.4I) in obese coronary arteries surrounded by PVAT. 
Despite these characteristics, similarities in coronary perivascular adipocyte diameter 
were documented in lean and obese swine (Figure 2.4A and 2.4B), suggesting that 
Figure 4.1 Factors derived from lean and obese coronary perivascular adipose 
tissue (PVAT) inhibit K+ channel-mediated vasodilation. Coronary PVAT attenuates 
vasodilation via differential inhibition of vascular smooth muscle K+ channels. Lean PVAT-
derived factors inhibit KCa and KV7 channels, while obese PVAT-derived factors inhibit 
KATP channels. These inhibitory effects occur independently of underlying differences in 
smooth muscle reactivity in coronary arteries from lean and obese swine. 
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phenotypic differences in coronary PVAT occur independently of gross changes in 
morphology. Additional studies were designed to examine the potential for the recently 
identified coronary perivascular adipokine, calpastatin, to influence coronary vasodilation. 
Calpastatin mimicked the effects of lean coronary PVAT, attenuating adenosine dilation in 
lean coronary arteries (Figure 2.9A). This effect of calpastatin was lost in obese arteries 
(Figure 2.9B), mimicking the lack of effect of obese PVAT on KCa and KV7 channel-
mediated dilation.  
Taken together, these findings demonstrate that although coronary perivascular 
adipocytes from lean and obese swine share similar morphology, lean and obese PVAT-
derived factors impair vasodilation via differential inhibition of vascular smooth muscle K+ 
channels. These results further support the paradigm of distinct “outside to inside” 
signaling influences of coronary PVAT and that alterations in specific factors such as 
calpastatin are capable of contributing to the initiation and/or progression of smooth 
muscle dysfunction in the setting of obesity.   
 
Aim 2. Test the hypothesis that leptin acts as an upstream mediator in the 
development of coronary vascular smooth muscle dysfunction and disease.  
Global proteomic analysis performed on coronary arteries chronically exposed to 
elevated levels of leptin (i.e., plasma concentrations typically observed in obese subjects) 
identified significant alterations in the coronary artery proteome relative to untreated, 
control arteries (Table 3.1). Overall, significant alterations in 69 proteins (P ≤ 0.05) were 
detected in leptin treated arteries. Further analysis with Ingenuity Pathway Analysis 
software revealed that leptin treatment was associated with alterations in numerous 
cellular functions, including calcium signaling (4 proteins) and cellular growth and 
proliferation (35 proteins).  
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 The mechanistic effects of leptin on coronary vascular reactivity were examined by 
comparing KCl-induced contractions of coronary arteries following acute (30 min) and 
chronic (3 day serum-free culture) exposure to obese concentrations of leptin (30 ng/mL). 
Both acute (Figure 3.1A) and chronic (Figure 3.1B) leptin administration potentiated KCl 
contraction of isolated coronary arteries. Importantly, the inhibition of Rho kinase 
significantly reduced leptin-mediated increases in depolarization-induced coronary 
contraction (Figure 3.2). The effects of leptin on the functional expression of Rho kinase 
were time-dependent, as acute treatment increased Rho kinase activity (Figure 3.3C) 
while chronic (3 day) exposure was associated with increases in Rho kinase protein 
abundance (Figure 3.3D and 3.3E).    
Studies were also conducted to directly investigate the effects of obese 
concentrations of leptin (30 ng/mL) on coronary vascular proliferation. Quantitation of both 
BrdU incorporation and co-immunostaining for PCNA and α-smooth muscle actin revealed 
a significant increase in cellular proliferation in coronary arteries chronically exposed to 
leptin (8 day, serum-containing culture, Figure 3.4). This increase in proliferation was 
associated with a significant increase in Rho kinase activity (Figure 3.5C) and a modest 
increase in Rho kinase protein abundance (Figure 3.5A and 3.5B). Inhibition of Rho 
kinase significantly reduced leptin-mediated increases in proliferation and Rho kinase 
activity (Figure 3.4D and 3.5C). 
Taken together, these studies indicate that pathophysiologic, obese 
concentrations of leptin promote increases in coronary vasoconstriction and smooth 
muscle proliferation and that these phenotypic effects are associated with alterations in 
the coronary artery proteome and dynamic effects on the Rho kinase pathway. Figure 4.2 
illustrates these findings.  
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Implications 
 Findings from this investigation substantially contribute to the growing body of 
evidence that changes in the phenotype of coronary PVAT occur concomitantly with 
mechanistic alterations in endothelium and smooth muscle in the setting of obesity-
induced coronary disease. The present findings also support the paradigm of outside-to-
inside signaling influences of coronary PVAT and that alterations of specific factors, such 
as leptin and calpastatin, are capable of contributing to the initiation and/or progression of 
smooth muscle dysfunction in the setting of obesity. In particular, results from this 
investigation demonstrate that coronary perivascular adipokines have the potential to 
augment coronary vasoconstriction, diminish vasodilation, and promote vascular smooth 
Figure 4.2 Leptin increases coronary vasoconstriction and smooth muscle 
proliferation. Leptin promotes progressive increases in coronary vasoconstriction via 
alterations in Rho kinase signaling. Acute (30 min) leptin administration increases Rho 
kinase (ROCK) activity, whereas chronic (3 day culture) leptin exposure increases ROCK 
protein abundance. Leptin mediated increases in vascular smooth muscle cell proliferation 
following chronic (8 day culture) administration are associated with increases in Rho 
kinase activity. 
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muscle proliferation in the setting of obesity. These phenotypic effects are related to 
alterations in the coronary artery proteome, Rho kinase signaling, and the functional 
expression of smooth muscle K+ channels. Taken together, we submit that factors derived 
from coronary PVAT causally contribute to the development of coronary vascular smooth 
muscle dysfunction (i.e., altered vascular reactivity) in the setting of obesity and propose 
that obese coronary PVAT-derived leptin is a critical upstream modulator of the 
development of the hypercontractile and proliferative smooth muscle phenotype reported 
in obesity-induced coronary disease (see schematic diagram in Figure 4.3 below). 
Figure 4.3 Proposed mechanisms of action of coronary PVAT-derived factors on 
vascular smooth muscle function. Lean and obese PVAT-derived factors attenuate 
vasodilation via inhibitory effects on vascular smooth muscle K+ channels. Inhibitory 
effects on K+ channels serve to increase CaV1.2 channel activity, further potentiating 
contraction. In the setting of obesity, alterations in specific factors are capable of 
influencing smooth muscle function. Increased leptin promotes progressive increases in 
coronary vasoconstriction and augments smooth muscle proliferation. These leptin-
mediated effects are associated with increases in Rho kinase (ROCK) activity and/or 
expression. Increased calpastatin promotes vasoconstriction, which is proposed to occur 
via activation of CaV1.2 channels. 
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Future Directions and Proposed Studies 
 This investigation produced several novel observations regarding the effects of 
coronary perivascular adipokines on coronary smooth muscle function. However, it is 
important to identify remaining questions as well as logical future directions of this 
research work in order to continue to advance our understanding of the role of coronary 
PVAT in obesity-induced coronary disease. 
 
Causal Role for Coronary PVAT-derived Factors in Vivo 
 Present findings clearly demonstrate the potential for obese PVAT and relevant 
obese concentrations of adipokines (i.e., leptin) to influence coronary smooth muscle 
reactivity via influences on K+ channels and Rho kinase signaling. These findings are 
consistent with alterations in the functional expression of K+ channels and Rho kinase-
dependent contraction in obese coronary arteries. However, a critical question remains as 
to whether chronic exposure of the coronary vasculature to the PVAT milieu directly 
contributes to these phenotypic alterations of coronary arteries in the setting of obesity. 
Thus, there is a need to further characterize a causal link between coronary PVAT-derived 
factors and the initiation and/or progression of coronary vascular dysfunction and disease. 
An experimental approach that could selectively overexpress a specific target in coronary 
PVAT would examine the potential for a causal relationship in vivo. The use of lentiviral 
vectors to selectively overexpress these factors in coronary PVAT would address this 
critical question. Preliminary “proof of principle” experiments were performed to assess 
the feasibility of transfecting porcine coronary PVAT both in vitro and in vivo. Successful 
in vivo transfection of coronary PVAT was confirmed  in vitro  following injection of 
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lentivirus expressing GFP (150 µL virus, 
infectious titer 1 x 109 per mL) and in vivo 8 days 
after injection of lentiviral GFP (350 µL virus, 
infectious titer 1 x 109 per mL) (Figure 4.4).  
 The identification of the precise factor(s) 
responsible for the vascular effects of coronary 
PVAT remains an ongoing endeavor. Based on 
recent data implicating a role for leptin and 
calpastatin in the development of coronary 
vascular dysfunction in obesity, there is rationale 
for investigating the effects these factors on the 
development of coronary vascular dysfunction and atherogenesis in vivo. In particular, 
there is substantial rationale to support the hypothesis that overexpression of leptin in 
coronary PVAT accelerates the development of a hypercontractile and proliferative 
coronary smooth muscle phenotype in the setting of obesity. However, although present 
studies were conducted using relevant, obese concentrations of leptin (Chapter 3), the 
extent to which locally produced (i.e., PVAT-derived) versus circulating plasma leptin 
contributes to the progression of coronary artery disease in vivo has not been addressed. 
Accordingly, the overexpression of leptin in specific PVAT depots would allow for direct 
comparisons between regions of the coronary tree that receive lentiviral transfection (e.g., 
circumflex artery region), null vector transfection (e.g., right coronary artery region), or no 
injection (e.g., left anterior descending coronary artery region) in the same animal, such 
that each animal would serve as its own control. Following the injections, swine could be 
placed on a normal caloric diet (i.e., normal, healthy plasma leptin concentration) or a 
high-calorie, atherogenic diet (i.e., elevated plasma leptin concentration) for a period of 3-
Figure 4.4 Lentiviral transfection of 
coronary PVAT. Representative 
image of in vitro lentiviral GFP (green) 
transfection of coronary PVAT (top). 
Confocal image of GFP expression in 
PVAT following in vivo lentiviral 
injection (bottom).  
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6 months. Throughout several months of leptin overexpression with or without atherogenic 
diet, the degree of atherosclerotic disease and plaque morphology among the different 
artery regions could be mapped using intravascular ultrasound. Subsequently, these 
tissues could support several in vitro, immunohistochemical, and molecular studies 
including: isometric tension studies to assess vascular reactivity to K+ and Ca2+ channel 
agonists, immunohistochemistry to assess vascular smooth muscle proliferation (BrdU) 
and the degree of macrophage infiltration-foam cell formation (serum response antigen), 
and Western blot analyses to determine effects on signaling pathways (e.g., Rho kinase, 
PKC) and ion channels (e.g., K+ and Ca2+). Results from these studies would elucidate the 
effects of coronary PVAT-derived leptin on coronary vascular function and atherogenesis 
in the presence and absence of systemically elevated leptin. Furthermore, these studies 
would be the first to systematically investigate a potential causal contribution of PVAT-
derived factors to the initiation and development of coronary disease in vivo.  
 
Coronary PVAT and Coronary Artery Calcification 
 Strong and growing evidence supports that coronary PVAT displays a unique 
phenotype relative to other adipose tissue depots and is capable of locally producing 
factors with the potential to influence the development of coronary disease. Recent studies 
have identified the expression of osteogenic factors including osteoprotegerin and 
osteoglycin in coronary PVAT, particularly in obese subjects with coronary artery 
disease.9;73 This unique expression profile is directly associated with the severity of 
coronary artery disease and the degree of underlying artery calcification.18;100;180 
Interestingly, numerous studies implicate a role for leptin in the production of osteogenic 
factors such as osteoprotegerin, receptor activator of nuclear factor-κB ligand (RANKL), 
and osteocalcin.10;278-281 Furthermore, recent evidence suggests that there is a distinct 
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relationship between serum RANKL and osteoprotegerin levels (i.e., increased 
RANKL/osteoprotegerin ratio) with the severity of atherosclerotic disease in humans.19;281-
283 Despite these promising findings, there is still no unifying hypothesis regarding the 
contribution of coronary PVAT-derived factors to the development of coronary vascular 
calcification and atherogenesis.  Accordingly, future studies should explore a potential 
mechanistic link between coronary PVAT-derived factors, such as leptin and 
osteoprotegerin, and coronary vascular calcification in the setting of obesity. In 
accordance with the findings of the current investigation of leptin as an upstream mediator 
of coronary vascular dysfunction and disease, future studies should investigate the 
hypothesis that leptin released from coronary PVAT promotes coronary vascular 
calcification via influences on the RANKL/osteoprotegerin signaling axis (see schematic 
diagram in Figure 4.5 below).  
 Both in vitro and in vivo approaches should be utilized to investigate this 
hypothesis. Similar to the culture studies described in Chapter 3, coronary arteries could 
be cultured in a pro-calcification media containing fetal bovine serum, PO43, and alkaline 
phosphatase with/without relevant, obese concentrations of leptin, osteoprotegerin, or 
RANKL for a period of 2-8 days. Following the culture period, coronary arteries could be 
subjected to a variety of relevant analyses, including isometric tension studies to assay 
vascular reactivity, histologic analysis of artery calcification using Von Kossa staining, and 
Western blot analyses to probe relevant downstream signaling pathways such as bone 
morphogenic protein-4, nuclear factor-κB, and Rho kinase. Additionally, measures of 
osteoprotegerin and RANKL in leptin treated arteries, as well as the surrounding culture 
media, should be performed in order to investigate the potential for leptin signaling to 
regulate the production of these factors. Co-culture studies of leptin and 
osteoprotegerin/RANKL should also be considered to assay a possible interrelationship 
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of these factors in mediating vascular calcification. The use of lentiviral vectors to 
overexpress these factors in coronary PVAT in vivo and subsequent in vitro and molecular 
analyses could be performed, as described above. Results from these experiments would 
provide critical examination of the functional relevance of PVAT-derived leptin, 
osteoprotegerin, and/or RANKL in the development of coronary vascular calcification and 
atherogenesis in vivo.  
Figure 4.5 Proposed mechanism of coronary PVAT-derived leptin action on 
coronary vascular calcification and disease. Leptin has been associated with 
increased release of osteoprotegerin (OPG) and receptor activator of nuclear factor-κB 
ligand (RANKL),10 which could be mediated through leptin-stimulated release from 
coronary PVAT or inflammatory tumor necrosis factor-α  (TNF-α) signaling from coronary 
endothelial cells. Studies suggest that OPG exacerbates endothelial dysfunction and 
promotes inflammatory cell infiltration.18;19 Leptin has been shown to upregulate RANKL 
expression and promote osteogenic differentiation and calcification of vascular smooth 
muscle cells,22 which may also be stimulated via leptin receptor (ObR) signaling. Overall, 
these promising findings support the hypothesis of leptin as an upstream regulator of the 
calcification of coronary vascular smooth muscle cells.  
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 An investigation regarding a potential mechanistic link between PVAT-derived 
factors, such as leptin, and the initiation and/or progression of vascular calcification is 
warranted based on recent findings and is a logical extension of the present work which 
supports leptin as an upstream mediator of coronary vascular disease. Findings from 
these studies would substantially advance current knowledge regarding the functional 
mechanistic effects of coronary PVAT in the context of obesity-related coronary disease.  
 
Concluding Remarks 
 Despite the alarming obesity pandemic and the growing body of evidence 
implicating coronary PVAT, the adipose tissue immediately surrounding large coronary 
arteries, in the initiation and progression of coronary disease, the mechanisms underlying 
the link between coronary PVAT and vascular dysfunction and the precise PVAT-derived 
factors involved remain poorly understood. The central goal of this work was to delineate 
the mechanisms by which PVAT-derived factors influence coronary vascular smooth 
muscle function and the development of obesity-induced coronary disease. Results from 
these investigations clearly illustrate that factors released from lean and obese coronary 
PVAT influence vascular smooth muscle reactivity via differential inhibition of smooth 
muscle K+ channels. Data also support that alterations in specific factors, such as leptin 
and calpastatin, are capable of contributing to the development of smooth muscle 
dysfunction in the setting of obesity. In particular, chronic exposure to elevated levels of 
leptin markedly alters the coronary artery proteome and progressively augments coronary 
artery contractions. Further studies implicated leptin-induced alterations in Rho kinase 
signaling in the development of a hypercontractile and proliferative smooth muscle 
phenotype. Taken together, findings from this investigation provide novel mechanistic 
evidence linking coronary PVAT and vascular dysfunction. Above all, the present findings 
98 
support a role for coronary PVAT in the initiation and progression of coronary disease and 
highlight specific PVAT-derived factors as potential targets for therapeutic intervention. 
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APPENDIX A: Supplemental Table 
Table I. Complete list of protein changes detected in leptin-treated coronary arteries 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
calsarcin 1 [Sus scrofa] 0.258 0.258 1.490 0.281 5.784 0.02224 
ras-related protein Rab-21 [Bos 
taurus] 
0.258 0.258 1.231 0.215 4.780 0.00024 
PREDICTED: sorbin and SH3 
domain-containing protein 1 
isoform 1 [Ceratotherium simum 
simum] 
1.291 0.975 5.667 0.915 4.391 0.00710 
PREDICTED: LIM and SH3 
domain protein 1 isoform X1 
[Loxodonta africana] 
1.004 0.421 3.247 0.778 3.234 0.04793 
PREDICTED: eukaryotic 
translation initiation factor 6 
isoform X1 [Equus caballus] 
1.260 0.258 1.994 0.052 1.582 0.04877 
adipose specific 2 [Sus scrofa] 3.586 1.391 5.547 1.081 1.547 0.01758 
PREDICTED: non-muscle 
caldesmon isoform X1 [Sus 
scrofa] 
34.882 3.369 52.065 4.141 1.493 0.00491 
myotrophin [Homo sapiens] 4.024 0.424 5.947 0.589 1.478 0.02820 
protein S100-A11 [Sus scrofa] 4.309 0.562 6.181 0.802 1.435 0.03670 
60S ribosomal protein L12 [Mus 
musculus] 
6.139 1.680 8.180 1.548 1.333 0.01125 
PREDICTED: tropomyosin 
alpha-4 chain isoform 3 
[Trichechus manatus latirostris] 
83.834 6.385 109.518 7.208 1.306 0.01805 
PREDICTED: tropomyosin 
alpha-4 chain isoform 2 
[Trichechus manatus latirostris] 
96.952 7.387 123.493 7.044 1.274 0.02291 
  
1
0
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
hypothetical protein 
CB1_000172007 [Camelus ferus] 
92.690 7.586 116.227 7.239 1.254 0.02265 
PREDICTED: tubulin alpha 
chain-like [Canis lupus familiaris] 
17.534 0.968 20.608 1.172 1.175 0.01756 
PREDICTED: tropomyosin beta 
chain isoform 1 [Canis lupus 
familiaris] 
185.488 11.935 215.973 5.359 1.164 0.03469 
PREDICTED: tubulin alpha-1A 
chain-like [Equus caballus] 
75.314 3.450 82.436 3.646 1.095 0.00926 
PREDICTED: transitional 
endoplasmic reticulum ATPase 
[Ovis aries] 
10.398 1.452 11.243 1.614 1.081 0.03649 
PREDICTED: LOW QUALITY 
PROTEIN: myoferlin [Sus scrofa] 
1.984 0.550 0.261 0.261 -7.590 0.02799 
PREDICTED: delta-1-pyrroline-5-
carboxylate dehydrogenase, 
mitochondrial [Equus caballus] 
1.476 0.448 0.243 0.243 -6.080 0.00918 
ATPase inhibitor, mitochondrial 
precursor [Sus scrofa] 
1.267 0.272 0.259 0.259 -4.894 0.00003 
sorcin [Bos taurus] 1.260 0.258 0.261 0.261 -4.821 0.00003 
PREDICTED: translocon-
associated protein subunit delta 
isoformX1 [Sus scrofa] 
2.483 0.425 0.954 0.551 -2.603 0.04270 
cAMP-dependent protein kinase 
type II-alpha regulatory subunit 
[Sus scrofa] 
1.267 0.272 0.493 0.285 -2.569 0.04252 
PREDICTED: LOW QUALITY 
PROTEIN: chondroitin sulfate 
proteoglycan 4 [Sus scrofa] 
4.764 0.933 1.976 0.384 -2.411 0.02713 
heat shock protein 90 alpha 
[Equus caballus] 
16.304 0.884 6.962 2.030 -2.342 0.02046 
  
1
0
2
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
phosphate carrier protein, 
mitochondrial [Sus scrofa] 
5.769 0.721 2.487 0.280 -2.319 0.01566 
PREDICTED: fibrillin-1 
[Erinaceus europaeus] 
31.725 6.279 14.566 8.410 -2.178 0.01951 
protein disulfide isomerase family 
A, member 4 precursor [Sus 
scrofa] 
5.769 0.721 2.706 0.399 -2.132 0.03800 
RecName: Full=Ribonuclease 
inhibitor; AltName: 
Full=Ribonuclease/angiogenin 
inhibitor 1 [Sus scrofa] 
5.783 0.492 2.724 0.433 -2.123 0.00433 
PREDICTED: LOW QUALITY 
PROTEIN: fibrillin-1 [Felis catus] 
45.016 9.359 21.334 12.353 -2.110 0.03330 
dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 2 precursor [Sus scrofa] 
7.757 0.711 3.934 0.724 -1.972 0.01836 
Chain A, Structure Of Glutamate 
Dehydrogenase Complexed With 
Bithionol 
4.519 0.253 2.471 0.227 -1.828 0.00041 
PREDICTED: integrin alpha-1 
[Sus scrofa] 
11.781 0.983 6.486 0.868 -1.816 0.04630 
Chain A, Crystal Structure Of 
Porcine Aldehyde Reductase 
Ternary Complex 
6.535 0.654 3.676 0.745 -1.778 0.00017 
hypothetical protein 
PANDA_012129 [Ailuropoda 
melanoleuca] 
1.755 0.245 0.997 0.026 -1.760 0.04256 
PREDICTED: ATP synthase 
subunit b, mitochondrial [Sus 
scrofa] 
3.020 0.069 1.736 0.238 -1.740 0.01894 
  
1
0
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: calreticulin [Equus 
caballus] 
9.489 1.636 5.628 1.584 -1.686 0.01366 
PREDICTED: prostacyclin 
synthase isoform X1 [Sus scrofa] 
12.396 1.539 7.377 1.684 -1.680 0.02832 
PREDICTED: collagen alpha-
1(XIV) chain isoform X1 [Sus 
scrofa] 
78.779 3.063 47.471 4.658 -1.660 0.01278 
PREDICTED: LOW QUALITY 
PROTEIN: ubiquitin-like modifier 
activating enzyme 1 [Sus scrofa] 
12.607 1.346 7.704 1.591 -1.637 0.03853 
hypothetical protein 
PANDA_019876 [Ailuropoda 
melanoleuca] 
2.766 0.254 1.724 0.440 -1.604 0.04743 
PREDICTED: LOW QUALITY 
PROTEIN: neuroblast 
differentiation-associated protein 
AHNAK [Capra hircus] 
26.261 2.876 17.150 2.095 -1.531 0.00744 
calpain-2 catalytic subunit [Sus 
scrofa] 
12.114 1.105 7.959 0.335 -1.522 0.03649 
RecName: Full=L-lactate 
dehydrogenase A chain; 
Short=LDH-A; AltName: 
Full=LDH muscle subunit; 
Short=LDH-M [Sus scrofa] 
16.064 1.286 10.635 1.669 -1.510 0.02359 
PREDICTED: transmembrane 
protein 109-like [Ailuropoda 
melanoleuca] 
7.509 0.498 5.013 0.520 -1.498 0.02765 
dermatopontin precursor [Bos 
taurus] 
7.035 0.922 4.725 0.207 -1.489 0.04980 
  
1
0
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
alpha-crystallin B chain 
[Oryctolagus cuniculus] 
27.360 1.370 18.690 1.113 -1.464 0.01028 
protein disulfide-isomerase A3 
precursor [Sus scrofa] 
20.767 1.652 14.538 2.162 -1.429 0.04491 
lumican precursor [Sus scrofa] 34.624 4.503 24.337 3.975 -1.423 0.00826 
PREDICTED: LOW QUALITY 
PROTEIN: neuroblast 
differentiation-associated protein 
AHNAK [Ovis aries] 
27.025 3.273 19.104 1.750 -1.415 0.01529 
Moesin [Pteropus alecto] 34.832 2.058 25.027 1.669 -1.392 0.03728 
glyceraldehyde-3-phosphate 
dehydrogenase [Sus scrofa] 
38.195 3.502 27.918 2.370 -1.368 0.00487 
hypothetical protein 
CB1_001341009 [Camelus ferus] 
18.356 0.507 13.443 1.192 -1.366 0.01312 
Chain A, Structure Of Pig Muscle 
Pgk Complexed With Mgatp 
32.384 1.055 24.059 1.313 -1.346 0.00197 
PREDICTED: elongation factor 2 
[Sus scrofa] 
26.117 1.288 19.803 2.247 -1.319 0.03958 
PREDICTED: LOW QUALITY 
PROTEIN: neuroblast 
differentiation-associated protein 
AHNAK [Tursiops truncatus] 
24.972 2.460 19.120 2.026 -1.306 0.00849 
PREDICTED: 78 kDa glucose-
regulated protein-like [Ailuropoda 
melanoleuca] 
28.360 1.661 22.023 1.574 -1.288 0.01731 
PREDICTED: T-complex protein 
1 subunit zeta isoformX1 [Equus 
caballus] 
7.347 0.884 5.732 0.620 -1.282 0.01049 
PREDICTED: LOW QUALITY 
PROTEIN: AHNAK nucleoprotein 
[Sus scrofa] 
33.820 3.865 26.585 2.561 -1.272 0.02246 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: elongation factor 
1-delta isoform X4 [Sus scrofa] 
4.047 0.633 3.269 0.545 -1.238 0.01977 
Chain A, X-Ray Structure Of Full-
Length Annexin 1 
57.789 3.069 46.700 2.254 -1.237 0.00267 
annexin A2 [Sus scrofa] 81.978 4.401 68.049 4.666 -1.205 0.02374 
PREDICTED: WD repeat-
containing protein 1 isoform X2 
[Mustela putorius furo] 
24.342 1.691 20.421 2.096 -1.192 0.00872 
thioredoxin-dependent peroxide 
reductase, mitochondrial [Sus 
scrofa] 
7.023 0.292 5.983 0.156 -1.174 0.02274 
PREDICTED: vinculin isoform X1 
[Sus scrofa] 
119.348 4.302 106.039 5.949 -1.126 0.02628 
PREDICTED: EH domain-
containing protein 2 [Sus scrofa] 
26.506 2.799 23.891 2.757 -1.109 0.00404 
heat shock protein 70kDa protein 
8 [Capra hircus] 
18.079 0.613 17.123 0.848 -1.056 0.03843 
reticulocalbin 2, EF-hand calcium 
binding domain precursor [Sus 
scrofa] 
1.476 0.448 0.000 0.000 0.000 0.04580 
PREDICTED: cytochrome b-c1 
complex subunit 1, mitochondrial 
isoform X1 [Sus scrofa] 
1.476 0.448 0.000 0.000 0.000 0.04580 
              
MULTISPECIES: nitrogen 
regulatory protein P-II 1 
[Pseudomonas] 
0.23493 0.23493 1.9427 1.9427 8.269271698 0.391002219 
PREDICTED: synaptopodin-2 
isoform X1 [Orycteropus afer 
afer] 
0.488805 0.28263531 4.01695 1.27273008 8.217898753 0.082955279 
  
1
0
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: synemin isoform 
X1 [Lipotes vexillifer] 
0.260075 0.260075 1.231365 0.21457457 4.734653465 0.085621219 
PREDICTED: collagen alpha-
2(IV) chain [Sus scrofa] 
1.007805 0.72902688 4.7238 1.12860976 4.687216277 0.055005478 
PREDICTED: filamin-A isoform 
X1 [Ornithorhynchus anatinus] 
78.0625 78.0625 322.545 1.93813699 4.131881505 0.050705015 
similar to cytoplasmic dynein 
light chain 1 [Bos taurus] 
0.260075 0.260075 1.04305 0.73940262 4.010573873 0.391899516 
hypothetical protein 
PANDA_002907 [Ailuropoda 
melanoleuca] 
0.488805 0.28263531 1.490165 0.28137997 3.048587883 0.172658966 
PREDICTED: LOW QUALITY 
PROTEIN: laminin subunit alpha-
5 [Bos taurus] 
0.77405 0.49698584 2.34755 1.72776503 3.032814418 0.391903963 
PREDICTED: SUN domain-
containing protein 2 isoform X1 
[Sus scrofa] 
0.253875 0.253875 0.744475 0.46804115 2.93244707 0.499101166 
dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit DAD1 [Sus scrofa] 
0.5177 0.29890093 1.5040775 0.67349178 2.905307128 0.375166859 
PREDICTED: laminin subunit 
alpha-5 [Ceratotherium simum 
simum] 
1.507725 0.66091962 4.323375 1.42480154 2.867482465 0.225458215 
PREDICTED: glycine--tRNA 
ligase isoform X1 [Sus scrofa] 
0.260075 0.260075 0.7271 0.4533045 2.795732 0.392505995 
PREDICTED: 40S ribosomal 
protein S14-like [Sarcophilus 
harrisii] 
1.006505 0.02283821 2.734865 1.03865183 2.717189681 0.189377295 
TPA: cellular retinoic acid-
binding protein 1 [Bos taurus] 
1.02545 0.41462076 2.705575 0.39869136 2.638427032 0.091648916 
  
1
0
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain A, Structural Basis Of The 
70-Kilodalton Heat Shock 
Cognate Protein Atp Hydrolytic 
Activity, Ii. Structure Of The 
Active Site With Adp Or Atp 
Bound To Wild Type And Mutant 
Atpase Fragment 
6.343 6.343 16.4375 5.52484271 2.591439382 0.263224284 
PREDICTED: cellular nucleic 
acid-binding protein isoform X2 
[Ornithorhynchus anatinus] 
0.492555 0.28497986 1.231365 0.21457457 2.49995432 0.05436688 
Ribosomal protein L3 [Bos 
taurus] 
0.51395 0.29677235 1.2746025 0.50326453 2.480012647 0.058569339 
PREDICTED: small nuclear 
ribonucleoprotein Sm D1 [Equus 
caballus] 
0.5115 0.29533054 1.24875 0.60687726 2.441348974 0.444372388 
unconventional myosin-Ic 
isoform b [Camelus ferus] 
6.751625 4.40886367 16.311525 2.62500349 2.415940607 0.248428968 
PREDICTED: 40S ribosomal 
protein S21 [Ornithorhynchus 
anatinus] 
0.77405 0.49698584 1.7602775 0.27651465 2.274113429 0.090337268 
tubulin beta-6 chain [Bos taurus] 7.2135 7.2135 15.48925 8.94971651 2.147258612 0.340052857 
collagen alpha-1(IV) chain 
precursor [Bos taurus] 
1.52423 0.31599565 3.269 0.5450397 2.14468945 0.050983207 
PREDICTED: nexilin isoformX1 
[Equus caballus] 
1.0292 0.42073099 2.2013 0.56323131 2.138845705 0.070796767 
hypothetical protein 
PANDA_015940 [Ailuropoda 
melanoleuca] 
1.1936 0.88796798 2.5213 1.45764816 2.112349196 0.27468909 
D-dopachrome decarboxylase 
[Sus scrofa] 
0.5115 0.29533054 1.037825 0.73200165 2.028983382 0.597589397 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
hypothetical protein 
PANDA_001588 [Ailuropoda 
melanoleuca] 
0.74643 0.24960188 1.49279 0.2864035 1.99990622 0.054829328 
ubiquitin-conjugating enzyme E2 
D2 [Sus scrofa] 
1.25793 0.49381205 2.508565 0.67382356 1.99420079 0.094704976 
leiomodin-1 [Bos taurus] 3.077675 1.25067503 6.11965 1.31619116 1.988400335 0.195584174 
matrin-3 [Bos taurus] 0.77405 0.49698584 1.5334025 0.67642755 1.981012209 0.058559222 
Copper transport protein ATOX1, 
partial [Bos mutus] 
0.771575 0.25724221 1.5174425 0.3254179 1.966681787 0.076545378 
TPA: elongin B-like [Bos taurus] 0.51395 0.29677235 0.988525 0.38354477 1.923387489 0.3837056 
galectin-3 [Sus scrofa] 1.02545 0.41462076 1.969775 0.36453145 1.92088839 0.173083485 
calcium/calmodulin-dependent 
protein kinase type II subunit 
gamma [Oryctolagus cuniculus] 
1.521755 0.52368543 2.74355 0.88718926 1.802885484 0.312661824 
PREDICTED: laminin subunit 
alpha-5 [Pteropus alecto] 
1.965175 0.6423131 3.54175 0.95017397 1.802256796 0.237217836 
PREDICTED: sorbin and SH3 
domain-containing protein 2 
isoform X5 [Sus scrofa] 
14.2028 2.6755844 25.43625 5.63425141 1.79093207 0.065176462 
PREDICTED: polypyrimidine 
tract-binding protein 1 isoform X1 
[Sorex araneus] 
1.546925 0.66745894 2.746175 0.50194035 1.775247669 0.113055905 
Chain A, Refined Structure Of 
Porcine Cytosolic Adenylate 
Kinase At 2.1 Angstroms 
Resolution 
1.52423 0.31599565 2.69425 0.78564622 1.767613812 0.117340448 
PREDICTED: thioredoxin 
domain-containing protein 17 
isoform 1 [Sus scrofa] 
2.008125 0.84254326 3.505775 0.68487716 1.745795207 0.21637304 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Leiomodin-1 [Tupaia chinensis] 2.262 0.88215829 3.9369 0.58914 1.740450928 0.07525657 
PREDICTED: transcriptional 
activator protein Pur-alpha-like, 
partial [Ailuropoda melanoleuca] 
1.2818 0.76585626 2.228575 0.1965077 1.738629271 0.354120077 
PREDICTED: poly [ADP-ribose] 
polymerase 6 isoform X2 [Sus 
scrofa] 
39.84425 23.2293831 69.26025 4.59655199 1.738274657 0.240371352 
PREDICTED: keratin, type I 
cytoskeletal 14 isoform X1 
[Galeopterus variegatus] 
4.5088 1.89907393 7.75565 2.68631712 1.720113999 0.357797129 
PREDICTED: translocon-
associated protein subunit alpha 
isoform X1 [Monodelphis 
domestica] 
1.2893 0.49657962 2.192615 0.86717125 1.70062437 0.238883247 
heart fatty acid-binding protein 
[Sus scrofa] 
2.54968 0.53687186 4.290875 0.84929843 1.682907267 0.09331917 
PREDICTED: B-cell receptor-
associated protein 31 isoform X1 
[Sus scrofa] 
1.49905 0.27457939 2.498675 0.31019821 1.666838998 0.124311312 
PREDICTED: keratin, type I 
cytoskeletal 19-like [Galeopterus 
variegatus] 
3.038475 0.44727697 5.039175 1.16511484 1.658455311 0.07505649 
PREDICTED: 40S ribosomal 
protein S8 [Equus caballus] 
0.765375 0.48680041 1.2647 0.47925842 1.652392618 0.606466474 
PREDICTED: tryptophan--tRNA 
ligase, cytoplasmic isoformX1 
[Sus scrofa] 
0.755105 0.49427151 1.231365 0.21457457 1.630720231 0.505692042 
PREDICTED: dynactin subunit 2 
isoformX2 [Equus caballus] 
1.543175 0.51449313 2.5073525 0.64249711 1.624801141 0.435830313 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
extracellular superoxide 
dismutase precursor [Sus scrofa] 
0.765375 0.48680041 1.231365 0.21457457 1.608838805 0.407883873 
leukotriene A-4 hydrolase [Sus 
scrofa] 
1.991625 0.55919918 3.179925 0.78088465 1.596648465 0.072458048 
hypothetical protein 
PANDA_018340 [Ailuropoda 
melanoleuca] 
1.546925 0.66745894 2.426765 1.09341726 1.56876707 0.235371407 
fatty acid binding protein 4 [Sus 
scrofa] 
3.610275 1.37406546 5.569275 2.01228983 1.542617945 0.27818017 
PREDICTED: septin-9-like 
isoform X1 [Sus scrofa] 
1.776955 1.14867041 2.74009 0.60774177 1.542014288 0.413519855 
PREDICTED: coronin-1B [Sus 
scrofa] 
0.9851 0.56995448 1.5174425 0.3254179 1.540394376 0.593919161 
interleukin enhancer-binding 
factor 2 [Mus musculus] 
1.266605 0.27209125 1.9425 0.63780214 1.533627295 0.459408797 
thrombospondin 1 precursor [Sus 
scrofa] 
6.63105 1.66591513 10.111 1.14489085 1.524796224 0.12336597 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 
B1 [Homo sapiens] 
4.847925 1.11369535 7.37835 1.10650044 1.521960426 0.24418042 
PREDICTED: cysteine and 
glycine-rich protein 2 isoform X1 
[Sus scrofa] 
7.57495 1.40920328 11.51795 1.43420852 1.520531489 0.110276528 
PREDICTED: laminin subunit 
beta-2-like [Odobenus rosmarus 
divergens] 
7.206 1.83984677 10.825975 2.6690736 1.502355676 0.437927026 
protein SET isoform 2 [Homo 
sapiens] 
0.520175 0.520175 0.779025 0.49602796 1.497620993 0.396468174 
PREDICTED: protein DJ-1 
[Camelus ferus] 
0.939725 0.939725 1.4049 1.4049 1.495011839 0.825346305 
  
1
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
40S ribosomal protein S12 
[Homo sapiens] 
1.53043 0.67716146 2.2804775 0.52714099 1.490089387 0.468677593 
chitinase-3-like protein 1 
precursor [Sus scrofa] 
1.002755 0.41514941 1.4841 0.61443455 1.480022538 0.593770093 
glycogenin-1 [Oryctolagus 
cuniculus] 
1.037875 0.73563086 1.5334025 0.67642755 1.477444297 0.420607147 
PREDICTED: 60S ribosomal 
protein L38 isoform X1 
[Monodelphis domestica] 
2.053375 0.93260476 3.026165 0.75548118 1.47375175 0.064054278 
cystatin B protein [Sus scrofa] 2.553455 0.68677109 3.76195 0.67617061 1.473278362 0.13238317 
PREDICTED: collagen alpha-
1(VI) chain isoform X2 [Mustela 
putorius furo] 
10.528875 2.5107948 15.4846 3.97701308 1.470679441 0.194501553 
proteasome 26S non-ATPase 
subunit 11 [Bos taurus] 
0.495005 0.28652777 0.7271 0.4533045 1.468874052 0.720305909 
PREDICTED: keratin, type I 
cytoskeletal 10-like [Ailuropoda 
melanoleuca] 
19.756 4.69138395 28.9255 1.70821527 1.464137477 0.175508717 
PREDICTED: plectin isoform 1 
[Ceratotherium simum simum] 
2.846175 1.6554083 4.1299 1.78220671 1.451035161 0.190155206 
PREDICTED: smoothelin isoform 
X1 [Sus scrofa] 
11.674325 2.58558251 16.8645 3.27450929 1.444580308 0.431351248 
PREDICTED: collagen alpha-
1(VI) chain [Physeter catodon] 
10.03385 2.57262692 14.4561 3.00627103 1.440733118 0.120999911 
EIF6 protein [Bos taurus] 1.031675 0.42476168 1.481475 0.61209667 1.435990016 0.384936899 
EH-domain containing 1 [Bos 
taurus] 
1.5507 0.98751958 2.223325 0.86807199 1.433755723 0.468684667 
PREDICTED: purine nucleoside 
phosphorylase isoform X1 [Sus 
scrofa] 
1.0292 0.42073099 1.471575 0.49222164 1.429824135 0.546759582 
  
1
1
2
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 4 [Sus scrofa] 
1.7554 0.24539619 2.47869 0.60705176 1.412037143 0.418220519 
PREDICTED: tropomyosin 
alpha-1 chain-like isoform X1 
[Bos mutus] 
129.185 43.7592934 180.0475 2.95107713 1.393718311 0.345376335 
PREDICTED: PRKC apoptosis 
WT1 regulator protein [Orcinus 
orca] 
1.26038 0.25786916 1.75419 0.50465304 1.391794538 0.179006114 
PREDICTED: LOW QUALITY 
PROTEIN: laminin subunit beta-2 
[Sus scrofa] 
13.027775 1.84186083 18.108 4.10386604 1.389953388 0.371397769 
aldose 1-epimerase [Sus scrofa] 2.530725 0.33377169 3.50315 0.52935184 1.384247597 0.113946917 
PREDICTED: keratin, type I 
cytoskeletal 10 [Chrysochloris 
asiatica] 
15.651725 3.877081 21.64425 2.39614275 1.382866745 0.292309369 
Sorting nexin-12 [Tupaia 
chinensis] 
2.533175 0.54416157 3.489825 0.67297229 1.377648603 0.452985295 
PREDICTED: dual specificity 
protein phosphatase 3 isoform 2 
[Sus scrofa] 
3.441575 1.07050772 4.72725 0.22616664 1.373571693 0.292557331 
PREDICTED: chloride 
intracellular channel protein 4 
[Erinaceus europaeus] 
3.064955 0.86015343 4.1957 0.52022727 1.368927113 0.172684508 
40S ribosomal protein S15a 
[Homo sapiens] 
2.03198 0.43064859 2.773425 0.54024765 1.364887942 0.2403883 
PREDICTED: palladin [Sus 
scrofa] 
10.2162 2.65349535 13.8811 2.06534778 1.358734167 0.3753886 
PREDICTED: perilipin-4 [Sus 
scrofa] 
0.767825 0.48725115 1.04045 0.60071938 1.355061375 0.359980012 
  
1
1
3
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: KN motif and 
ankyrin repeat domain-containing 
protein 2 isoformX1 [Canis lupus 
familiaris] 
1.804575 0.88158463 2.44415 0.57821994 1.35441863 0.463770462 
PREDICTED: SH3 domain-
binding glutamic acid-rich-like 
protein-like [Sus scrofa] 
12.750675 3.23306656 17.18675 0.29984451 1.347909032 0.259086153 
T-complex protein 1 subunit delta 
[Tupaia chinensis] 
3.32618 1.16688007 4.470475 0.84414999 1.344026781 0.338577461 
40S ribosomal protein S28 
[Homo sapiens] 
2.78705 0.52494877 3.743375 0.50890497 1.343131627 0.061700102 
PREDICTED: integrin alpha-5 
isoform 1 [Sus scrofa] 
3.816275 0.69668978 5.12245 1.34118798 1.342264381 0.484314315 
PREDICTED: histone H2A type 
1-E-like [Equus caballus] 
9.501725 3.37631706 12.72675 4.28976902 1.339414685 0.651800203 
hypothetical protein 
PANDA_004938 [Ailuropoda 
melanoleuca] 
1.5028 0.65435142 2.01039 0.43822103 1.337762843 0.615573943 
PREDICTED: coronin-1C isoform 
X1 [Sus scrofa] 
5.036325 0.44775143 6.735 0.53687657 1.337284627 0.064926766 
polymerase I and transcript 
release factor isoform 2 [Bos 
taurus] 
21.03875 2.96604645 28.04 3.0381976 1.332778801 0.141552484 
protein DJ-1 [Sus scrofa] 4.279925 0.28083418 5.70325 0.561163 1.332558398 0.187209781 
protein S100-A6 [Sus scrofa] 2.81108 0.89857662 3.728615 0.98125638 1.326399462 0.13910146 
PREDICTED: uncharacterized 
protein LOC102248938 [Myotis 
brandtii] 
35.76475 5.85671562 46.956 9.83965082 1.312912854 0.455225418 
coactosin-like protein [Bos 
taurus] 
1.518005 0.30559001 1.98834 0.57278126 1.309837583 0.184420273 
  
1
1
4
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: EF-hand domain-
containing protein D1 [Sus 
scrofa] 
3.04225 0.45866798 3.977525 0.56060922 1.307428712 0.112362335 
PREDICTED: 26S protease 
regulatory subunit 6B isoform 1 
[Equus caballus] 
0.775325 0.4937467 1.0105525 0.73241178 1.303392126 0.746981565 
heterogeneous nuclear 
ribonucleoprotein A/B [Sus 
scrofa] 
1.49155 0.64528063 1.939875 0.76614252 1.300576581 0.770070384 
Chain A, Destrin, Nmr, Minimized 
Average Structure 
10.606525 1.12625845 13.71595 2.59087894 1.293161521 0.202319846 
PREDICTED: vimentin 
[Pantholops hodgsonii] 
227.3375 76.875569 293.21 16.7337623 1.289756419 0.438023043 
PREDICTED: ATP synthase 
subunit gamma, mitochondrial 
isoform X2 [Equus caballus] 
4.054975 0.64959546 5.2016 0.36583681 1.282769931 0.183054568 
PREDICTED: fatty acid-binding 
protein, heart isoform X2 
[Pantholops hodgsonii] 
2.553455 0.68677109 3.275075 0.69090141 1.282605333 0.527725063 
PREDICTED: basal cell 
adhesion molecule isoform X1 
[Sus scrofa] 
4.521075 0.26841515 5.785075 1.01727916 1.279579525 0.285037185 
PREDICTED: thioredoxin 
domain-containing protein 5, 
partial [Sus scrofa] 
0.771575 0.25724221 0.9859 0.57063117 1.277775978 0.677580829 
PREDICTED: LOW QUALITY 
PROTEIN: transcriptional 
activator protein Pur-beta [Canis 
lupus familiaris] 
10.62235 2.16909059 13.5705 1.77825952 1.277542163 0.336544375 
  
1
1
5
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: T-complex protein 
1 subunit epsilon [Monodelphis 
domestica] 
2.530725 0.33377169 3.225775 0.18039649 1.274644618 0.07329543 
hypothetical protein 
PANDA_008751 [Ailuropoda 
melanoleuca] 
4.3013 0.80003162 5.479 0.28951373 1.273800944 0.214683206 
PREDICTED: keratin, type I 
cytoskeletal 14 [Myotis brandtii] 
6.32065 1.33241743 8.04195 2.76458309 1.272329586 0.559425712 
PREDICTED: LOW QUALITY 
PROTEIN: NADH 
dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 6 
[Oryctolagus cuniculus] 
0.771575 0.25724221 0.9812525 0.39721785 1.271752584 0.759416369 
PREDICTED: hypothetical 
protein LOC100468944 
[Ailuropoda melanoleuca] 
79.379 27.6583902 100.915 33.6530805 1.271306013 0.708948754 
60S ribosomal protein L23 
[Pongo abelii] 
2.025755 0.72446126 2.5738275 1.24715816 1.270552214 0.685368718 
PREDICTED: histone H2A type 
1-like [Equus caballus] 
90.69825 17.8658617 115.07925 20.6674042 1.268814448 0.514641686 
PREDICTED: alpha/beta 
hydrolase domain-containing 
protein 14B [Equus caballus] 
2.547255 0.67892223 3.23185 0.47715041 1.268757937 0.567034803 
40S ribosomal protein S4 [Bos 
taurus] 
1.807 0.77825968 2.28395 1.13690856 1.263945766 0.744415125 
PREDICTED: SH3 domain-
binding glutamic acid-rich-like 
protein-like isoform X1 [Equus 
caballus] 
11.428775 1.95312085 14.41075 0.29299015 1.260918165 0.206290878 
  
1
1
6
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: protein-glutamine 
gamma-glutamyltransferase 2 
[Sus scrofa] 
61.02275 8.48150406 76.54025 6.9991197 1.254290408 0.17770027 
dynein light chain roadblock-type 
1 [Rattus norvegicus] 
1.00898 0.42538844 1.2612425 0.66449335 1.250017344 0.794736677 
PREDICTED: importin-5 isoform 
X1 [Monodelphis domestica] 
1.006505 0.02283821 1.2560175 0.27241258 1.247899911 0.410953137 
PREDICTED: lysine--tRNA 
ligase isoform X2 [Sorex 
araneus] 
1.006505 0.02283821 1.2560175 0.27241258 1.247899911 0.410953137 
PREDICTED: plectin [Lipotes 
vexillifer] 
3.5637 1.01671112 4.431925 1.70669267 1.243630216 0.394339605 
PREDICTED: PDZ and LIM 
domain protein 7-like [Ailuropoda 
melanoleuca] 
14.794075 2.77525033 18.359 2.31226314 1.24096978 0.378847811 
PREDICTED: plectin [Vicugna 
pacos] 
3.8816 2.24962597 4.8163 2.34113035 1.240802762 0.59853346 
PREDICTED: carbonyl reductase 
[NADPH] 1-like, partial [Sus 
scrofa] 
2.785925 0.79005233 3.438725 0.8148219 1.234320737 0.476211292 
heterogeneous nuclear 
ribonucleoprotein D0 [Bos 
taurus] 
1.9941 0.37085747 2.4601 0.60135043 1.233689384 0.467889234 
PREDICTED: platelet-activating 
factor acetylhydrolase IB subunit 
beta [Equus caballus] 
1.807 0.77825968 2.228575 0.1965077 1.233301051 0.574429779 
PREDICTED: adenylyl cyclase-
associated protein 2, partial [Sus 
scrofa] 
1.006505 0.02283821 1.2400525 0.23550094 1.232038092 0.431761829 
  
1
1
7
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain B, Crystal Structure Of 
The Mammalian 20s Proteasome 
At 2.75 A Resolution 
4.84925 1.18917601 5.96205 0.68521504 1.229478785 0.47872135 
Keratin, type II cytoskeletal 1 
[Pteropus alecto] 
40.3265 3.48275204 49.4775 4.35272107 1.226922743 0.235063617 
F-actin-capping protein subunit 
beta [Bos taurus] 
4.843 1.10250498 5.940025 0.42900206 1.226517654 0.456361893 
laminin subunit gamma-1 
precursor [Sus scrofa] 
17.15375 2.85096274 20.92625 4.45260778 1.219922757 0.616231791 
PREDICTED: LOW QUALITY 
PROTEIN: chloride intracellular 
channel protein 1 [Sus scrofa] 
0.769125 0.49267537 0.9366 0.9366 1.21774744 0.784314392 
PREDICTED: zyxin isoform X1 
[Sus scrofa] 
6.354525 1.42574826 7.73685 1.42119916 1.217533962 0.200222494 
Galectin-1, partial [Tupaia 
chinensis] 
7.32945 1.21369013 8.915725 0.73158932 1.216424834 0.464394676 
proteasome subunit alpha type-6 
[Ovis aries] 
2.247975 0.19068227 2.732825 0.23111146 1.215683004 0.166515154 
RecName: Full=UMP-CMP 
kinase; AltName: 
Full=Deoxycytidylate kinase; 
Short=CK; Short=dCMP kinase; 
AltName: Full=Nucleoside-
diphosphate kinase; AltName: 
Full=Uridine 
monophosphate/cytidine 
monophosphate kinase; 
Short=UMP/CMP kinase; 
Short=UMP/CMPK [Sus scrofa] 
2.060875 0.73224263 2.487375 0.27982541 1.206950931 0.464925018 
  
1
1
8
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: F-actin-capping 
protein subunit alpha-1 [Capra 
hircus] 
0.77288 0.77288 0.9366 0.9366 1.21184 0.391 
prelamin-A/C [Sus scrofa] 42.78225 2.77303334 51.59225 2.34840192 1.205926523 0.057785816 
calumenin isoform 2 precursor 
[Oryctolagus cuniculus] 
1.235225 0.46689688 1.48754 0.66119014 1.204266429 0.836218043 
ubiquitin-conjugating enzyme 
E2N-like [Bos taurus] 
4.5614 0.92941628 5.481625 0.30698353 1.20174179 0.349888496 
PREDICTED: LOW QUALITY 
PROTEIN: ribosomal protein S19 
[Bos mutus] 
6.86095 1.15715389 8.244225 1.13779425 1.201615665 0.492356667 
PREDICTED: biglycan [Sus 
scrofa] 
42.489 5.49115156 51.003 7.52154533 1.200381275 0.195546575 
thioredoxin [Sus scrofa] 9.36775 1.27117254 11.2335 0.79139566 1.199167356 0.366628784 
PREDICTED: proteasome 
activator complex subunit 1-like 
[Ailuropoda melanoleuca] 
1.0292 0.42073099 1.22874 0.47432116 1.193878741 0.712578513 
PREDICTED: histone H1.1-like 
[Ochotona princeps] 
74.49175 16.1394595 88.91375 12.814068 1.193605332 0.61338643 
long-chain 3-ketoacyl-CoA 
thiolase [Sus scrofa] 
2.252875 0.87022431 2.686975 0.68511265 1.192687122 0.757444135 
dynein light chain 2, cytoplasmic 
[Mus musculus] 
2.547255 0.67892223 3.03485 0.65082687 1.191419783 0.640460409 
PREDICTED: LOW QUALITY 
PROTEIN: profilin-2 [Oryctolagus 
cuniculus] 
2.526975 0.32394161 3.0102 0.4622025 1.191226664 0.179612141 
  
1
1
9
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: glycogen 
phosphorylase, brain form 
isoform X1 [Pteropus alecto] 
1.266605 0.27209125 1.50875 0.50531196 1.191176413 0.633578133 
PREDICTED: serine/threonine-
protein phosphatase 2A activator 
[Leptonychotes weddellii] 
1.035425 0.59781643 1.231365 0.21457457 1.189236304 0.721837265 
Peptidyl-prolyl cis-trans 
isomerase NIMA-interacting 1 
[Myotis brandtii] 
1.26038 0.25786916 1.4988525 0.29511734 1.189206827 0.656472165 
PREDICTED: cullin-associated 
NEDD8-dissociated protein 1-like 
[Monodelphis domestica] 
4.57515 1.04412008 5.43575 0.5038974 1.188103122 0.480778418 
Chain A, Crevice-Forming 
Mutants In The Rigid Core Of 
Bovine Pancreatic Trypsin 
Inhibitor: Crystal Structures Of 
F22a, Y23a, N43g, And F45a 
4.296425 0.79184256 5.078575 1.39602843 1.182046702 0.682662587 
PREDICTED: 40S ribosomal 
protein S16 [Anolis carolinensis] 
4.298875 0.67442198 5.072525 1.27654156 1.179965689 0.466138671 
RecName: Full=Transforming 
growth factor-beta-induced 
protein ig-h3; Short=Beta ig-h3; 
AltName: Full=Kerato-epithelin; 
AltName: Full=RGD-containing 
collagen-associated protein; 
Short=RGD-CAP; Flags: 
Precursor [Sus scrofa] 
5.492475 0.78738755 6.476775 1.36578225 1.179208827 0.264589329 
PREDICTED: UTP--glucose-1-
phosphate uridylyltransferase 
isoformX2 [Equus caballus] 
1.26413 0.26648333 1.490165 0.28137997 1.178806768 0.46830929 
  
1
2
0
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: astrocytic 
phosphoprotein PEA-15 
[Monodelphis domestica] 
2.7846 0.30212183 3.275075 0.69090141 1.176138404 0.532130403 
hypothetical protein 
CB1_000606063 [Camelus ferus] 
32.53325 3.24208918 38.063 3.6659892 1.169972259 0.344357648 
PREDICTED: PDZ and LIM 
domain protein 3 isoform X1 [Sus 
scrofa] 
8.075125 1.64654425 9.44065 0.51786431 1.169102645 0.528783167 
PREDICTED: proteasome 
subunit alpha type-5 
[Monodelphis domestica] 
2.765675 0.25413744 3.23185 0.47715041 1.168557405 0.264359223 
PREDICTED: collagen alpha-
2(VI) chain [Sus scrofa] 
21.704775 6.06120125 25.34625 2.8813512 1.16777299 0.538906978 
RecName: Full=Gelsolin; 
AltName: Full=Actin-
depolymerizing factor; 
Short=ADF; AltName: 
Full=Brevin; Flags: Precursor, 
partial [Sus scrofa] 
44.84425 2.93491506 52.36625 4.5699961 1.167736109 0.165225148 
hypothetical protein 
PANDA_003128 [Ailuropoda 
melanoleuca] 
7.0822 1.30338013 8.25775 0.79313502 1.165986558 0.149295125 
septin-7 isoform 2 [Homo 
sapiens] 
7.0947 1.19324901 8.184575 0.44011937 1.153618194 0.275939425 
PREDICTED: 
phosphoglucomutase-like protein 
5 [Equus przewalskii] 
29.19225 1.9147396 33.58775 3.19927399 1.150570785 0.215533548 
  
1
2
1
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: histone H2B type 
1-B-like [Ceratotherium simum 
simum] 
38.324 5.57846251 43.975 9.85522613 1.147453293 0.666416865 
serine/threonine-protein 
phosphatase 2A catalytic subunit 
beta isoform [Bos taurus] 
1.514255 0.51124989 1.735625 0.23786866 1.146190701 0.656661828 
Keratin, type II cytoskeletal 5 
[Myotis davidii] 
17.22625 6.1305061 19.7375 7.45241035 1.145780422 0.826868341 
peptidyl-prolyl cis-trans 
isomerase FKBP2 isoform 1 [Bos 
taurus] 
1.518005 0.30559001 1.738225 0.64794714 1.145071986 0.696446641 
PREDICTED: keratin, type II 
cytoskeletal 1 [Loxodonta 
africana] 
37.066 4.24267795 42.40425 4.78551734 1.144020126 0.535495959 
PREDICTED: elongation factor 
1-gamma [Sus scrofa] 
1.270355 0.50040816 1.44955 0.602617 1.141058995 0.827928896 
PREDICTED: keratin, type II 
cytoskeletal 1 [Mustela putorius 
furo] 
40.87075 4.6208469 46.6275 4.73014534 1.140852566 0.520209353 
PREDICTED: 3-hydroxyacyl-CoA 
dehydrogenase type-2 isoform 2 
[Sus scrofa] 
6.066675 0.80607318 6.9126 0.73376624 1.139437995 0.613744691 
hypothetical protein 
PANDA_001716 [Ailuropoda 
melanoleuca] 
1.781855 0.50834451 2.0297925 1.4118414 1.139145722 0.867830067 
ras-related protein Rab-5B [Bos 
taurus] 
8.787175 1.09329727 9.995375 1.16939645 1.137495839 0.544999332 
elongation factor 1-beta 
[Oryctolagus cuniculus] 
1.52423 0.31599565 1.733 0.23271051 1.136967518 0.494165352 
catechol O-methyltransferase 
[Sus scrofa] 
1.511805 0.66268013 1.71705 0.44468545 1.135761557 0.826407178 
  
1
2
2
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
programmed cell death protein 5 
[Bos taurus] 
3.29855 0.53104064 3.746 0.2941983 1.135650513 0.163879593 
galectin-1 [Sus scrofa] 25.35725 4.96405599 28.762 1.29962065 1.134271264 0.606390857 
protein phosphatase 1 regulatory 
subunit 14A [Sus scrofa] 
6.995275 0.67180323 7.934475 0.38174402 1.134262055 0.118943323 
PREDICTED: histidine triad 
nucleotide-binding protein 1-like 
[Sus scrofa] 
1.746725 0.63618883 1.978475 0.38611276 1.132676867 0.668194913 
hydroxyacyl-coenzyme A 
dehydrogenase/3-ketoacyl-
coenzyme A thiolase/enoyl-
coenzyme A hydratase alpha 
subunit [Sus scrofa] 
9.649425 1.50633661 10.9256 1.54813276 1.132253994 0.375670977 
PREDICTED: alpha-actinin-3 
[Sorex araneus] 
25.796 3.67551849 29.2065 3.13021643 1.13221042 0.242941591 
PREDICTED: flavin reductase 
(NADPH) [Sus scrofa] 
3.307225 1.01129631 3.743375 0.50890497 1.131877934 0.518734721 
cytochrome c [Bos taurus] 2.014325 0.73071291 2.274415 0.67958931 1.129120177 0.839672126 
heterogeneous nuclear 
ribonucleoprotein K [Oryctolagus 
cuniculus] 
6.85325 1.76415191 7.6903 1.13070146 1.122139131 0.528616568 
rho GDP-dissociation inhibitor 1 
[Bos taurus] 
7.04315 0.43823997 7.898575 0.85935234 1.121454889 0.254294058 
PREDICTED: lysozyme C 
[Chrysochloris asiatica] 
2.2682 0.65524251 2.5419025 0.70391636 1.120669474 0.84071795 
PREDICTED: 60S ribosomal 
protein L31-like [Chrysochloris 
asiatica] 
2.039505 0.74145197 2.2778775 0.67185046 1.116877625 0.851154337 
  
1
2
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: calcium-binding 
protein 39 isoform X1 [Equus 
caballus] 
1.778105 0.27964838 1.98574 0.37929463 1.116773194 0.334446264 
septin 2 [Sus scrofa] 3.7722 0.25830315 4.211675 0.69226697 1.116503632 0.458639266 
PREDICTED: filamin-C 
isoformX1 [Sus scrofa] 
65.54525 3.79476333 73.08825 6.10449208 1.115080803 0.180313109 
PREDICTED: myosin-9 
[Dasypus novemcinctus] 
92.7255 3.38214632 103.36725 5.36620871 1.114766165 0.15265488 
filamin-A [Sus scrofa] 51.5625 5.20962779 57.47075 3.4937609 1.114584242 0.074065937 
calpain small subunit 1 
[Oryctolagus cuniculus] 
5.795475 0.79626803 6.44165 0.52478918 1.111496469 0.614146065 
glutathione S-transferase mu 2 
[Sus scrofa] 
4.254775 0.42590501 4.72725 0.22616664 1.111045825 0.105667983 
alpha-actinin-1 [Sus scrofa] 115.883 10.8352274 128.3 11.5450891 1.107151178 0.158117808 
PREDICTED: LOW QUALITY 
PROTEIN: bromodomain 
adjacent to zinc finger domain 
protein 1A [Oryctolagus 
cuniculus] 
11.902125 1.71310656 13.16915 1.34342271 1.106453679 0.425037782 
PREDICTED: 
dihydropyrimidinase-related 
protein 3 isoform 1 
[Ceratotherium simum simum] 
26.24275 2.57663739 28.86525 1.6589642 1.099932362 0.343598809 
profilin-1 [Sus scrofa] 55.1165 5.29946426 60.622 2.5720382 1.099888418 0.325798338 
PREDICTED: ATP synthase 
subunit delta, mitochondrial-like 
isoform 1 [Sus scrofa] 
2.2731 0.28541387 2.496075 0.30248977 1.098092913 0.477569494 
PREDICTED: NAD(P)H-hydrate 
epimerase [Equus caballus] 
2.03818 0.44531691 2.237275 0.23089851 1.097682737 0.775376708 
  
1
2
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: guanine 
nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
isoform X1 [Equus caballus] 
6.554325 0.57770388 7.187375 0.45924546 1.096585079 0.094199315 
PREDICTED: uncharacterized 
protein LOC101365636 
[Odobenus rosmarus divergens] 
5.54535 0.91900348 6.076975 1.70217388 1.095868611 0.822312031 
PREDICTED: pyruvate kinase 
PKM [Ornithorhynchus anatinus] 
20.91425 2.08962299 22.90625 1.76328313 1.095246064 0.458722057 
PREDICTED: LanC lantibiotic 
synthetase component C-like 1 
[Sus scrofa] 
2.288305 0.77675231 2.50594 0.51680876 1.095107514 0.725868444 
actin, cytoplasmic 1 [Camelus 
ferus] 
79.59875 2.41055939 87.14725 1.66523964 1.094831891 0.119447522 
PREDICTED: EH domain-
containing protein 4 [Pteropus 
alecto] 
4.797625 0.34718232 5.2495 1.15191 1.094187228 0.660667028 
prohibitin-2 [Bos taurus] 2.4891 0.6032175 2.721525 0.42832117 1.093377124 0.781981315 
PREDICTED: 3-hydroxybutyrate 
dehydrogenase type 2-like 
isoform 1 [Sus scrofa] 
2.285855 0.64932137 2.496075 0.30248977 1.091965588 0.820826869 
PREDICTED: unconventional 
myosin-Ic [Sus scrofa] 
22.6025 3.57810198 24.67525 4.35537496 1.091704457 0.680428527 
PREDICTED: myosin-9 [Felis 
catus] 
111.4875 0.91799033 121.61 4.62177996 1.090794932 0.107402993 
PREDICTED: filamin-A isoform 
X2 [Bos mutus] 
553.145 15.2830879 603.2 8.21748846 1.090491643 0.056319923 
PREDICTED: filamin-A isoform 2 
[Trichechus manatus latirostris] 
533.665 14.7728543 580.8575 9.06294597 1.088430945 0.05469397 
PREDICTED: filamin-A isoform 
X2 [Pteropus alecto] 
581.04 16.0971369 631.38 10.1905405 1.086637753 0.070615551 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: filamin-A isoform 2 
[Canis lupus familiaris] 
587.8475 16.2863754 637.7625 9.7739376 1.084911478 0.084979188 
ubiquitin carboxyl-terminal 
hydrolase isozyme L1 [Sus 
scrofa] 
2.280955 1.06315581 2.4726 0.98331121 1.084019632 0.806931595 
proteasome (prosome, 
macropain) subunit, alpha type 
[Sus scrofa] 
2.045705 0.9520061 2.217265 0.71017819 1.083863509 0.613353384 
PREDICTED: ATP-dependent 
RNA helicase DDX3X isoform X1 
[Galeopterus variegatus] 
5.0301 0.42781927 5.433125 0.77968441 1.080122662 0.668850776 
non-specific lipid-transfer protein 
[Sus scrofa] 
3.0158 0.41391385 3.25305 0.31587818 1.07866901 0.263941308 
PREDICTED: 14-3-3 protein 
theta isoform X1 [Monodelphis 
domestica] 
7.865 1.0925427 8.47325 0.34298231 1.0773363 0.578377479 
PREDICTED: calpain-2 catalytic 
subunit-like [Oryctolagus 
cuniculus] 
1.545775 1.545775 1.665125 0.97625674 1.077210461 0.920044005 
PREDICTED: cysteine and 
glycine-rich protein 1-like isoform 
1 [Sus scrofa] 
78.18575 8.35505995 84.20575 2.01887004 1.076996128 0.431408645 
PREDICTED: filamin-A [Sorex 
araneus] 
515.105 12.1973307 554.6625 6.91957414 1.076795022 0.051417459 
PREDICTED: LOW QUALITY 
PROTEIN: filamin-A [Equus 
caballus] 
571.795 13.0916497 615.625 9.97395316 1.076653346 0.075390125 
hypothetical protein 
PANDA_005634 [Ailuropoda 
melanoleuca] 
11.3304 0.94679677 12.19175 0.52417274 1.076021147 0.472052855 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: myosin light chain 
kinase, smooth muscle [Ursus 
maritimus] 
13.8345 1.37748711 14.871 1.6063071 1.074921392 0.68482649 
PREDICTED: prohibitin 
[Oryctolagus cuniculus] 
6.003675 0.83774931 6.451575 0.36082733 1.074604305 0.701972403 
PREDICTED: filamin-A 
[Odobenus rosmarus divergens] 
541.91 16.0226772 582.3225 16.9593491 1.074574191 0.138609386 
proteasome activator complex 
subunit 2 [Sus scrofa] 
2.27555 0.6660169 2.44415 0.57821994 1.074091978 0.884541193 
PREDICTED: tubulin beta chain-
like [Tursiops truncatus] 
57.8905 2.14919948 62.1595 3.77151721 1.073742669 0.366724161 
SH3 domain-binding glutamic 
acid-rich-like protein 3 [Homo 
sapiens] 
3.273425 0.27149294 3.514475 0.57458207 1.073638467 0.504061753 
beta-actin [Oryctolagus 
cuniculus] 
145.2225 7.9113077 155.43 4.41626728 1.070288695 0.232248219 
PREDICTED: 2-oxoglutarate 
dehydrogenase, mitochondrial-
like [Ailuropoda melanoleuca] 
0.729925 0.45489984 0.779025 0.49602796 1.067267185 0.947583602 
desmin [Sus scrofa] 266.23 12.0357419 284.055 4.32476685 1.066953386 0.320722843 
PREDICTED: collagen alpha-1(I) 
chain isoform 1 [Ceratotherium 
simum simum] 
6.886825 2.10183644 7.339525 1.66854868 1.06573421 0.892126711 
ras-related protein Rap-1A 
precursor [Homo sapiens] 
16.085 0.31829206 17.1235 0.9693273 1.064563258 0.269964172 
glutathione peroxidase 1 [Sus 
scrofa] 
3.057405 0.84509252 3.250425 0.30453486 1.06313197 0.83461508 
Chain A, Refined Crystal 
Structure Of Cytoplasmic Malate 
Dehydrogenase At 2.5-
Angstroms Resolution 
6.76035 0.5267832 7.186525 1.3172269 1.063040375 0.711633973 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: myosin-11-like, 
partial [Sus scrofa] 
95.7635 7.03697218 101.47575 1.97985809 1.059649553 0.458999714 
PREDICTED: collagen alpha-
3(VI) chain isoformX2 [Sus 
scrofa] 
104.42875 21.0385481 110.433 18.6325441 1.05749614 0.802750381 
PREDICTED: T-complex protein 
1 subunit eta [Sarcophilus 
harrisii] 
3.050875 0.76592902 3.225775 0.18039649 1.057327816 0.833519327 
PREDICTED: talin-1 [Camelus 
ferus] 
117.6355 8.13962327 124.305 5.19469682 1.05669632 0.1941455 
ATP synthase, H+ transporting, 
mitochondrial Fo complex, 
subunit d [Sus scrofa] 
7.04805 0.46521602 7.444125 0.80002689 1.056196395 0.762877979 
PREDICTED: mitochondrial 
fission 1 protein [Equus caballus] 
3.30475 0.69172677 3.4872 0.2922566 1.055208412 0.827192145 
ATP synthase subunit f, 
mitochondrial [Sus scrofa] 
4.045 0.46439077 4.2636 0.70049605 1.054042027 0.756295952 
PREDICTED: poly(rC)-binding 
protein 1 isoform X1 [Sus scrofa] 
3.79245 0.79946386 3.98015 0.37608683 1.049493072 0.778053669 
PREDICTED: alpha-actinin-4 
isoformX2 [Sus scrofa] 
96.687 11.0438724 101.31425 14.4406351 1.047858037 0.421831439 
PREDICTED: guanine 
nucleotide-binding protein 
subunit beta-2-like 1 [Trichechus 
manatus latirostris] 
3.074905 1.27936489 3.214475 0.70079436 1.04539002 0.831336635 
PREDICTED: 
phosphatidylethanolamine-
binding protein 1 [Sus scrofa] 
27.20875 1.51188714 28.338 0.58650504 1.041503193 0.370896738 
PREDICTED: nucleolin-like [Sus 
scrofa] 
4.2886 0.68195489 4.4632 0.45369991 1.040712587 0.814924039 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PDZ and LIM domain protein 1 
[Sus scrofa] 
13.91705 1.5453354 14.481 0.65814829 1.040522237 0.711837576 
RecName: Full=Tubulin beta 
chain; AltName: Full=Beta-
tubulin [Sus scrofa] 
44.465 0.68683186 46.14625 2.07191322 1.037810638 0.369871172 
PREDICTED: ras-related protein 
Rab-5A [Monodelphis domestica] 
3.6078 1.36941737 3.743375 0.50890497 1.037578303 0.909219577 
PREDICTED: tropomyosin 
alpha-3 chain-like, partial 
[Bubalus bubalis] 
50.8085 2.24638408 52.70225 0.63518939 1.037272307 0.515079117 
RecName: Full=Actin, 
cytoplasmic 1; AltName: 
Full=Beta-actin; Contains: 
RecName: Full=Actin, 
cytoplasmic 1, N-terminally 
processed [Bos grunniens] 
759.3025 23.0702039 786.86 18.2428365 1.036293177 0.464742184 
PREDICTED: LOW QUALITY 
PROTEIN: talin-1 [Sus scrofa] 
117.1105 8.12752506 121.3175 5.80936367 1.035923337 0.346893093 
PREDICTED: myosin-11 isoform 
1 [Dasypus novemcinctus] 
409.3675 37.4415434 423.8775 17.9360207 1.035444924 0.588460147 
ras suppressor protein 1 [Ovis 
aries] 
17.72525 2.25756518 18.33625 1.22885261 1.0344706 0.721147869 
PREDICTED: collagen alpha-
1(XVIII) chain, partial [Sus 
scrofa] 
7.309425 0.57117644 7.559875 1.36303208 1.034263981 0.87260921 
PREDICTED: cysteine-rich 
protein 2 [Orcinus orca] 
11.363625 1.17595829 11.74215 0.82964448 1.033310233 0.455974522 
PREDICTED: polyubiquitin-B-like 
[Elephantulus edwardii] 
18.70025 2.21261205 19.28325 2.46988422 1.031176054 0.774019783 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: prolargin isoform 
X1 [Sus scrofa] 
37.17225 3.76657985 38.28075 1.5915955 1.029820632 0.695980185 
PREDICTED: creatine kinase B-
type [Canis lupus familiaris] 
25.561 1.39036368 26.29925 1.62741735 1.02888189 0.822472656 
PREDICTED: myosin-11 isoform 
X1 [Camelus ferus] 
481.145 46.075851 493.52 22.189093 1.025719897 0.721919941 
PREDICTED: cell division control 
protein 42 homolog [Equus 
caballus] 
7.27155 1.07075706 7.45485 0.42612188 1.025207831 0.809061989 
PREDICTED: tubulointerstitial 
nephritis antigen-like 1 isoform 
X1 [Sus scrofa] 
4.2156 0.92422259 4.314675 1.42388903 1.023501993 0.960395363 
PREDICTED: actin, alpha 
cardiac muscle 1, partial [Ovis 
aries] 
1167.65 34.353566 1194.55 50.8746417 1.023037725 0.697189911 
PREDICTED: 60S ribosomal 
protein L15 isoform X3 [Gallus 
gallus] 
1.002755 0.41514941 1.02449 0.42727959 1.021675285 0.248971411 
beta-actin, partial [Eubalaena 
glacialis] 
810.49 23.6480024 828.025 18.3145154 1.02163506 0.643088375 
tenascin precursor [Sus scrofa] 1.940025 1.00866848 1.981075 0.71548314 1.021159521 0.953802824 
transgelin [Sus scrofa] 405.495 31.3765065 413.9625 34.1881535 1.020881885 0.760187956 
PREDICTED: myosin-11 isoform 
1 [Ceratotherium simum simum] 
453.2575 42.0935746 462.49 17.095224 1.020369216 0.78111452 
PREDICTED: sepiapterin 
reductase [Sus scrofa] 
8.532275 0.83841287 8.701475 0.97388836 1.019830584 0.806245496 
PREDICTED: protein kinase C 
delta-binding protein-like [Sus 
scrofa] 
11.85065 1.38848759 12.073625 2.30546031 1.018815424 0.871722529 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: haloacid 
dehalogenase-like hydrolase 
domain-containing protein 2 
isoform X1 [Equus caballus] 
0.765375 0.48680041 0.779025 0.49602796 1.017834395 0.986172946 
PREDICTED: heat shock 
cognate 71 kDa protein 
[Loxodonta africana] 
28.618 1.09609078 29.089 0.67896183 1.016458173 0.468032315 
PREDICTED: myosin-11 isoform 
X2 [Mustela putorius furo] 
466.81 42.2603603 474.3125 21.6496183 1.016071849 0.791903312 
PREDICTED: myosin-11 isoform 
X3 [Bubalus bubalis] 
493.7775 44.4286464 501.3925 21.9039283 1.015421926 0.825630595 
transaldolase [Sus scrofa] 6.598425 0.97889853 6.69705 0.52799021 1.014946749 0.933594724 
PREDICTED: myosin-11 isoform 
X2 [Bubalus bubalis] 
503.525 45.2117803 510.3625 21.1845484 1.013579266 0.845497809 
PREDICTED: beta-actin-like 
protein 2 [Sarcophilus harrisii] 
574.9525 21.8765759 582.335 8.8715552 1.012840191 0.797849738 
PREDICTED: LOW QUALITY 
PROTEIN: calponin 1, basic, 
smooth muscle [Dasypus 
novemcinctus] 
17.7025 3.37865075 17.922 1.90815386 1.012399379 0.963187102 
PREDICTED: 14-3-3 protein 
epsilon isoform X1 [Oryctolagus 
cuniculus] 
7.60865 1.17255664 7.69365 1.27219129 1.011171496 0.930927139 
15 kDa selenoprotein precursor 
[Sus scrofa] 
0.74888 0.25054158 0.7570025 0.49656999 1.010846197 0.989658351 
PREDICTED: inter-alpha-trypsin 
inhibitor heavy chain H5-like [Sus 
scrofa] 
4.33775 1.10838832 4.3799425 1.99113501 1.009726817 0.985849628 
PREDICTED: myosin regulatory 
light polypeptide 9 isoform X2 
[Elephantulus edwardii] 
34.9375 5.60404634 35.23025 2.68430902 1.008379249 0.945990554 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
actin related protein 2/3 complex 
subunit 1B [Bos taurus] 
0.74643 0.24960188 0.7517525 0.49187288 1.007130608 0.994560992 
PREDICTED: myosin-11 isoform 
X31 [Canis lupus familiaris] 
478.2975 43.3625667 481.6825 20.076938 1.007077185 0.910067121 
PREDICTED: myosin-11 isoform 
X4 [Physeter catodon] 
477.3425 42.7105862 479.9275 19.3345767 1.005415399 0.934532054 
PREDICTED: 
phosphatidylethanolamine-
binding protein 1 [Ovis aries] 
18.335 1.39998661 18.43075 1.30662398 1.005222253 0.960720388 
PREDICTED: myosin-11 [Felis 
catus] 
469.2275 39.9691678 471.6775 19.507573 1.005221348 0.927346831 
neuroplastin precursor [Bos 
taurus] 
0.9838 0.38450823 0.988525 0.38354477 1.004802805 0.995465867 
high mobility group protein B2 
[Homo sapiens] 
0.51525 0.51525 0.5176 0.5176 1.004560893 0.997951554 
PREDICTED: laminin subunit 
beta-1 isoform X1 [Sus scrofa] 
1.76535 0.64901617 1.772775 0.88997059 1.004205965 0.996249334 
PREDICTED: LOW QUALITY 
PROTEIN: laminin subunit alpha-
4 [Sus scrofa] 
6.491125 1.25621669 6.516825 0.97721846 1.003959252 0.985502692 
40S ribosomal protein S9 [Homo 
sapiens] 
1.5407 0.66266705 1.54469 0.67863814 1.002589732 0.997158433 
TPA: alpha-actinin-2 [Bos taurus] 22.3635 8.05206591 22.404 8.1956671 1.001810987 0.984826227 
Chain A, Structure Of Camp-
Dependent Protein Kinase 
Complexed With A- 443654 
2.48665 0.59955131 2.489975 0.28816698 1.00133714 0.996983515 
CLTLB protein [Bos taurus] 0 0 0.7271 0.4533045 #DIV/0! 0.207050872 
PREDICTED: chaperonin 
CPN60-1, mitochondrial-like, 
partial [Lipotes vexillifer] 
0 0 0.485675 0.485675 #DIV/0! 0.391002219 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
ELAV-like protein 1 [Sus scrofa] 0 0 0.4683 0.4683 #DIV/0! 0.391002219 
PREDICTED: lamin-B1 isoform 
X1 [Sus scrofa] 
0 0 0.4683 0.4683 #DIV/0! 0.391002219 
              
fatty acid synthase [Sus scrofa] 6.160875 2.88207528 0.5176 0.5176 -11.90277241 0.098587972 
PREDICTED: delta-1-pyrroline-5-
carboxylate dehydrogenase, 
mitochondrial [Galeopterus 
variegatus] 
1.24765 0.47406619 0.24284 0.24284 -5.137745017 0.099491641 
ERO1-like protein alpha 
precursor [Sus scrofa] 
1.238975 0.47177585 0.2588 0.2588 -4.78738408 0.261005804 
fibrinogen A-alpha-chain [Sus 
scrofa] 
1.237675 0.46654509 0.261425 0.261425 -4.734340633 0.084691496 
PREDICTED: LOW QUALITY 
PROTEIN: prolow-density 
lipoprotein receptor-related 
protein 1 [Oryctolagus cuniculus] 
3.28095 0.66484621 0.763065 0.25488478 -4.299699239 0.069659192 
PREDICTED: adenosine 
deaminase [Sus scrofa] 
0.98755 0.38462955 0.2341525 0.2341525 -4.217550528 0.187408776 
Chain A, C28s Mutant Of 
Succinyl-Coa:3-Ketoacid Coa 
Transferase From Pig Heart 
4.20285 1.33200503 0.9972175 0.026037 -4.214577061 0.095570026 
cAMP-dependent protein kinase 
type I-alpha regulatory subunit 
[Bos taurus] 
1.01273 0.42542412 0.24284 0.24284 -4.170359084 0.222501527 
PREDICTED: ribonuclease 
UK114 isoform 1 [Sus scrofa] 
1.023 0.59066107 0.2588 0.2588 -3.952859351 0.393940074 
calnexin precursor [Sus scrofa] 2.702625 1.1711954 0.7384175 0.24718843 -3.660022954 0.19165605 
fumarate hydratase [Sus scrofa] 1.75165 0.63701833 0.4955775 0.28698701 -3.534563212 0.18470584 
  
1
3
3
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain A, Fructose-1,6-
Bisphosphatase (Mutant Y57w) 
ProductZN COMPLEX (R-State) 
1.746725 0.63618883 0.4955775 0.28698701 -3.524625311 0.072520899 
PREDICTED: atlastin-3 [Sus 
scrofa] 
0.775325 0.4937467 0.2341525 0.2341525 -3.311196763 0.18217009 
phospholipase C, delta 1 [Sus 
scrofa] 
0.77405 0.49698584 0.2341525 0.2341525 -3.305751594 0.467192101 
PREDICTED: elongation factor 
Tu, mitochondrial [Equus 
caballus] 
0.77405 0.49698584 0.2341525 0.2341525 -3.305751594 0.467192101 
PREDICTED: endoplasmic 
reticulum resident protein 29 
[Sus scrofa] 
0.772875 0.772875 0.2341525 0.2341525 -3.300733496 0.391002219 
Dihydrolipoyl dehydrogenase, 
mitochondrial [Tupaia chinensis] 
3.237975 0.69689868 0.9859 0.57063117 -3.284283396 0.093472785 
dihydrolipoyl dehydrogenase, 
mitochondrial precursor [Sus 
scrofa] 
4.523525 0.66128086 1.46814 0.61851502 -3.081126459 0.096019624 
PREDICTED: lysosome-
associated membrane 
glycoprotein 1 isoform X1 [Sus 
scrofa] 
2.97415 0.75157072 0.96994 0.38307126 -3.06632369 0.140625466 
heat shock protein 90 beta 
[Equus caballus] 
12.534 1.05647772 4.177775 2.41222845 -3.000161569 0.053270731 
PREDICTED: 14 kDa 
phosphohistidine phosphatase 
isoform X2 [Sus scrofa] 
0.769125 0.49267537 0.2588 0.2588 -2.97188949 0.498788177 
PREDICTED: LOW QUALITY 
PROTEIN: cytoplasmic dynein 1 
heavy chain 1 [Sus scrofa] 
7.75825 4.64716656 2.67125 2.67125 -2.904351895 0.49233898 
  
1
3
4
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: tubulointerstitial 
nephritis antigen-like isoform X1 
[Lipotes vexillifer] 
3.725475 1.28550436 1.294 1.294 -2.879037867 0.188312399 
LIM and cysteine-rich domains 
protein 1 [Sus scrofa] 
4.493775 1.6794797 1.675015 1.03056686 -2.682826721 0.184931023 
PREDICTED: cytochrome P450 
1B1-like, partial [Sus scrofa] 
5.94365 2.76569313 2.257875 1.13238106 -2.632408791 0.111360356 
Chain B, Structure Determination 
Of Aquomet Porcine Hemoglobin 
At 2.8 Angstrom Resolution 
87.1385 38.5343127 33.2095 8.28249482 -2.623902799 0.216870632 
hemoglobin subunit beta [Sus 
scrofa] 
86.90725 38.7152766 33.16875 7.65392652 -2.620154513 0.225976476 
RecName: Full=Hemoglobin 
subunit alpha; AltName: 
Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain 
[Sus scrofa] 
39.1875 11.9733243 15.188975 3.3727781 -2.579996346 0.131069506 
RecName: Full=Aminopeptidase 
N; Short=AP-N; Short=pAPN; 
AltName: Full=Alanyl 
aminopeptidase; AltName: 
Full=Aminopeptidase M; 
Short=AP-M; AltName: 
Full=Microsomal 
aminopeptidase; AltName: 
Full=gp130; AltName: 
CD_antigen=CD13 [Sus scrofa] 
4.330225 0.92479788 1.6837 0.79391971 -2.571850686 0.17785867 
  
1
3
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain A, Crystallographic 
Refinement And Atomic Models 
Of Two Different Forms Of 
Citrate Synthase At 2.7 And 1.7 
Angstroms Resolution 
4.47815 1.27738105 1.75419 0.50465304 -2.552830651 0.185699335 
ribosomal protein S6 (predicted) 
[Dasypus novemcinctus] 
1.279325 0.63761448 0.5176 0.5176 -2.471647991 0.445736625 
Syntenin-1 [Pteropus alecto] 1.7616 0.49606935 0.7357925 0.2461123 -2.394153243 0.0870198 
clusterin precursor [Sus scrofa] 2.9704 1.04180222 1.269925 0.77265852 -2.33903577 0.106090262 
PREDICTED: integrin alpha-8 
[Sus scrofa] 
5.181775 1.4286791 2.231175 0.47160187 -2.322442211 0.16969718 
PREDICTED: UDP-glucose 6-
dehydrogenase isoform 1 [Sus 
scrofa] 
4.5387 1.00265705 1.95584 0.88140816 -2.320588596 0.205792828 
3-ketoacyl-CoA thiolase, 
mitochondrial [Sus scrofa] 
1.76405 0.88658111 0.763065 0.25488478 -2.311795194 0.269627441 
PREDICTED: 40S ribosomal 
protein S2 [Equus caballus] 
1.788375 1.05135134 0.779025 0.49602796 -2.295658034 0.479719854 
PREDICTED: high mobility group 
protein B1 isoform X2 
[Monodelphis domestica] 
2.243075 0.86308633 0.9859 0.57063117 -2.275154681 0.343963829 
vesicle-associated membrane 
protein 3 [Bos taurus] 
2.7846 0.30212183 1.23399 0.47744521 -2.256582306 0.060640028 
dihydrolipoamide dehydrogenase 
[Sus scrofa] 
2.250425 0.46706264 0.9998425 0.42778425 -2.250779498 0.197948978 
apolipoprotein A-I [Sus scrofa] 2.238 0.73921755 0.9972175 0.026037 -2.244244611 0.186946687 
  
1
3
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
S-phase kinase-associated 
protein 1 isoform b [Homo 
sapiens] 
0.520175 0.520175 0.2341525 0.2341525 -2.221522299 0.684174184 
PREDICTED: cytochrome b-c1 
complex subunit 2, 
mitochondrial-like [Sus scrofa] 
2.18115 1.15239462 0.987325 0.68704532 -2.209150989 0.12445382 
PREDICTED: annexin A8-like 
[Monodelphis domestica] 
0.51525 0.51525 0.2341525 0.2341525 -2.200488998 0.391002219 
heterogeneous nuclear 
ribonucleoprotein H3 isoform a 
[Homo sapiens] 
1.031675 0.42476168 0.4769925 0.27548309 -2.162874678 0.456668256 
PREDICTED: spectrin beta 
chain, non-erythrocytic 1 isoform 
X1 [Equus caballus] 
4.018225 1.25488674 1.939875 0.76614252 -2.071383465 0.241379766 
60S ribosomal protein L9 [Homo 
sapiens] 
1.539425 0.65784292 0.744475 0.46804115 -2.067799456 0.495705299 
signal peptidase complex 
catalytic subunit SEC11A isoform 
6 [Homo sapiens] 
1.01273 0.42542412 0.4929525 0.28531688 -2.054417008 0.154625988 
PREDICTED: 
fumarylacetoacetate hydrolase 
domain-containing protein 2-like 
[Sus scrofa] 
1.543175 0.51449313 0.7543775 0.25265658 -2.045627024 0.058477265 
RPL35 [Sus scrofa] 1.02545 0.41462076 0.50164 0.28991501 -2.04419504 0.477810785 
actin-related protein 2/3 complex 
subunit 2 [Sus scrofa] 
2.5345 0.6831894 1.2400525 0.23550094 -2.043865078 0.206727527 
PREDICTED: peptidyl-prolyl cis-
trans isomerase D [Equus 
caballus] 
2.014325 0.73071291 0.9972175 0.026037 -2.019945498 0.270492921 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: malectin [Equus 
caballus] 
0.98755 0.38462955 0.4955775 0.28698701 -1.992725658 0.491216636 
2,4-dienoyl-CoA reductase 1 
[Sus scrofa] 
0.520175 0.520175 0.261425 0.261425 -1.98976762 0.719397173 
annexin A7 [Bos taurus] 5.40275 2.19368687 2.748775 0.27861618 -1.96551191 0.353795202 
PREDICTED: pre-B-cell 
leukemia transcription factor-
interacting protein 1 [Sus scrofa] 
1.52913 0.9072751 0.779025 0.49602796 -1.962876673 0.230846412 
surfeit locus protein 4 [Bos 
taurus] 
1.48505 0.85960435 0.76044 0.49303655 -1.952882542 0.20488549 
delta-sarcoglycan [Sus scrofa] 0.50775 0.50775 0.261425 0.261425 -1.942239648 0.391002219 
PREDICTED: fibrinogen beta 
chain isoform X2 [Sus scrofa] 
0.46985 0.46985 0.24284 0.24284 -1.934813046 0.391002219 
glycogen phosphorylase, liver 
form [Sus scrofa] 
4.784925 0.66381636 2.489975 0.28816698 -1.92167592 0.081124968 
PREDICTED: dihydrolipoyl 
dehydrogenase, mitochondrial 
isoform X1 [Eptesicus fuscus] 
3.751925 0.72770203 1.98574 0.37929463 -1.889434166 0.18441278 
ras-related protein Rap-2b 
precursor [Mus musculus] 
2.2731 0.28541387 1.206715 0.58504704 -1.883709078 0.271383643 
PREDICTED: heat shock protein 
HSP 90-beta-like [Leptonychotes 
weddellii] 
3.216875 1.15546044 1.713 0.99761333 -1.877918856 0.51026988 
Calpain-2 catalytic subunit 
[Myotis davidii] 
5.83305 0.86020099 3.2072 0.40886266 -1.818735969 0.069826564 
guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-2 [Mus musculus] 
2.846175 1.6554083 1.568525 1.568525 -1.814555076 0.685301003 
PREDICTED: myosin-10 isoform 
X5 [Camelus ferus] 
100.2375 34.0291371 55.46175 32.7072011 -1.807326671 0.187828002 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
histone H1.0 [Bos taurus] 1.79705 0.64165417 0.9972175 0.026037 -1.802064244 0.293040893 
PREDICTED: very long-chain 
specific acyl-CoA 
dehydrogenase, mitochondrial-
like isoform X3 [Sus scrofa] 
1.780555 0.51064514 0.9972175 0.026037 -1.785523218 0.207928031 
Spectrin alpha chain, brain 
[Myotis brandtii] 
9.282 1.36351891 5.20365 1.37619799 -1.783747946 0.079628982 
dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1 precursor [Sus scrofa] 
6.96365 1.30327525 3.97145 0.7585914 -1.753427589 0.206486857 
40S ribosomal protein S3 isoform 
1 [Homo sapiens] 
3.0839 1.10860328 1.7602775 0.27651465 -1.75193968 0.375746643 
hypothetical protein 
PANDA_006316 [Ailuropoda 
melanoleuca] 
1.78705 1.12360856 1.02709 0.73963131 -1.739915684 0.304683022 
aspartate aminotransferase, 
mitochondrial precursor [Sus 
scrofa] 
12.930525 3.15164855 7.446175 0.5367193 -1.736532515 0.211204304 
PREDICTED: prenylcysteine 
oxidase 1 isoform X1 [Sus 
scrofa] 
3.445325 1.07245777 1.994425 0.05207953 -1.727477844 0.279273618 
thy-1 membrane glycoprotein 
precursor [Sus scrofa] 
2.526975 0.32394161 1.465515 0.44839593 -1.724291461 0.206306058 
hypothetical protein 
PANDA_002264 [Ailuropoda 
melanoleuca] 
2.9844 0.89501823 1.735625 0.23786866 -1.719495859 0.175885816 
albumin [Sus scrofa] 12.107375 3.56451879 7.057025 1.21945976 -1.715648591 0.239224044 
integrin alpha-7 [Bos taurus] 5.15045 1.79271426 3.002925 0.59975777 -1.715144401 0.256087414 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: ATP synthase 
subunit beta, mitochondrial [Sus 
scrofa] 
43.737 7.77338482 25.5665 2.38792562 -1.710715194 0.094175489 
GTP-binding protein SAR1a 
[Mus musculus] 
2.547255 0.67892223 1.490165 0.28137997 -1.709377821 0.186016784 
Chain E, Structure Of Bovine 
Heart Cytochrome C Oxidase At 
The Fully Oxidized State 
2.51425 0.6619073 1.471575 0.49222164 -1.708543567 0.077002703 
PREDICTED: transmembrane 
emp24 domain-containing 
protein 9 [Equus caballus] 
2.50805 0.27385404 1.4829025 0.47769807 -1.691311465 0.105311968 
PREDICTED: membrane primary 
amine oxidase [Sus scrofa] 
81.58075 13.950869 48.797 8.10738263 -1.671839457 0.108289056 
PREDICTED: LOW QUALITY 
PROTEIN: oligoribonuclease, 
mitochondrial [Canis lupus 
familiaris] 
2.4602 0.78436331 1.4742 0.25083635 -1.668837336 0.272196413 
collagen, type I, alpha 2 
precursor [Sus scrofa] 
5.182925 1.76495656 3.10799 1.65908684 -1.667613152 0.45305447 
PREDICTED: fibrillin-1 isoform 1 
[Orcinus orca] 
48.58975 10.3163756 29.29875 11.5011143 -1.658423994 0.126457917 
PREDICTED: microfibril-
associated glycoprotein 4 [Equus 
caballus] 
13.1784 2.0368127 7.967025 1.11113631 -1.654118068 0.069421647 
PREDICTED: cytoplasmic 
FMR1-interacting protein 1 
isoform 1 [Monodelphis 
domestica] 
1.2439 0.47465323 0.7543775 0.25265658 -1.6489092 0.484483449 
PREDICTED: glucose-6-
phosphate 1-dehydrogenase X-
like isoform X1 [Sus scrofa] 
0.771575 0.25724221 0.4683 0.4683 -1.647608371 0.550591044 
  
1
4
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
plasma membrane Ca2+-
ATPase isoform 4xb [Bos taurus] 
1.99035 0.36721019 1.212775 0.45380868 -1.641153553 0.283772312 
3-hydroxyisobutyrate 
dehydrogenase, mitochondrial 
precursor [Bos taurus] 
2.013025 0.04569851 1.22874 0.47432116 -1.638283933 0.185806354 
PREDICTED: mitochondrial 2-
oxoglutarate/malate carrier 
protein [Monodelphis domestica] 
1.245175 0.4708367 0.763065 0.25488478 -1.631807251 0.518306661 
isocitrate dehydrogenase 
[NADP], mitochondrial [Sus 
scrofa] 
5.206925 1.16942107 3.201125 0.54474672 -1.626592214 0.257010539 
PREDICTED: sideroflexin-3 
isoform X1 [Canis lupus 
familiaris] 
2.01055 0.42105586 1.2426775 0.48719316 -1.617917762 0.243460632 
PREDICTED: fibrillin-1 
[Oryctolagus cuniculus] 
29.81475 12.4498705 18.47175 10.6884779 -1.614072841 0.066145988 
PREDICTED: serpin H1 isoform 
X1 [Leptonychotes weddellii] 
11.484975 1.41216371 7.13815 1.10783476 -1.608956803 0.087063905 
PREDICTED: fibrillin-1-like 
[Physeter catodon] 
35.98725 15.1869706 22.37725 12.9915466 -1.608206996 0.069876657 
COP9 complex subunit 7a [Bos 
taurus] 
0.74888 0.25054158 0.4683 0.4683 -1.599145847 0.722146909 
cytosolic non-specific 
dipeptidase [Sus scrofa] 
1.549375 0.67189723 0.96994 0.38307126 -1.597392622 0.43624171 
PREDICTED: nidogen-2 [Sus 
scrofa] 
9.238175 1.22680194 5.837325 2.25145449 -1.582604189 0.190963744 
Chain A, Structure Of Full Length 
Grp94 With Amp-Pnp Bound 
10.018525 1.27971735 6.379575 1.70023357 -1.570406336 0.30329757 
PREDICTED: sushi domain-
containing protein 2 [Sus scrofa] 
1.968925 0.64445403 1.2586425 0.27833549 -1.564324262 0.452746172 
  
1
4
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: receptor 
expression-enhancing protein 5 
[Sus scrofa] 
4.54625 0.57081005 2.92234 1.2392042 -1.55568825 0.33775244 
PREDICTED: CD109 antigen 
isoformX1 [Sus scrofa] 
0.765375 0.48680041 0.4955775 0.28698701 -1.544410309 0.341969737 
fibrillin-1 precursor [Sus scrofa] 53.63 11.4266967 34.78075 10.5058638 -1.541944898 0.102293382 
dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit precursor [Sus 
scrofa] 
3.001925 0.91254926 1.96715 0.36175354 -1.526027502 0.189842154 
PREDICTED: aflatoxin B1 
aldehyde reductase member 2-
like [Sarcophilus harrisii] 
1.52048 0.30981711 0.9972175 0.026037 -1.52472254 0.164268007 
PREDICTED: tumor protein D54 
[Ochotona princeps] 
1.518005 0.30559001 0.9998425 0.42778425 -1.518244123 0.210424098 
Chain A, Crystal Structure Of Pig 
Phosphoglucose Isomerase 
15.48825 2.45353291 10.220175 0.91843838 -1.515458395 0.16336746 
PREDICTED: aconitate 
hydratase, mitochondrial 
[Oryctolagus cuniculus] 
7.90645 2.32859981 5.2408 1.38364799 -1.508634178 0.244033665 
PRA1 family protein 2 [Bos 
taurus] 
1.539425 0.65784292 1.021865 0.42296105 -1.50648569 0.478776288 
lactadherin precursor [Sus 
scrofa] 
42.047 3.42527267 28.00125 4.80928585 -1.501611535 0.061125083 
PREDICTED: guanine 
nucleotide-binding protein G(k) 
subunit alpha [Monodelphis 
domestica] 
7.3107 1.09889986 4.8743 1.88306845 -1.499846132 0.461689393 
calmodulin 3.369875 2.38182598 2.257875 1.13238106 -1.492498478 0.480047268 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain A, Refinement And 
Comparison Of The Crystal 
Structures Of Pig Cytosolic 
Aspartate Aminotransferase And 
Its Complex With 2-
Methylaspartate 
6.288025 0.88714647 4.222975 0.16682193 -1.489003605 0.076628192 
caveolin-2 [Sus scrofa] 3.022 0.43428616 2.043725 0.8459223 -1.478672522 0.101384505 
prolyl 4-hydroxylase beta 
polypeptide [Sus scrofa] 
19.397 2.96928215 13.1419 1.58337236 -1.475966184 0.226457793 
glutaredoxin-1 [Sus scrofa] 0.771575 0.25724221 0.52285 0.52285 -1.475710051 0.655834607 
neutral alpha-glucosidase AB 
precursor [Sus scrofa] 
2.5056 0.26573937 1.699665 0.68244269 -1.474172852 0.222411534 
FAH protein [Bos taurus] 0.729925 0.45489984 0.4955775 0.28698701 -1.472877602 0.768747872 
PREDICTED: LOW QUALITY 
PROTEIN: nucleosome 
assembly protein 1-like 4 [Sus 
scrofa] 
1.778105 0.27964838 1.212775 0.45380868 -1.466145823 0.444821955 
cytoskeleton-associated protein 
4 [Sus scrofa] 
6.8309 0.95490761 4.675325 0.72326458 -1.46105351 0.069109656 
sorting nexin-3 isoform a [Homo 
sapiens] 
1.75915 0.25198929 1.206715 0.58504704 -1.457800723 0.433243947 
aldehyde dehydrogenase, 
mitochondrial precursor [Sus 
scrofa] 
5.6019 1.2883994 3.91695 1.29318158 -1.430168881 0.056634917 
PREDICTED: extended 
synaptotagmin-1 isoform 1 
[Ceratotherium simum simum] 
6.0226 0.54357822 4.211675 0.69226697 -1.429977384 0.123765089 
protein Niban-like [Sus scrofa] 4.28825 1.95238654 3.027 1.42114528 -1.416666667 0.226421458 
PREDICTED: coatomer subunit 
zeta-1 [Oryctolagus cuniculus] 
1.02545 0.41462076 0.7271 0.4533045 -1.410328703 0.658777445 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
rho GTPase-activating protein 1 
[Canis lupus familiaris] 
1.02545 0.41462076 0.729725 0.45390642 -1.405255404 0.556722786 
rab GDP dissociation inhibitor 
beta [Sus scrofa] 
13.5266 1.5036395 9.6501 0.86438785 -1.401705682 0.07609482 
hypothetical protein 
PANDA_017913 [Ailuropoda 
melanoleuca] 
1.034125 0.73565295 0.7384175 0.24718843 -1.400461121 0.779669575 
hypothetical protein 
PANDA_002275 [Ailuropoda 
melanoleuca] 
4.3126 0.82271623 3.08415 1.3478422 -1.398310718 0.525413753 
protein disulfide-isomerase A6 
precursor [Sus scrofa] 
11.6906 1.76495462 8.375425 1.08108163 -1.395821705 0.174062673 
Golgi-associated plant 
pathogenesis-related protein 1 
[Bos taurus] 
2.78085 0.50726747 1.994425 0.05207953 -1.394311644 0.186706 
PREDICTED: LOW QUALITY 
PROTEIN: serine/threonine-
protein kinase WNK4-like 
[Ailuropoda melanoleuca] 
1.01273 0.42542412 0.7271 0.4533045 -1.392834548 0.565376584 
PREDICTED: ADP/ATP 
translocase 1 isoform 2 [Sus 
scrofa] 
9.071125 0.9083301 6.51945 0.78101791 -1.391394213 0.070693095 
PREDICTED: cytosol 
aminopeptidase [Odobenus 
rosmarus divergens] 
3.74085 0.57168406 2.696875 0.6628564 -1.387105446 0.276631903 
60S ribosomal protein L7 [Homo 
sapiens] 
3.52485 0.66774685 2.5506 0.89486815 -1.381968948 0.448410546 
progesterone receptor 
membrane component 2 [Sus 
scrofa] 
2.03573 0.43950094 1.4742 0.25083635 -1.380904898 0.362304787 
  
1
4
4
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: EGF-containing 
fibulin-like extracellular matrix 
protein 1 [Ornithorhynchus 
anatinus] 
1.004055 0.42126092 0.7271 0.4533045 -1.38090359 0.601226645 
60S ribosomal protein L6 [Sus 
scrofa] 
2.80385 1.91722074 2.033 0.93658249 -1.379168716 0.670400232 
PREDICTED: fatty aldehyde 
dehydrogenase isoform X1 [Sus 
scrofa] 
0.98755 0.38462955 0.7198275 0.46356545 -1.371925913 0.378173608 
PREDICTED: ATP-citrate 
synthase isoformX1 [Equus 
caballus] 
3.757 0.93601953 2.74355 0.88718926 -1.369393669 0.348024802 
alpha-parvin [Bos taurus] 9.102825 1.80262959 6.664525 0.89588824 -1.365862533 0.207311423 
hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 
precursor [Sus scrofa] 
5.7852 0.27226689 4.236325 0.76683572 -1.365617605 0.071489812 
PREDICTED: 60 kDa heat shock 
protein, mitochondrial [Equus 
caballus] 
14.7845 1.50989395 10.87875 1.22417679 -1.359025623 0.182320414 
PREDICTED: myosin-11 isoform 
X2 [Ochotona princeps] 
411.165 33.3527591 302.7425 102.903688 -1.358134388 0.310995941 
PREDICTED: myosin-11-like, 
partial [Bos mutus] 
326.11 28.5793238 240.64 81.0810974 -1.355177859 0.314296069 
dihydropteridine reductase [Sus 
scrofa] 
3.017125 0.42208794 2.228575 0.1965077 -1.353835971 0.064844498 
decorin precursor [Sus scrofa] 39.3584 10.3158506 29.135 4.92463791 -1.350897546 0.414573314 
ATP synthase subunit g, 
mitochondrial [Sus scrofa] 
5.0388 0.45921264 3.730025 0.22716198 -1.350875664 0.152236076 
  
1
4
5
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
hypothetical protein 
PANDA_001608 [Ailuropoda 
melanoleuca] 
2.013025 0.04569851 1.49279 0.2864035 -1.348498449 0.149497727 
hypothetical protein 
PANDA_002799 [Ailuropoda 
melanoleuca] 
8.24785 0.96477213 6.151575 1.36308221 -1.340770453 0.348158449 
copine-1 [Sus scrofa] 3.28715 0.89551721 2.4601 0.60135043 -1.336185521 0.073716604 
PREDICTED: vacuolar protein 
sorting-associated protein 35, 
partial [Sus scrofa] 
2.292055 0.51141417 1.715625 0.79802261 -1.335988342 0.518727324 
PREDICTED: BAG family 
molecular chaperone regulator 2 
isoform X1 [Sus scrofa] 
0.9838 0.38450823 0.7384175 0.24718843 -1.332308619 0.631033022 
gi|585690381-DECOY 1.01273 0.42542412 0.76044 0.49303655 -1.33176845 0.402741576 
guanine nucleotide-binding 
protein G(i) subunit alpha-2 [Sus 
scrofa] 
11.386975 1.51222918 8.553625 1.61578465 -1.331245525 0.288724258 
programmed cell death protein 6 
[Bos taurus] 
5.273725 0.46128626 3.964175 0.33012865 -1.330346163 0.16807527 
PREDICTED: LOW QUALITY 
PROTEIN: neuroblast 
differentiation-associated protein 
AHNAK [Canis lupus familiaris] 
31.3815 4.31393989 23.59825 2.13276051 -1.329823186 0.053492617 
PREDICTED: integral membrane 
protein 2B-like [Echinops telfairi] 
1.006505 0.02283821 0.7570025 0.49656999 -1.329592703 0.645789549 
integrin beta-1 precursor [Sus 
scrofa] 
36.688 4.26264667 27.66775 0.99726454 -1.326020367 0.155336418 
ras-related protein Rab-5C [Bos 
taurus] 
6.3029 0.55768437 4.765225 0.83204873 -1.322686757 0.126649183 
  
1
4
6
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
hypothetical protein 
PANDA_002213 [Ailuropoda 
melanoleuca] 
3.55995 0.70628341 2.705575 0.39869136 -1.315783151 0.292963937 
farnesyl pyrophosphate synthase 
precursor [Sus scrofa] 
1.262855 0.49649909 0.96125 0.66273479 -1.313763329 0.795599411 
PREDICTED: 4-
trimethylaminobutyraldehyde 
dehydrogenase [Sus scrofa] 
3.2445 0.7291109 2.477475 0.63192311 -1.309599491 0.541985267 
PREDICTED: myosin-11 
[Loxodonta africana] 
441.7825 41.0335293 337.4625 113.921156 -1.309130644 0.355796909 
parathymosin [Bos taurus] 8.350075 0.98524629 6.388425 1.37132552 -1.307063165 0.334332752 
PREDICTED: 40S ribosomal 
protein S10-like isoform 1 
[Ailuropoda melanoleuca] 
3.585105 1.01481746 2.746175 0.50194035 -1.305490364 0.311123918 
Chain A, Atomic Structure Of 
Fkbp12, An Immunophilin 
Binding Protein 
7.093425 0.84510035 5.481625 0.30698353 -1.294036896 0.127449517 
PREDICTED: annexin A6 
isoform X1 [Ochotona princeps] 
27.26825 6.78341323 21.0745 1.19657355 -1.293897839 0.446971547 
PREDICTED: translationally-
controlled tumor protein [Equus 
caballus] 
0.9838 0.38450823 0.76044 0.49303655 -1.293724686 0.670805317 
Chain A, Structure Of Calmodulin 
Bound To A Calcineurin Peptide: 
A New Way Of Making An Old 
Binding Mode 
7.389725 2.12033643 5.74245 1.41039447 -1.286859267 0.188854332 
PREDICTED: selenium-binding 
protein 1 [Sus scrofa] 
4.532175 1.37565 3.522575 1.25562693 -1.286608518 0.253229016 
PREDICTED: importin subunit 
beta-1 [Monodelphis domestica] 
3.818725 0.92291576 2.969015 1.13645257 -1.286192559 0.434592888 
  
1
4
7
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: adenylyl cyclase-
associated protein 1 isoform 1 
[Dasypus novemcinctus] 
13.65175 1.55256881 10.62155 1.05018815 -1.285287929 0.192257436 
PREDICTED: annexin A11 
isoform X1 [Sus scrofa] 
6.7514 1.02596667 5.25475 0.79402083 -1.284818498 0.436706849 
EF-hand domain-containing 
protein D2 [Bos taurus] 
3.768425 0.24132537 2.94315 0.98444329 -1.280405348 0.503506406 
PREDICTED: RNA binding motif 
(RNP1, RRM) protein 3 isoform 
X2 [Sus scrofa] 
5.036325 0.44775143 3.943 0.63575269 -1.277282526 0.096377669 
PREDICTED: annexin A1 
isoform X1 [Sus scrofa] 
42.4065 14.5571938 33.27175 11.2756871 -1.274549731 0.090754502 
CD81 [Sus scrofa] 3.7735 0.8788462 2.964375 0.34109145 -1.27294961 0.257322884 
PREDICTED: fibromodulin 
[Tupaia chinensis] 
14.096 0.93043637 11.0783 1.8690696 -1.272397389 0.16743862 
smooth muscle protein SM22 
homolog - bovine (fragments) 
340.115 30.1063887 267.6225 90.8107283 -1.270875954 0.339347464 
amine oxidase [flavin-containing] 
A [Sus scrofa] 
2.809755 0.67448333 2.2112 0.95887857 -1.270692384 0.497805534 
PREDICTED: fibulin-5 isoformX1 
[Sus scrofa] 
9.249525 0.72096609 7.28425 1.79291086 -1.269797852 0.452921438 
PREDICTED: uncharacterized 
protein LOC100739300 [Sus 
scrofa] 
1.26413 0.26648333 0.9972175 0.026037 -1.267657256 0.419460284 
PREDICTED: 60S ribosomal 
protein L22 isoform X1 [Ursus 
maritimus] 
2.54348 0.67035068 2.01039 0.43822103 -1.265167455 0.480455973 
UDP-N-acetylhexosamine 
pyrophosphorylase [Bos taurus] 
1.26038 0.25786916 0.9972175 0.026037 -1.263896793 0.356654368 
  
1
4
8
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
glutathione S-transferase 
omega-1 [Sus scrofa] 
3.76465 0.63134118 2.98555 0.57279261 -1.260956943 0.431948136 
PREDICTED: annexin A6 
isoform X1 [Equus caballus] 
35.884 9.844228 28.5245 1.34860796 -1.258006275 0.494243173 
PREDICTED: adenylyl cyclase-
associated protein 1 isoform X1 
[Physeter catodon] 
8.081 0.72299192 6.435625 0.4884483 -1.255666699 0.178612314 
PREDICTED: S-methyl-5'-
thioadenosine phosphorylase 
[Oryctolagus cuniculus] 
1.518005 0.30559001 1.212775 0.45380868 -1.251679001 0.662192658 
ADP/ATP translocase 3 
[Pteropus alecto] 
12.86985 1.59773262 10.302225 1.8815333 -1.249230142 0.317927805 
PREDICTED: musculoskeletal 
embryonic nuclear protein 1 
[Oryctolagus cuniculus] 
2.54103 0.89580115 2.0350425 0.75140786 -1.248637313 0.736945541 
laminin receptor precursor 
[Oryctolagus cuniculus] 
5.56515 1.34435887 4.470475 0.84414999 -1.244867715 0.285429436 
TPA: calcium channel, voltage-
dependent, alpha 2/delta subunit 
1 [Bos taurus] 
1.241425 0.21271946 0.9998425 0.42778425 -1.241620555 0.65356975 
PREDICTED: annexin A6-like 
[Sus scrofa] 
38.04 11.126893 30.67275 2.40523822 -1.240188767 0.499768779 
versican [Sus scrofa] 4.302925 1.84010039 3.476475 1.29591227 -1.237726433 0.478333944 
PREDICTED: heat shock protein 
beta-6 [Sus scrofa] 
5.8306 0.95102941 4.715925 0.40849298 -1.236364022 0.144482594 
PREDICTED: asporin isoform X1 
[Sus scrofa] 
22.2115 3.45933526 17.989 2.55937307 -1.234726777 0.351739383 
PREDICTED: 60S ribosomal 
protein L8 [Loxodonta africana] 
1.26038 0.25786916 1.021865 0.42296105 -1.233411458 0.659027211 
  
1
4
9
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: alpha-enolase 
isoform X3 [Bos taurus] 
31.031 4.31426809 25.19225 2.36803584 -1.231767706 0.067641133 
L-lactate dehydrogenase B chain 
[Sus scrofa] 
14.8275 0.83297984 12.04095 1.97062707 -1.23142277 0.360367085 
RecName: Full=Protein S100-
A10; AltName: Full=Calpactin I 
light chain; AltName: 
Full=Calpactin-1 light chain; 
AltName: Full=Cellular ligand of 
annexin II; AltName: Full=S100 
calcium-binding protein A10; 
AltName: Full=p10 protein; 
AltName: Full=p11 [Sus scrofa] 
1.543175 0.51449313 1.2560175 0.27241258 -1.228625397 0.597065538 
PREDICTED: LOW QUALITY 
PROTEIN: dicarbonyl/L-xylulose 
reductase [Lipotes vexillifer] 
1.521755 0.52368543 1.2400525 0.23550094 -1.227169817 0.701070815 
PREDICTED: annexin A5 
[Sarcophilus harrisii] 
16.65225 1.55984189 13.5795 1.31843572 -1.226278582 0.116014441 
thioredoxin reductase [Sus 
scrofa] 
1.507725 0.66091962 1.231365 0.21457457 -1.22443386 0.735560948 
PREDICTED: annexin A6 
isoform X1 [Panthera tigris 
altaica] 
34.9115 8.91736319 28.51475 1.57800942 -1.224331267 0.478112118 
cadherin-13 precursor [Equus 
caballus] 
1.237675 0.46654509 1.0131775 0.42339583 -1.22157766 0.775930589 
PREDICTED: 6-
phosphogluconate 
dehydrogenase, decarboxylating 
[Sus scrofa] 
1.779405 0.78119128 1.456825 0.80162773 -1.221426733 0.247554694 
  
1
5
0
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: basement 
membrane-specific heparan 
sulfate proteoglycan core protein 
[Sus scrofa] 
62.70375 6.62593037 51.3585 12.6552016 -1.220903064 0.584729897 
phosphatidylinositol-binding 
clathrin assembly protein [Bos 
taurus] 
1.75425 0.87775855 1.43824 0.8050132 -1.219719935 0.550789744 
PREDICTED: alpha-enolase 
isoform X1 [Sus scrofa] 
34.02675 5.21988841 27.9025 2.77665667 -1.219487501 0.151990668 
plasminogen activator inhibitor 1 
RNA-binding protein [Felis catus] 
1.52423 0.31599565 1.24995 0.47477813 -1.219432777 0.61394988 
ribosomal protein L7a, partial 
[Equus caballus] 
1.5407 0.66266705 1.2647 0.47925842 -1.218233573 0.821283941 
PREDICTED: collagen alpha-
1(XVIII) chain isoform X1 [Equus 
caballus] 
4.048775 0.47811445 3.3235525 1.18946319 -1.218207024 0.624313588 
elongation factor 1-alpha 1 
[Equus caballus] 
27.91775 3.4072849 22.968 3.3848888 -1.215506357 0.442729277 
PREDICTED: fibronectin 
isoformX2 [Sus scrofa] 
23.835 2.73066698 19.6285 5.73129189 -1.214305729 0.270310187 
PREDICTED: ras-related protein 
Rab-1A isoform X1 [Loxodonta 
africana] 
10.84795 1.25421776 8.939 0.55504782 -1.21355297 0.234607685 
PREDICTED: serpin peptidase 
inhibitor, clade B (ovalbumin), 
member 1 isoform X1 [Sus 
scrofa] 
4.54245 0.70082381 3.743375 0.50890497 -1.213463786 0.235018698 
hypothetical protein 
PANDA_004987 [Ailuropoda 
melanoleuca] 
1.52048 0.30981711 1.2560175 0.27241258 -1.210556382 0.353848941 
  
1
5
1
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
ras-related protein Rab-1B [Bos 
taurus] 
11.10555 1.17013816 9.18185 0.42180876 -1.209511155 0.198134515 
peptidyl-prolyl cis-trans 
isomerase B [Equus caballus] 
11.2724 1.63583832 9.3441 1.99440196 -1.206365514 0.597177309 
ras-related protein Rab-6A 
[Rattus norvegicus] 
3.60405 1.2298058 2.991625 0.07809964 -1.204713158 0.649041657 
PREDICTED: transforming 
growth factor beta-1-induced 
transcript 1 protein isoform 1 
[Ovis aries] 
6.569525 0.73249273 5.4596 0.93841886 -1.203297861 0.21488821 
ras-related protein Rab-14 
[Rattus norvegicus] 
6.875 1.41224521 5.715775 0.41304117 -1.202811517 0.362175913 
PREDICTED: acyl-coenzyme A 
thioesterase 2, mitochondrial-
like, partial [Sus scrofa] 
1.476375 0.44763738 1.231365 0.21457457 -1.198974309 0.695834925 
electron-transfer-flavoprotein, 
alpha polypeptide [Sus scrofa] 
3.813825 0.6902082 3.189825 0.85013522 -1.195622017 0.340832216 
PREDICTED: lupus La protein 
homolog isoform X1 [Sus scrofa] 
1.514255 0.51124989 1.267325 0.48263389 -1.19484347 0.640784595 
heterogeneous nuclear 
ribonucleoprotein A1 isoform b 
[Homo sapiens] 
3.543475 0.70097196 2.966975 0.34677735 -1.194305648 0.569768461 
PREDICTED: transgelin-2 
[Ochotona princeps] 
25.27875 2.84307267 21.1675 2.54238082 -1.194224637 0.208550173 
PREDICTED: cytoplasmic dynein 
1 heavy chain 1 [Eptesicus 
fuscus] 
20.9735 3.67103685 17.56675 3.69280709 -1.193931718 0.587030187 
PREDICTED: macrophage-
capping protein isoformX2 [Sus 
scrofa] 
10.019775 0.63893033 8.401375 1.35565755 -1.192635134 0.474303413 
  
1
5
2
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: barrier-to-
autointegration factor-like 
isoformX1 [Sus scrofa] 
3.279625 0.29987223 2.7514 0.51395419 -1.191984081 0.488300872 
voltage-dependent anion-
selective channel protein 1 
[Oryctolagus cuniculus] 
8.32845 1.34871331 6.996425 0.52559708 -1.190386519 0.358354165 
PREDICTED: galactokinase 
isoform X1 [Sus scrofa] 
2.029505 0.60057404 1.705725 0.599835 -1.189819578 0.757599425 
PREDICTED: NADH-cytochrome 
b5 reductase 3-like isoform X1 
[Sus scrofa] 
14.91325 1.33256678 12.538775 1.2609289 -1.189370572 0.200156128 
PREDICTED: N(G),N(G)-
dimethylarginine 
dimethylaminohydrolase 2 [Sorex 
araneus] 
13.90805 1.83229177 11.69625 0.38914787 -1.189103345 0.279579974 
RecName: Full=ATP synthase-
coupling factor 6, mitochondrial; 
Short=ATPase subunit F6 [Sus 
scrofa] 
1.774355 0.49683465 1.49279 0.2864035 -1.188616617 0.573588726 
putative cation-transporting 
ATPase 13A2 isoform 2 
[Camelus ferus] 
1.784305 0.51378486 1.5014775 0.29988551 -1.188366126 0.743544712 
superoxide dismutase [Mn], 
mitochondrial [Sus scrofa] 
17.41775 2.88180853 14.69275 1.36084823 -1.185465621 0.227723188 
T-complex protein 1 subunit 
alpha [Sus scrofa] 
1.784305 0.51378486 1.506125 0.65659907 -1.184699145 0.3051032 
PREDICTED: LOW QUALITY 
PROTEIN: neuroblast 
differentiation-associated protein 
AHNAK [Myotis davidii] 
30.0005 3.16808129 25.3445 2.73484568 -1.183708497 0.057801799 
  
1
5
3
 
Protein Name 
Control                              
MEAN 
Control                           
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: neuroblast 
differentiation-associated protein 
AHNAK [Sorex araneus] 
17.64575 1.8930727 14.9289 2.59028699 -1.181985947 0.174634577 
PREDICTED: basement 
membrane-specific heparan 
sulfate proteoglycan core protein 
[Erinaceus europaeus] 
20.35875 2.15909354 17.230775 5.80682729 -1.181534203 0.71339185 
PREDICTED: neuroblast 
differentiation-associated protein 
AHNAK [Mustela putorius furo] 
20.48825 3.15589442 17.3825 1.04336319 -1.178671077 0.241518847 
PREDICTED: actin-related 
protein 2/3 complex subunit 5-
like protein-like [Macaca mulatta] 
1.7554 0.24539619 1.490165 0.28137997 -1.177990357 0.58143468 
SYNCRIP protein [Bos taurus] 1.75915 0.25198929 1.4962275 0.66716352 -1.175723612 0.639290834 
PREDICTED: transmembrane 
emp24 domain-containing 
protein 10 [Sus scrofa] 
5.253475 0.99852019 4.4731 0.60023216 -1.174459547 0.603456822 
PREDICTED: PDZ and LIM 
domain protein 5 isoformX3 [Sus 
scrofa] 
5.805425 0.8198995 4.950075 0.60229262 -1.172795362 0.086345087 
ras-related protein Rab-18 
isoform 1 [Homo sapiens] 
2.03198 0.43064859 1.735625 0.23786866 -1.17074829 0.576095035 
Annexin A6, partial [Bos mutus] 35.3525 9.46636129 30.2635 1.2782723 -1.16815636 0.591966354 
PREDICTED: actin-related 
protein 2/3 complex subunit 5 
[Ornithorhynchus anatinus] 
2.013025 0.04569851 1.724315 0.44021889 -1.167434604 0.532588548 
  
1
5
4
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
Chain A, Refined Structure Of 
Mitochondrial Malate 
Dehydrogenase From Porcine 
Heart And The Consensus 
Structure For Dicarboxylic Acid 
Oxidoreductases 
25.472 1.84719684 21.8555 1.61009531 -1.165473222 0.153098556 
PREDICTED: proteasome 
subunit beta type-6 isoform X1 
[Equus caballus] 
2.013025 0.04569851 1.733 0.23271051 -1.161583958 0.32917887 
PREDICTED: LOW QUALITY 
PROTEIN: ezrin [Equus caballus] 
8.2309 3.06107739 7.08665 2.44674386 -1.161465573 0.829448341 
ras-related protein Rab-2A [Bos 
taurus] 
2.251725 0.46410772 1.9425 0.63780214 -1.159189189 0.494636811 
PREDICTED: rab GDP 
dissociation inhibitor alpha 
isoform 1 [Sus scrofa] 
11.507475 1.25466249 9.927475 0.91987211 -1.159154266 0.410417609 
PREDICTED: ras-related protein 
Rab-7a [Equus caballus] 
8.626525 1.38022067 7.446175 0.5367193 -1.158517628 0.470918575 
PREDICTED: proteasome 
subunit alpha type-4 
[Ornithorhynchus anatinus] 
1.77188 0.49463337 1.5307775 0.90110268 -1.157503295 0.845743891 
TPA: ras-related C3 botulinum 
toxin substrate 1 precursor [Bos 
taurus] 
1.9941 0.37085747 1.724315 0.44021889 -1.156459232 0.659725704 
ATP synthase subunit O, 
mitochondrial precursor [Sus 
scrofa] 
6.32055 0.84772936 5.472925 0.60716323 -1.154876049 0.428793679 
PREDICTED: annexin A5 [Ovis 
aries] 
44.821 5.65734434 38.898 3.34266311 -1.15227004 0.330048421 
  
1
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
leucine-rich repeat-containing 
protein 59 [Sus scrofa] 
2.016775 0.42627688 1.75159 0.26467881 -1.151396731 0.642268063 
60S ribosomal protein L14 [Sus 
scrofa] 
2.054675 0.72348057 1.784925 0.64864985 -1.151126798 0.824912129 
ADP-ribosylation factor 3 [Ovis 
aries] 
8.7908 1.02977428 7.644275 1.36818537 -1.149984793 0.561456455 
PREDICTED: annexin A5 [Sus 
scrofa] 
60.41675 6.8273921 52.5405 4.13781185 -1.149908166 0.288460397 
PREDICTED: alpha-enolase 
isoform X1 [Lipotes vexillifer] 
33.29575 4.63001266 28.957 2.0921992 -1.149834237 0.211755742 
transketolase [Sus scrofa] 8.598725 1.93813134 7.49245 1.53471202 -1.14765197 0.602870314 
heat shock 70 kDa protein 1B 
[Sus scrofa] 
22.63725 2.82906614 19.73075 1.52781256 -1.147308136 0.492521939 
Chain B, Crystal Structure Of 
Bovine Arp23 COMPLEX CO-
Crystallized With Atp And 
Crosslinked With Glutaraldehyde 
2.806005 0.78805669 2.44879 1.15592546 -1.145874085 0.812545983 
PREDICTED: 40S ribosomal 
protein S7 [Equus caballus] 
4.55895 0.70613795 3.9862 0.42860523 -1.143683207 0.549420249 
PREDICTED: ras-related protein 
R-Ras [Sus scrofa] 
6.007725 0.64400147 5.253525 0.54155139 -1.143560752 0.504894879 
PREDICTED: integrin alpha-3 
isoform X2 [Sus scrofa] 
6.232375 0.78799086 5.479 0.28951373 -1.137502281 0.487641237 
Chain A, Structure Of Porcine 
Class Pi Glutathione S-
Transferase 
16.314 0.2736351 14.36875 1.41164262 -1.1353806 0.200787588 
PREDICTED: integrin alpha-3 
isoform X1 [Pteropus alecto] 
4.774925 0.24247829 4.207025 0.39396367 -1.134988501 0.410024298 
annexin A4 [Sus scrofa] 22.183 3.93306401 19.55525 1.70141732 -1.134375679 0.468396688 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: myosin light 
polypeptide 6 isoform X2 
[Bubalus bubalis] 
77.29325 6.3036946 68.233 4.92754007 -1.13278399 0.46467675 
PREDICTED: serine/threonine-
protein phosphatase PP1-beta 
catalytic subunit [Panthera tigris 
altaica] 
7.8901 1.45352968 6.969175 0.56139177 -1.132142614 0.424763401 
PREDICTED: fermitin family 
homolog 2, partial [Sus scrofa] 
18.916 2.12793425 16.7564 2.52569672 -1.128882099 0.370481388 
ARP3 actin-related protein 3 
homolog (yeast) [Bos taurus] 
7.55055 0.90752262 6.6918 0.50846839 -1.128328701 0.164120212 
armadillo repeat containing 10 
[Sus scrofa] 
3.068705 1.12958694 2.721525 0.42832117 -1.127568183 0.668504137 
PREDICTED: basement 
membrane-specific heparan 
sulfate proteoglycan core protein 
[Vicugna pacos] 
44.06 6.21747018 39.0955 9.40416728 -1.126983924 0.760242864 
PREDICTED: serine/threonine-
protein phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform-like isoform 1 [Equus 
caballus] 
5.011175 0.5315006 4.4519 0.92877797 -1.125626137 0.587353944 
histidine triad nucleotide-binding 
protein 2, mitochondrial isoform 1 
precursor [Sus scrofa] 
2.78085 0.50726747 2.471425 0.22651322 -1.125201048 0.696698187 
PREDICTED: basement 
membrane-specific heparan 
sulfate proteoglycan core protein 
[Orcinus orca] 
37.8465 4.85194608 33.63825 9.20422111 -1.125103119 0.769080254 
PREDICTED: myelin protein P0 
[Sus scrofa] 
6.48625 0.69993042 5.7865025 1.8634034 -1.120927538 0.625764461 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: plastin-3 
isoformX1 [Sus scrofa] 
14.7305 1.54279322 13.1515 1.06818674 -1.12006235 0.444717897 
PREDICTED: neuroblast 
differentiation-associated protein 
AHNAK [Mustela putorius furo] 
26.722 3.43361816 23.8585 1.27434679 -1.120020119 0.318463806 
PREDICTED: vesicle-associated 
membrane protein 2 
[Ornithorhynchus anatinus] 
2.7846 0.30212183 2.487375 0.27982541 -1.119493442 0.289147949 
actin-related protein 2/3 complex 
subunit 3 [Bos taurus] 
5.5251 0.25014426 4.957375 1.21413038 -1.114521294 0.655745917 
T-complex protein 1 subunit beta 
[Sus scrofa] 
8.57595 0.76917748 7.729625 0.90905514 -1.109491081 0.098073633 
PREDICTED: fructose-
bisphosphate aldolase A isoform 
X1 [Camelus ferus] 
23.21675 2.35707143 20.94525 1.35524434 -1.10844941 0.366209047 
PREDICTED: stress-70 protein, 
mitochondrial [Felis catus] 
8.803375 0.66575315 7.945175 1.05824738 -1.108015242 0.489185811 
RecName: Full=Neurofilament 
light polypeptide; Short=NF-L; 
AltName: Full=68 kDa 
neurofilament protein; AltName: 
Full=Neurofilament triplet L 
protein [Sus scrofa] 
1.87945 1.87945 1.699875 1.699875 -1.105640121 0.391002219 
PREDICTED: collagen alpha-
1(XII) chain [Sus scrofa] 
8.565225 3.7329803 7.7482 0.94495428 -1.105447072 0.86527439 
Alpha-centractin [Pteropus 
alecto] 
3.273425 0.27149294 2.964375 0.34109145 -1.104254691 0.627075641 
rho-related GTP-binding protein 
RhoC precursor [Homo sapiens] 
5.76005 0.36810942 5.22485 1.01179706 -1.102433563 0.686818778 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
mitochondrial succinate 
dehydrogenase complex subunit 
A [Sus scrofa] 
3.0068 0.69946256 2.7276 0.6368844 -1.10236105 0.258090622 
ATP synthase subunit alpha, 
mitochondrial [Sus scrofa] 
30.6055 1.53563583 27.81175 1.31957041 -1.100452147 0.153177958 
PREDICTED: 14-3-3 protein 
zeta/delta [Myotis brandtii] 
26.96975 1.31090792 24.5185 1.71325054 -1.099975529 0.328273634 
14-3-3 protein zeta chain [cattle, 
brain, Peptide, 245 aa] 
27.22975 1.46981276 24.78575 1.32330831 -1.098605045 0.341554376 
peroxiredoxin-6 [Sus scrofa] 11.13345 1.45950377 10.1417 0.97913727 -1.097789325 0.650866097 
PREDICTED: T-complex protein 
1 subunit theta isoform 1 [Sus 
scrofa] 
3.79735 0.54756535 3.466 0.46542102 -1.095600115 0.547043947 
hypothetical protein 
PANDA_015972 [Ailuropoda 
melanoleuca] 
4.026075 0.09136907 3.6781 0.74665276 -1.09460727 0.679662553 
four and a half LIM domains 1 
protein, isoform C [Sus scrofa] 
12.703025 2.44925296 11.61115 1.44630693 -1.094036766 0.496633493 
ran-specific GTPase-activating 
protein [Sus scrofa] 
0.7778 0.49760689 0.71114 0.44995723 -1.093736817 0.930636518 
PREDICTED: ubiquitin carboxyl-
terminal hydrolase 5 isoform 1 
[Sus scrofa] 
0.5115 0.29533054 0.4683 0.4683 -1.092248559 0.916695964 
PREDICTED: peroxiredoxin-1 
[Oryctolagus cuniculus] 
10.61445 1.1847935 9.722625 1.66487748 -1.091726771 0.625025575 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
RecName: Full=Mimecan; 
AltName: Full=Osteoglycin; 
Contains: RecName: 
Full=Corneal keratan sulfate 
proteoglycan 25 core protein; 
Short=KSPG25 protein; 
Contains: RecName: 
Full=Osteoinductive factor; 
Short=OIF; Flags: Precursor [Bos 
taurus] 
12.602925 3.31146521 11.547525 2.99502017 -1.091396208 0.704597335 
Annexin A5 [Tupaia chinensis] 34.3385 4.39287329 31.46975 3.07340312 -1.09115897 0.668391307 
PREDICTED: lipoma-preferred 
partner [Sus scrofa] 
4.318825 1.10518255 3.974925 0.92083803 -1.086517356 0.438931126 
pyruvate kinase PKM [Bos 
taurus] 
41.747 2.33290666 38.48775 2.55487189 -1.084682789 0.200318345 
RecName: Full=Caveolin-1 
[Rhinolophus ferrumequinum] 
5.992375 1.31314029 5.527075 1.52150848 -1.084185577 0.624502275 
PREDICTED: dnaJ homolog 
subfamily B member 4 isoform 
X1 [Equus caballus] 
0.769125 0.49267537 0.71114 0.44995723 -1.081538094 0.895967902 
RecName: Full=Eukaryotic 
translation initiation factor 5A-1; 
Short=eIF-5A-1; Short=eIF-5A1; 
AltName: Full=Eukaryotic 
initiation factor 5A isoform 1; 
Short=eIF-5A; AltName: 
Full=eIF-4D [Oryctolagus 
cuniculus] 
4.252325 0.73065954 3.9456 0.47727335 -1.077738494 0.657162971 
  
1
6
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: 40S ribosomal 
protein S25 [Ornithorhynchus 
anatinus] 
3.302325 0.54006412 3.065575 1.26888248 -1.077228579 0.872469409 
14-3-3 protein eta [Oryctolagus 
cuniculus] 
9.3125 0.34698797 8.6517 0.93249808 -1.076378053 0.639626178 
GTP-binding nuclear protein 
Ran, partial [Bos mutus] 
5.290175 0.31627978 4.915525 0.77931367 -1.076217698 0.625781682 
enoyl-CoA hydratase, 
mitochondrial [Sus scrofa] 
4.8001 0.55525912 4.465825 0.17931059 -1.074851791 0.675676155 
PREDICTED: poly [ADP-ribose] 
polymerase 6 isoformX1 [Sus 
scrofa] 
78.8525 5.55985792 73.535 4.33516161 -1.072312504 0.142445178 
hypothetical protein 
PANDA_006098 [Ailuropoda 
melanoleuca] 
9.53835 0.81024023 8.903025 1.21843458 -1.071360577 0.616516687 
PREDICTED: myosin-10, partial 
[Sus scrofa] 
131.5275 10.4840103 122.775 8.5520022 -1.071288943 0.515237189 
vesicle-trafficking protein 
SEC22b precursor [Bos taurus] 
1.0292 0.42073099 0.96125 0.66273479 -1.070689207 0.863126164 
peroxiredoxin-2 [Sus scrofa] 19.12525 0.85722774 17.919 0.83041867 -1.067316815 0.308175688 
hypothetical protein 
PANDA_010030 [Ailuropoda 
melanoleuca] 
5.7725 0.93666766 5.424475 0.93327894 -1.064158283 0.638223917 
hypothetical protein 
PANDA_020401 [Ailuropoda 
melanoleuca] 
12.32615 1.91734325 11.5866 1.7732813 -1.063828043 0.32116651 
peptidyl-prolyl cis-trans 
isomerase A [Sus scrofa] 
47.32375 2.98390771 44.6705 2.45889299 -1.059396022 0.612418637 
PREDICTED: protein canopy 
homolog 4 [Equus caballus] 
0.771575 0.25724221 0.729725 0.45390642 -1.057350372 0.920470443 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
macrophage migration inhibitory 
factor [Sus scrofa] 
12.1135 1.10487175 11.479525 0.74578394 -1.055226588 0.697340924 
PREDICTED: vimentin isoform 
X1 [Sus scrofa] 
384.66 18.8224011 365.59 23.1313975 -1.052162258 0.171569586 
PREDICTED: acidic leucine-rich 
nuclear phosphoprotein 32 family 
member A isoform X1 [Equus 
caballus] 
0.492555 0.28497986 0.4683 0.4683 -1.051793722 0.951078813 
nucleoside diphosphate kinase B 
[Sus scrofa] 
8.84505 0.89644578 8.412575 0.99803469 -1.05140816 0.767507612 
PREDICTED: 
dihydropyrimidinase-related 
protein 2 isoform X2 [Loxodonta 
africana] 
11.966 1.90159216 11.383025 0.97822823 -1.051214418 0.759338806 
Cofilin-1, partial [Bos mutus] 23.26025 2.4078032 22.19125 4.15564294 -1.04817214 0.777088432 
clathrin heavy chain 1 [Bos 
taurus] 
24.925 1.54139936 23.78375 2.76416085 -1.047984443 0.516480751 
superoxide dismutase [Cu-Zn] 
[Sus scrofa] 
10.62725 1.81888807 10.1411 1.03745386 -1.047938587 0.815802279 
erythrocyte band 7 integral 
membrane protein [Bos taurus] 
7.074475 0.70426834 6.752375 0.81069818 -1.047701735 0.803385053 
hypothetical protein 
PANDA_012739 [Ailuropoda 
melanoleuca] 
1.26413 0.26648333 1.206715 0.58504704 -1.047579586 0.886152766 
RecName: Full=ATP synthase 
subunit e, mitochondrial; 
Short=ATPase subunit e [Sus 
scrofa] 
6.521675 0.60742213 6.2261 0.24137727 -1.047473539 0.6609292 
PREDICTED: pyruvate kinase 
isozymes M1/M2 isoform 2 
[Dasypus novemcinctus] 
44.54275 3.60412626 42.54575 3.42249018 -1.046937708 0.63949077 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: T-complex protein 
1 subunit gamma isoform 1 
[Equus caballus] 
1.53043 0.67716146 1.46289 0.61677142 -1.046168885 0.866973354 
60S ribosomal protein L11 [Mus 
musculus] 
1.80325 0.65233432 1.724315 0.44021889 -1.045777599 0.893870769 
PREDICTED: myb-binding 
protein 1A isoform X1 [Sus 
scrofa] 
0.767825 0.48725115 0.7357925 0.2461123 -1.043534692 0.966551466 
PREDICTED: peptidyl-prolyl cis-
trans isomerase A-like [Physeter 
catodon] 
39.798 1.92668242 38.22775 1.78456542 -1.041076182 0.638995453 
PREDICTED: ras-related protein 
Rab-10 [Monodelphis domestica] 
8.823675 0.43771078 8.476725 0.70080432 -1.040929722 0.707554362 
aldolase C 12.1045 0.89141147 11.63365 1.22156629 -1.04047311 0.742859698 
tubulin-specific chaperone A 
[Bos taurus] 
0.765375 0.48680041 0.7357925 0.2461123 -1.040204949 0.969623824 
PREDICTED: heat shock protein 
beta-1-like isoform 1 [Sus scrofa] 
37.3635 2.91939402 36.0625 1.78203687 -1.036076256 0.703369425 
PREDICTED: synemin [Sus 
scrofa] 
1.52668 0.5318112 1.4742 0.25083635 -1.035598969 0.945763145 
PREDICTED: heterogeneous 
nuclear ribonucleoprotein L-like 
[Elephantulus edwardii] 
2.01055 0.42105586 1.9425 0.63780214 -1.035032175 0.854062683 
PREDICTED: transgelin 
[Dasypus novemcinctus] 
301.895 26.2347322 291.6825 24.2320646 -1.035012385 0.669083906 
PREDICTED: heat shock-related 
70 kDa protein 2 [Sus scrofa] 
22.8735 1.71882045 22.106 1.12857764 -1.034719081 0.695449464 
PREDICTED: small nuclear 
ribonucleoprotein Sm D2-like 
[Macaca mulatta] 
1.031675 0.42476168 0.9972175 0.026037 -1.034553646 0.938684944 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
acylphosphatase-1 isoform 1 
[Sus scrofa] 
2.060875 0.73224263 1.994425 0.05207953 -1.033317874 0.932963789 
PREDICTED: LOW QUALITY 
PROTEIN: IQ motif containing 
GTPase activating protein 1 [Sus 
scrofa] 
14.6655 1.60058346 14.203125 2.89162068 -1.032554455 0.773900075 
PREDICTED: poly(rC)-binding 
protein 2-like isoform X1 
[Monodelphis domestica] 
1.5407 0.66266705 1.49279 0.2864035 -1.032094266 0.92180872 
PREDICTED: integrin-linked 
protein kinase-like [Ailuropoda 
melanoleuca] 
2.832475 0.97884412 2.746175 0.50194035 -1.031425528 0.913259084 
Translational activator GCN1 
[Myotis davidii] 
9.145625 1.61278467 8.88705 1.11377917 -1.029095707 0.848024234 
hypothetical protein 
PANDA_006420 [Ailuropoda 
melanoleuca] 
1.26413 0.26648333 1.22874 0.47432116 -1.028801862 0.938255035 
voltage-dependent anion-
selective channel protein 2 
[Oryctolagus cuniculus] 
10.26505 0.88826586 9.990575 0.60300931 -1.027473394 0.790414175 
PREDICTED: proteasome 
subunit alpha type-3 
[Monodelphis domestica] 
1.26413 0.26648333 1.231365 0.21457457 -1.026608682 0.57592442 
PREDICTED: mimecan 
[Orycteropus afer afer] 
13.4109 3.42582852 13.0673 2.90139249 -1.026294644 0.923011558 
PREDICTED: calponin-1 
[Chrysochloris asiatica] 
154.2825 18.7091343 150.4475 9.1840227 -1.02549062 0.781386303 
PREDICTED: carbonyl reductase 
[NADPH] 1 [Physeter catodon] 
2.520775 0.51573535 2.4601 0.60135043 -1.024663632 0.957143961 
obg-like ATPase 1 [Bos taurus] 1.734 0.43608581 1.6924 0.70849443 -1.024580477 0.917659381 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
F-actin-capping protein subunit 
alpha-2 [Sus scrofa] 
4.32775 0.81651619 4.23895 0.4859385 -1.020948584 0.844063067 
PREDICTED: LOW QUALITY 
PROTEIN: collagen alpha-1(XV) 
chain [Vicugna pacos] 
3.068705 1.12958694 3.007575 0.45405795 -1.020325345 0.959334485 
PREDICTED: actin-related 
protein 2/3 complex subunit 4 
[Sarcophilus harrisii] 
8.5801 0.96384122 8.416175 0.88394137 -1.019477375 0.908160292 
PREDICTED: glyoxalase 
domain-containing protein 4 [Sus 
scrofa] 
1.75915 0.25198929 1.72694 0.44298441 -1.018651488 0.956992512 
PREDICTED: hsc70-interacting 
protein isoform 1 [Sus scrofa] 
1.006505 0.02283821 0.988525 0.38354477 -1.018188716 0.963741837 
ribosomal protein, large, P2 [Sus 
scrofa] 
6.2892 0.65088928 6.181475 0.80195676 -1.01742707 0.938272005 
PREDICTED: phosphoglycerate 
mutase 1 isoform 4 [Canis lupus 
familiaris] 
8.330075 1.05060864 8.193275 0.30657799 -1.01669662 0.909452389 
charged multivesicular body 
protein 4b [Bos taurus] 
1.26038 0.25786916 1.2400525 0.23550094 -1.016392451 0.963270496 
PREDICTED: serine--tRNA 
ligase, cytoplasmic [Sus scrofa] 
1.514255 0.51124989 1.490165 0.28137997 -1.016165995 0.97447564 
PREDICTED: 14-3-3 protein 
gamma [Chrysochloris asiatica] 
13.616 1.47600322 13.405 0.56572579 -1.015740395 0.849944079 
PREDICTED: stress-induced-
phosphoprotein 1 [Sus scrofa] 
0.9851 0.56995448 0.96994 0.38307126 -1.015629833 0.972224381 
ras-related protein Rab-11B 
[Rattus norvegicus] 
3.582655 1.09429246 3.5278 0.71725886 -1.015549351 0.963578787 
PREDICTED: protein 
phosphatase 1 regulatory subunit 
12B-like isoform X1 [Sus scrofa] 
5.0288 0.4176627 4.9614 0.31475411 -1.013584875 0.915710816 
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Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
guanine nucleotide-binding 
protein G(I)/G(S)/G(O) subunit 
gamma-12 [Sus scrofa] 
4.330225 0.92479788 4.272275 0.71039656 -1.013564202 0.942349406 
calponin-1 [Sus scrofa] 170.96 19.9725324 168.97 7.27052153 -1.011777239 0.908010134 
triosephosphate isomerase 1 
[Sus scrofa] 
33.11025 3.88675111 32.8385 0.96614574 -1.008275348 0.933895635 
Myosin regulatory light 
polypeptide 9 [Tupaia chinensis] 
40.485 6.16460668 40.20525 2.3241429 -1.006958047 0.960768187 
ribosomal protein L17 (predicted) 
[Oryctolagus cuniculus] 
0.50775 0.50775 0.504265 0.29153273 -1.006911049 0.993585989 
PREDICTED: tropomyosin 
alpha-1 chain isoform X2 [Sus 
scrofa] 
153.7025 8.31118361 152.8775 3.15580517 -1.005396478 0.941642608 
acyl-CoA-binding protein [Sus 
scrofa] 
2.745425 0.7350286 2.732825 0.23111146 -1.004610614 0.989576269 
tropomyosin 3, gamma isoform 
19-like protein [Camelus ferus] 
69.4605 4.22639045 69.151 0.6756191 -1.004475713 0.948874313 
PREDICTED: gelsolin isoform X5 
[Orycteropus afer afer] 
11.86605 0.86232527 11.8228 1.90746455 -1.003658186 0.986787531 
PREDICTED: tropomyosin 
alpha-4 chain isoform 6 [Orcinus 
orca] 
164.835 9.69610102 164.4525 3.43483472 -1.0023259 0.973819965 
transforming protein ras - rabbit 1.7554 0.24539619 1.75159 0.26467881 -1.002175167 0.992177908 
PREDICTED: synaptic vesicle 
membrane protein VAT-1 
homolog [Sus scrofa] 
1.4953 0.26732804 1.49279 0.2864035 -1.001681415 0.994846711 
nucleophosmin [Bos taurus] 1.26038 0.25786916 1.2586425 0.27833549 -1.001380456 0.961912311 
PREDICTED: cell surface 
glycoprotein MUC18 isoform X1 
[Sus scrofa] 
2.5105 0.66085529 2.5094 0.91191523 -1.000438352 0.998498186 
  
1
6
6
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: 60S ribosomal 
protein L23a-like [Equus 
caballus] 
0.5177 0.29890093 0.5176 0.5176 -1.000193199 0.999825232 
RecName: 
Full=Sodium/potassium-
transporting ATPase subunit 
alpha-1; Short=Sodium pump 
subunit alpha-1; AltName: 
Full=Na(+)/K(+) ATPase alpha-1 
subunit; Flags: Precursor [Equus 
caballus] 
0.98755 0.38462955 0 0 0 0.082670109 
PREDICTED: alpha-aminoadipic 
semialdehyde dehydrogenase-
like [Sus scrofa] 
0.98755 0.38462955 0 0 0 0.082670109 
coatomer subunit alpha [Bos 
taurus] 
1.80945 0.88970696 0 0 0 0.134854524 
PREDICTED: PRA1 family 
protein 3 [Camelus ferus] 
2.4437 1.24751852 0 0 0 0.145015048 
PREDICTED: adipocyte plasma 
membrane-associated protein 
[Sus scrofa] 
1.68615 1.03269894 0 0 0 0.201024176 
tenascin-X precursor [Sus scrofa] 0.729925 0.45489984 0 0 0 0.206926313 
PREDICTED: mitochondrial inner 
membrane protein, partial [Sus 
scrofa] 
0.765375 0.48680041 0 0 0 0.213938092 
PREDICTED: ATP-dependent 
RNA helicase DDX1 [Equus 
caballus] 
0.7778 0.49760689 0 0 0 0.21597607 
  
1
6
7
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: non-histone 
chromosomal protein HMG-17 
[Monodelphis domestica] 
0.7778 0.49760689 0 0 0 0.21597607 
PREDICTED: protein NipSnap 
homolog 3A [Sus scrofa] 
0.769125 0.49267537 0 0 0 0.21641467 
ch4 and secrete domains of 
swine IgM [Sus scrofa] 
0.50775 0.50775 0 0 0 0.391002219 
PREDICTED: NADH 
dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 
isoform X1 [Camelus ferus] 
0.520175 0.520175 0 0 0 0.391002219 
PREDICTED: ribosome 
maturation protein SBDS [Equus 
caballus] 
0.51525 0.51525 0 0 0 0.391002219 
DDRGK domain-containing 
protein 1 precursor [Bos taurus] 
0.51525 0.51525 0 0 0 0.391002219 
phosphatidylinositol 4-kinase 
alpha [Bos taurus] 
0.51525 0.51525 0 0 0 0.391002219 
PREDICTED: keratin, type II 
cytoskeletal 78 [Galeopterus 
variegatus] 
1.8034 1.8034 0 0 0 0.391002219 
fascin [Sus scrofa] 0.46985 0.46985 0 0 0 0.391002219 
phosphatidate 
cytidylyltransferase 2 [Bos 
taurus] 
0.46985 0.46985 0 0 0 0.391002219 
PREDICTED: elongation factor 
Tu, mitochondrial-like 
[Pantholops hodgsonii] 
0.7048 0.7048 0 0 0 0.391002219 
nitrogen regulatory protein P-II 1 
[Methylotenera sp. 1P/1] 
0.939725 0.939725 0 0 0 0.391002219 
  
1
6
8
 
Protein Name 
Control                              
MEAN 
Control                            
SEM 
Leptin                      
MEAN 
Leptin                           
SEM 
Ratio                        
(Leptin/Control) 
P value 
PREDICTED: 2',3'-cyclic-
nucleotide 3'-phosphodiesterase 
[Sus scrofa] 
1.17465 1.17465 0 0 0 0.391002219 
MHC class I antigen [Sus scrofa] 1.409575 1.409575 0 0 0 0.391002219 
MULTISPECIES: molecular 
chaperone GroEL 
[Mesorhizobium] 
2.3493 2.3493 0 0 0 0.391002219 
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APPENDIX B: Supplemental Figures 
 
Figure I Effects of acute versus chronic leptin treatment on coronary contraction. 
Leptin treatment had no effect on vasoconstriction to the thromboxane A2 receptor agonist, 
U46619 (1 µM) following acute, chronic 3 day, or chronic 8 day exposure. Contractile 
responses in untreated, control arteries were progressively reduced throughout the culture 
time course. Contractile responses in leptin treated arteries were also reduced following 
8 days of exposure. All groups n = 4. †P<0.05 versus acute control. ††P<0.05 versus 
acute leptin 
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Figure II Effects of leptin and/or fasudil treatment in the absence of coronary 
endothelium. Functional responses observed in endothelium intact arteries following 
acute (Fig. 1A, 2A, 2C) and chronic (Fig. 1B, 2B, 2D) leptin administration were similar to 
those observed in endothelium denuded arteries following acute (A-C) and chronic, 3 day 
(D-F) exposure. All groups n = 3 
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Figure III Leptin augments cellular proliferation in coronary arteries. Representative 
images of BrdU-proliferation assays in negative control (no BrdU added to culture media 
[A]), untreated, control (B) and leptin treated (C) arteries (8 day culture in serum containing 
media). A significantly higher percentage of BrdU-positive nuclei was detected in leptin 
treated, relative to untreated arteries (D). Each group n = 5. *P<0.05, leptin versus control 
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Figure IV Effects of chronic, 8 day leptin and/or fasudil treatment on depolarization-
induced contractions. Chronic leptin administration (8 day culture, serum-containing 
media) increased KCl-induced contractions ~2.2 g at doses >40 mM (A). Inhibition of Rho 
kinase with fasudil (1 µM) had no effect on vasoconstriction to KCl in the absence of leptin 
(B), but reduced the effect of leptin administration on KCl-induced contractions (C). 
Functional responses of all treatment groups were similar in endothelium denuded arteries 
(D-F). All groups n = 3 
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